

## CURRICULUM VITAE

Name: Hartmut Derendorf

Born: August 6, 1953 in Dortmund, Germany

Address: 100494, College of Pharmacy  
University of Florida  
Gainesville, Florida 32610  
Phone (352) 273-7856  
Fax (352) 392-3249  
E-mail: HARTMUT@COP.UFL.EDU

Present Position: Distinguished Professor and Chairman  
V. Ravi Chandran Professor of  
Pharmaceutical Sciences  
University of Florida Distinguished  
Alumini Professor  
Dept. of Pharmaceutics,  
College of Pharmacy  
University of Florida

Previous Positions:

1993 - 2003 Professor  
Dept. of Pharmaceutics  
College of Pharmacy  
University of Florida

1987 - 1995 Chairman  
1998 - Dept. of Pharmaceutics  
College of Pharmacy  
University of Florida

1987 - 1993 Associate Professor  
Dept. of Pharmaceutics  
College of Pharmacy  
University of Florida

1983 - 1987 Assistant Professor  
Dept. of Pharmaceutics  
College of Pharmacy  
University of Florida

## Education

- 1972 - 1976            B.S. in Pharmacy,  
University of Münster, Germany
- 1977                    Registered Pharmacist
- 1977 - 1979            Graduate Study of Pharmacy at  
University of Münster, Germany
- 1979                    Dr. rer. nat. (Ph.D.) with a  
dissertation on "Biopharmaceutical  
investigations of weak analgesics"  
(summa cum laude)
- 1979 - 1980            Assistant Scientist  
Institute for Pharmaceutical Chemistry,  
University of Münster
- 1981 - 1982            Postdoctoral Fellow with E.R. Garrett,  
College of Pharmacy, University of  
Florida

## Awards

- 1980                    Award for the best dissertation  
University of Münster, Germany
- 1983                    Rottendorf-Award for Outstanding Research in  
the Area of Pharmaceutical Sciences
- 1988                    Fellow of the American College of Clinical  
Pharmacology (ACCP)
- 1994                    McKeen-Cattell-Award for best publication in  
the Journal of Clinical Pharmacology
- 1995                    Teaching Improvement Award, University of  
Florida
- 1996                    Fellow of the American Association of  
Pharmaceutical Scientists (AAPS)
- 2000                    Honorary Regent, American College of  
Clinical Pharmacology
- 2001                    Honorary Fellowship, Slovakian Chemotherapy  
Society
- 2002                    University of Florida Research Foundation  
Professorship

2003 Nathaniel T. Kwit Distinguished Service Award, American College of Clinical Pharmacology

2003 Research Achievement Award in Clinical Sciences, American Association of Pharmaceutical Scientists

2004 International Educator of the Year Award University of Florida

2005 Faculty Award in Pharmaceutical Sciences University of Utrecht, The Netherlands

2005 International Educator of the Year Award University of Florida

2007-2013 CVS Professorship, College of Pharmacy, University of Florida

2007 International Educator of the Year Award University of Florida

2008 Howard Hughes Medical Institute Distinguished Mentor

2009 Doctoral Advisor/Mentoring Award University of Florida

2010 Volwiler Research Achievement Award American Association of Colleges of Pharmacy

2010 ACCP Distinguished Investigator Award American College of Clinical Pharmacology

2013 ISOP Leadership Award International Society of Pharmacometrics

2013 International Educator of the Year Award University of Florida

2013-2018 V. Ravi Chandran Professorship in Pharmaceutical Sciences

2014 Honorary Membership, Brazilian Association of Pharmaceutical Sciences

2015 Merit Medal, Westphalian Chamber of Pharmacy

2015 Bristol-Myers Squibb Mentorship Award, American College of Clinical Pharmacology

2015-2017 18<sup>th</sup> Distinguished Alumni Professor, University of Florida

2016-2019 University of Florida Research Foundation Professorship

2016-2019 Honorary Adjunct Professor, Medical  
University Vienna, Austria

### **Teaching Experience**

- 1983 - present Teacher for Biopharmaceutics,  
Pharmacokinetics (undergraduate and graduate  
courses) and Clinical Pharmacokinetics,  
University of Florida
- 1981 - present Instructor at more than 30 courses on  
Pharmacokinetics, Biopharmaceutics and  
Clinical Pharmacokinetics in Germany,  
England, Brazil and U.S.A
- 1990 - 2000 Adjunct Professor for Pharmacokinetics at  
the Federal University of Rio Grande do Sul,  
Porto Alegre, Brazil
- 1983 - 1990 Adjunct Lecturer for Pharmacokinetics and  
Biopharmaceutics at the University of  
Münster, Germany
- 1977 - 1980 Teaching assistant for courses in Medicinal  
Chemistry, Pharmacology for Pharmacists,  
Biochemistry for Pharmacists and Analytical  
Chemistry at University of Münster; Teacher  
for Pharmacology for Pharmacists at  
University of Münster; Teacher for  
Pharmacology and Toxicology at Schools for  
Pharmacy Technicians in Münster and  
Osnabrück

### **Textbooks**

- 1983 H. Derendorf, Drugs - Applied Pharmacology  
for Pharmacists and Pharmacy Technicians (in  
German), 280 p., Deutscher Apotheker-Verlag,  
Stuttgart, Germany
- 1987 H. Derendorf and E.R. Garrett,  
Pharmacokinetics - Introduction into Theory  
and Practice" (in German), 175 p., Deutscher  
Apotheker -Verlag, Stuttgart, Germany
- 1988 H. Derendorf, Drugs - Applied Pharmacology  
for Pharmacists and Pharmacy Technicians (in

- German), 4th edition, 286 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 1994 H. Derendorf, Drugs - Applied Pharmacology for Pharmacists and Pharmacy Technicians (in German), 5th edition, 264 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 1995 E. Mutschler and H. Derendorf, Drug Actions (in English), 799 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 1995 H. Derendorf and G. Hochhaus, Handbook of Pharmacokinetic-Pharmacodynamic Correlations (in English), 483 p., CRC Press, Boca Raton, Florida
- 1997 J. Framm, M. Schäfer, H. Derendorf, Pharmaceutical Care (in German), 118 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 1998 H. Derendorf, M. Schmidt, Drugs - Applied Pharmacology for Pharmacists and Pharmacy Technicians (in German), 6th edition, 269 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 1998 J. Framm, M. Anschütz, H. Derendorf, D. Hammersdorfer, E. Heydel, A. Mehrwald, G. Schomaker, Drug Profiles (in German), 252 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 2001 J. Framm, M. Anschütz, H. Derendorf, D. Hammersdorfer, E. Heydel, A. Mehrwald, G. Schomaker, Drug Profiles (in German), 2<sup>nd</sup> edition, 294 p., Deutscher Apotheker Verlag, Stuttgart, Germany
- 2002 H. Derendorf, T. Gramatte, H.G. Schaefer, Pharmacokinetics - Introduction into Theory and Practice" (in German), 2<sup>nd</sup> edition, 175 p., Deutscher Apotheker -Verlag, Stuttgart, Germany
- 2002 J. Framm, D. Placek, M. Anschütz, H. Derendorf, D. Hammersdorfer, E. Heydel, A. Mehrwald, G. Schomaker, Profily leziv (Drug Profiles, in Czech), 277 p., Grada Publishing, Prague, Czech Republic

- 2003 H. Derendorf, M. Schulz, R. Wemhöner  
Pharmacology for Pharmacists and Pharmacy  
Technicians (in German), 7th edition, 304  
p., Deutscher Apotheker Verlag, Stuttgart,  
Germany
- 2011 M. Rowland, T.N. Tozer  
Clinical Pharmacokinetics and  
Pharmacodynamics, with Online Simulations by  
H. Derendorf and G. Hochhaus, 4th edition,  
839 p., Wolters Kluwer Lippincott,  
Philadelphia
- 2011 H. Derendorf, T. Gramatté, H.G. Schäfer, A.  
Staab, Pharmacokinetics compact (in German),  
3rd edition, 378 p., Wissenschaftliche  
Verlagsgesellschaft, Stuttgart, Germany
- 2011 H. Derendorf, R. Wemhöner, H. Steen, A.J.  
Schrank, Pharmacology for Pharmacists and  
Pharmacy Technicians (in German), 8th  
edition, 304 p., Deutscher Apotheker Verlag,  
Stuttgart, Germany
- 2013 A.A. Vinks, H. Derendorf, J.W. Mouton  
Fundamentals of Antimicrobial  
Pharmacokinetics and Pharmacodynamics, 467  
p., Springer, New York
- 2014 H. Derendorf  
POP - Patient-oriented Pharmacy, Vol. 1 (in  
German), 160 p., Deutscher Apotheker Verlag,  
Stuttgart, Germany
- 2015 S. Schmidt, H. Derendorf  
Applied Pharmacometrics, 570 p., Springer,  
New York
- 2015 H. Derendorf  
POP - Patient-oriented Pharmacy, Vol. 2 (in  
German), 136 p., Deutscher Apotheker Verlag,  
Stuttgart, Germany

**Present Research Interest**

Pharmacokinetics and pharmacodynamics of glucocorticoids and antibiotics drugs.

Use of pharmacokinetic/pharmacodynamic modeling in drug development.

### **Affiliations**

American College of Clinical Pharmacology

American Association of Pharmaceutical Scientists

American Pharmacists Association

Florida Pharmacy Association

German Pharmaceutical Society

American Society for Clin. Pharmacology and Therapeutics

American Association of Colleges of Pharmacy

American Society for Microbiology

American Society of Pharmacometrics

International Society for Anti-infective Pharmacology

Paul Ehrlich Society

### **Other Activities**

President, American College of Clinical Pharmacology (2006-2008)

President, International Society for Anti-infective Pharmacology (2004-2006)

Program Co-Chair, ISSX Annual Meeting, Orlando (2015)

Member, Nutrition and Therapeutics Committee of the NASA Space Medicine Program (2008-2011)

Member, Scientific Organizing Committee, 2<sup>nd</sup> Symposium on Antimicrobial Resistance in Animals and the Environment, Tours (2007)

Co-Chair, EUFEPS Conference on Optimizing Drug Discovery and Development- Integrating Systems Approaches into Pharmaceutical Sciences, Basel (2007)

Member, Program Committee, Pharmaceutical Sciences World Congress, Amsterdam (2007)

Member, Advisory Committee for Pharmaceutical Science Clinical Pharmacology Subcommittee, FDA (2002-2006)

Member, Scientific Advisory Board, Bavarian Academy of Clinical Pharmacy (2006-present)

Program Chairman, National Meeting of the American College of Clinical Pharmacology (2003)

Member of the International Pharmaceutical Education Advisory Committee of the American Association of Colleges of Pharmacy (2001-03)

Chair, AAPS Microdialysis Focus Group (2003)

Secretary, American College of Clinical Pharmacology (1996-00)

Council Member, International Society for Anti-infective Pharmacology (1999-02)

Member of the Board of Regents, American College of Clinical Pharmacology (1991-00)

Member of the FDA Expert Panel on Oral Inhalation and Nasal Drug Products (OINDP) (1999-00)

Member of AAPS/PPDM Program Committee (1996/97)

Member, National RCMI Advisory Board, Florida A&M University (1992-05).

Member of Credentials Committee, American College of Clinical Pharmacology (1990-00).

Member of the Nutrition and Therapeutics Integrated Project Team of the NASA-JSC Space Medicine Program (1997-04).

Member of the AAPS Globalization Committee (1995)

National Chair of the AACP Meeting of Department Chairs of Pharmaceutics (1992).

Member of the Graduate Education and Research Committee (PDD) of the American Association of Pharmaceutical Scientists (1992-1993).

Program Chairman, National Meeting of the American College of Clinical Pharmacology (1992).



Chairman, Southeastern Regional Meeting of the American Association of Pharmaceutical Scientists 1991 and 1992.

President of the Southeastern Chapter of the American College of Clinical Pharmacology (1990-91).

Member of Scientific Excellence Committee, American Association of Pharmaceutical Scientists (1990-91).

Member of Scientific Program Committee, American College of Clinical Pharmacology (1989-1992, 1997).

Reviewer for J. Pharm. Sci., Int. J. Pharm., Pharm. Res., J. Pharmacokin. Biopharm., Life Sci., Biopharm. Drug Disp. and J. Pharm. Biomed. Anal.

Member of several ad-hoc NIH Study Sections (NCI, NIAID).  
Grant-Reviewer for the National Science Foundation.  
Grant Reviewer for the Italian Ministry for University and Research.

Book-Reviewer for Am. J. Pharm. Ed., J. Am. Chem. Soc. and J. Pharm. Sci.

### **Editorial Advisory Boards**

Editor, International Journal of Clinical Pharmacology and Therapeutics.

US-Editor, Editorial Board, Die Pharmazie.

Associate Editor, Journal of Clinical Pharmacology.

Editor, International Journal of Anti-Infective Agents.

Member, Honorary Editorial Board, Clinical Pharmacokinetics.

Member, Editorial Board, Journal of Pharmacokinetics and Pharmacodynamics.

Member, Editorial Board, Journal of Pharmaceutical Sciences

Member, Editorial Board, Planta Medica

Member, Editorial Board, CPT: Pharmacometrics and Systems Pharmacology

Member, Editorial Board, GMS Infectious Diseases.

Member, Editorial Board, Clinical Research and Regulatory Affairs.

Member, Editorial Board, Clinical Pharmacology in Drug Development

Member, Editorial Board, Antimicrobial Agents and Chemotherapy (until 2012)

Associate Editor, European Journal of Pharmaceutical Sciences (until 2016)

### **Special Issues - Guest Editorships**

V. Butterweck, H. Derendorf  
Herb-Drug Interactions, *Planta Medica* 78, September 2012.

W. Couet, H. Derendorf  
7<sup>th</sup> International Symposium on Microdialysis  
*Eur. J. Pharm. Sci.* 57, June 2014.

### **Patents**

H. Derendorf, M. Müller: Patent US 6,904,309 B2 (June 7, 2005), Microdialysis probes and methods of use.

### List of Publications

1. P. Rohdewald, H. Derendorf, C.E. Elger, O. Knoll  
Quantification of the attenuation of pain sensation through evoked potentials after the application of mild analgesics.  
Z. EEG-EMG 11, 199-204 (1980).
2. H. Derendorf  
Electroencephalography in drug research.  
Dtsch. Apoth. Ztg. 120, 1474-1476 (1980).
3. H. Derendorf, P. Rohdewald  
Pharmaceutical availability of analgesic derivatives of salicylic acid.  
Dtsch. Apoth. Ztg. 121, 493-498 (1981).
4. H. Derendorf, P. Rohdewald  
Pharmaceutical availability of analgesic derivatives of pyrazolone.  
Dtsch. Apoth. Ztg. 121, 549-552 (1981).
5. H. Derendorf, P. Rohdewald  
Measurement of analgesic action by subjective and objective parameters.  
In "Pain research - Pain measurement - Chest pain", ed. by A. Struppler and M. Gessler, pg. 143-150, Springer (1981).
6. H. Derendorf, P. Rohdewald  
Pharmaceutical availability of analgesic derivatives of p-aminophenol in tablets.  
Dtsch. Apoth. Ztg. 121, 653-656 (1981).
7. P. Rohdewald, H. Derendorf, C.E. Elger, O. Knoll  
Evoked potentials as objective parameters for the analgesic response of weak analgesics.  
Adv. in Neurology 32, 375-381 (1982).
8. P. Rohdewald, H. Derendorf, G. Drehsen, C.E. Elger, O. Knoll  
Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics.  
Pain 12, 329-341 (1982).

9. H. Derendorf, G. Drehsen, P. Rohdewald  
Cortical evoked potentials and saliva levels as basis  
for the comparison of pure analgesic to analgesic  
combinations.  
Pharmacology 25, 227-236 (1982).
10. H. Derendorf  
Phencyclidine - angel dust or devil's drug?  
Dtsch. Apoth. Ztg. 122, 2642-2646 (1982).
11. H. Derendorf, E.R. Garrett  
HPLC-Assay of methadone, phencyclidine and metabolites  
by post-column ion-pair extraction and "on-line"  
fluorescence detection of the counter-ion with  
applications.  
J. Pharm. Sci. 72, 630-635 (1983).
12. P. Rohdewald, G. Drehsen, E. Milsmann, H. Derendorf  
Relationship between saliva levels of metamizol  
metabolites, bioavailability and analgesic efficacy.  
Arzneimittelforschung (Drug Research) 33(II), 985-988  
(1983).
13. H. Derendorf, G. Drehsen, P. Rohdewald  
In vivo- in vitro- correlations of salicylate saliva  
levels and continuous flow cell dissolution rates.  
Int. J. Pharm. 15, 167-175 (1983).
14. H. Derendorf, A.A. El-Koussi, E.R. Garrett  
Electrochemical chromatographic determination of  
morphine - antagonists in biological fluids with  
applications.  
J. Pharm. Sci. 73, 621-624 (1984).
15. H. Derendorf, G. Drehsen, P. Rohdewald  
Antipyrine - new light on an old drug.  
Pharm. Res. 1, 225-229 (1984).
16. P. Rohdewald, G. Drehsen, H. Derendorf  
Phenazone, the underestimated analgesic.  
Pharm. Ztg. 129, 552-558 (1984).
17. G. Drehsen, H. Derendorf, P. Rohdewald  
Pain relief- but when ?  
Münch. Med. Wschr. 126, 736-738 (1984).

18. P. Rohdewald, J. Rehder, G. Drehsen, G. Hochhaus, H. Derendorf, H. Möllmann  
Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma.  
J. Pharm. Biomed. Anal. 3, 565-573 (1985).
19. H. Derendorf, H. Möllmann, P. Rohdewald, J. Rehder, E.W. Schmidt  
Kinetics of methylprednisolone and its hemisuccinate ester.  
Clin. Pharm. Ther. 37, 502-507 (1985).
20. R.L. Yost, H. Derendorf  
Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids.  
J. Chromatogr. 341, 131-138 (1985).
21. H. Derendorf, P. Rohdewald, H. Möllmann, J. Rehder, J. Barth, D. Neveling  
Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate.  
Biopharm. Drug Disp. 6, 423-432 (1985).
22. E.R. Garrett, H. Derendorf, A. Mattha  
Pharmacokinetics of morphine and its surrogates VI: HPLC-Analyses and pharmacokinetics of methadone and its derived metabolites in dogs.  
J. Pharm. Sci. 74, 1203-1214 (1985).
23. H. Möllmann, P. Rohdewald, E.W. Schmidt, V. Salomon, H. Derendorf  
Pharmacokinetics of triamcinolone acetonide and its phosphate ester.  
Eur. J. Clin. Pharmacol. 29, 85-89 (1985).
24. P. Rohdewald, H. Derendorf, G. Drehsen, H.W. Granitzki, E. Neddermann  
The attenuation of experimental pain by pyrazolones. In "100 years pyrazolones", ed. by K. Brune and R. Lanz, Urban & Schwarzenberg, pg. 61-67 (1985).
25. H. Möllmann, J. Barth, K.M. Müller, P. Rohdewald, A. Grüner, H. Derendorf  
Pulmonary complications in intensive care patients-therapeutic approaches for the treatment of ARDS  
BGA-Schriften 486, 193-207 (1986).

26. H. Derendorf, P. Rohdewald, G. Hochhaus, H. Möllmann  
HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids.  
J. Pharm. Biomed. Anal. 4, 197-206 (1986).
27. H. Derendorf, G. Mullersman, J. Barth, A. Grüner, H. Möllmann  
Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate.  
Eur. J. Clin. Pharmacol. 31, 363-365 (1986).
28. G. Mullersman, H. Derendorf  
Ranitidine - rapid analysis in biological fluids and determination of erythrocyte partitioning.  
J. Chromatogr. 381, 385-391 (1986).
29. G. Mullersman, V.P. Gotz, W.L. Russell, H. Derendorf  
Lack of clinically significant in vitro and in vivo interactions between ranitidine and sucralfate.  
J. Pharm. Sci. 75, 995-998 (1986).
30. R.L. Yost, H. Derendorf  
Pharmacokinetics of cefotaxime and its metabolite in normal and morbidly obese patients.  
Ther. Drug Monitor. 8, 189-194 (1986).
31. H. Derendorf, H. Möllmann, A. Grüner, D. Haack, G. Gyselby  
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intraarticular administration.  
Clin. Pharm. Ther. 39, 313-317 (1986).
32. H. Möllmann, J. Rehder, P. Rohdewald, B.E. Braun, J. Barth, H. Derendorf, B. Holtmann, A. Grüner  
Exogenous and endogenous glucocorticoid plasma level after intramuscular administration of diclofenac and triamcinolone diacetate  
Med. Welt 37, 371-377 (1986).

33. H. Möllmann, J. Barth, D. Haack, A. Grüner, D. Stroband G. Gyselby, P. Rohdewald, H. Derendorf  
Comparison of the kinetics and dynamics of intraarticular glucocorticoid suspensions.  
Akt. Rheumatol. 11, 55-60 (1986).
34. H. Derendorf, M. Kaltenbach  
Coulometric high-performance liquid chromatographic-analysis morphine in biological fluids.  
J. Pharm. Sci. 75, 1198-1200 (1986).
35. P. Rohdewald, H. Möllmann, J. Barth, J. Rehder, H. Derendorf  
Pharmacokinetics of dexamethasone and its phosphate ester.  
Biopharm. Drug Disp. 8, 205-212 (1987).
36. S.A. Stout, H. Derendorf  
Local treatment of respiratory infections with antibiotics.  
Drug Intel. Clin. Pharm. 21, 322-329 (1987).
37. H. Derendorf  
Erythrocyte - binding of cephalosporins.  
J. Pharm. Pharmacol. 39, 129-131 (1987).
38. P. Rohdewald, J. Rehder, H. Möllmann, J. Barth, H. Derendorf  
Pharmacokinetics and pharmacodynamics of prednisolone after extremely high doses of prednisolone hemisuccinate.  
Arzneimittelforschung (Drug Research), 37 (I), 194-198 (1987).
39. G. Mullersman, S. Toufflin, H. Derendorf  
HPLC analysis of buprenorphine in plasma and urine using coulometric detection.  
J. Pharm. Biomed. Anal. 5, 303-308 (1987).
40. S.A. Stout, C.M. Riley, H. Derendorf  
The correlation between the pharmacokinetics of melphalan and the pharmacodynamic response of neuroblastoma cells treated in vitro.  
Proc. Biopharm. Pharmacokin. II, 252-260 (1987).

41. H. Derendorf  
Pharmacokinetic evaluation of cefotaxime in normal and obese subjects.  
Proc. Biopharm. Pharmacokin. III, 11-18 (1987).
42. H. Möllmann, P. Rohdewald, J. Barth, H. Derendorf  
Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo.  
Med. Klinik 83, 159-163 (1988).
43. G. Mullersman, H. Derendorf, M.E. Brewster, K.S. Estes, N. Bodor  
HPLC-Assay of a CNS directed estradiol chemical delivery system and its application after intravenous administration to rats.  
Pharm. Res. 5, 172-177 (1988).
44. H. Möllmann, P. Rohdewald, J. Barth, H. Derendorf, C. Möllmann, M. Verho.  
Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.  
Pharm. Res. 5, 509-513 (1988).
45. L.A. Berglund, H. Derendorf, J.W. Simpkins  
Desensitization of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion.  
Endocrinology 122, 2718-2726 (1988).
46. R.W. Townsend, V. Keuth, K. Embil, G. Mullersman, J.H. Perrin, H. Derendorf  
High-performance liquid chromatographic determination of conjugated estrogens in tablets.  
J. Chromatogr. 450, 414-419 (1988).
47. J. Limberg, H. Derendorf  
Pharmacy education in the U.S.A.  
Deut. Apoth. Ztg. 128, 2458-2461 (1988).
48. E.W. Schmidt, H.W. Möllmann, B.E. Braun, J. Barth, H. Derendorf  
Circadian theophylline levels after single and multiple administration of a sustained released dosage form.  
Therapiewoche 38, 2046-2051 (1988).



49. M.E. Brewster, K.S. Estes, T. Loftsson, R. Perchalski  
H. Derendorf, G. Mullersman, N. Bodor  
Improved delivery through biological membranes XXXI:  
Solubilization and stabilization of an estradiol  
chemical delivery system by modified  $\beta$ -cyclodextrins.  
J. Pharm. Sci. 77, 981-985 (1988).
50. H. Derendorf  
Pharmacokinetic evaluation of  $\beta$ -lactam antibiotics.  
J. Antimicrob. Chemother. 24, 407-413 (1989).
51. H. Möllmann, J. Barth, D. Schött, W.T. Ulmer, H.  
Derendorf, G. Hochhaus  
Differential therapeutic aspects of the treatment of  
toxic gas poisoning with glucocorticoids.  
Intensivmed. 26, 2-15 (1989).
52. M.E. Brewster, T. Loftsson, K.E. Estes, G. Mullersman,  
H. Derendorf, N. Bodor  
Water soluble complexes of a brain-targeted drug  
delivery system.  
Proc. Intl. Symp. Cyclodextr. 4, 399-405 (1989).
53. H. Möllmann, P. Rohdewald, J. Barth, M. Verho, H.  
Derendorf  
Pharmacokinetics and dose linearity testing of  
methylprednisolone phosphate.  
Biopharm. Drug Disp. 10, 453-464 (1989).
54. H. Derendorf, H. Möllmann, P. Rohdewald, D. Strohsband,  
J. Barth, G. Hochhaus  
Pharmacokinetic aspects of intra-articular  
administration of glucocorticoids.  
in Willert, Heuck (ed.), New Results in Osteology,  
Springer, Berlin, pp. 474-481 (1989).
55. J. Barth, H.W. Möllmann, H. Derendorf, G. Hochhaus  
Pharmacodynamic interactions in systemic  
glucocorticoid therapy.  
in Willert, Heuck (ed.), New Results in Osteology,  
Springer, Berlin, pp. 533-541 (1989).
56. J. Barth, A. Möllmann, G. Hochhaus, H. Derendorf, H.W.  
Möllmann  
Absorption and transfer of water-soluble  
glucocorticoids through pulmonary membranes.  
Atemw.-Lungenkrkh. 15, 412-416 (1989).

57. E.W. Schmidt, H. Derendorf, B. Rasche, H.W. Möllmann  
Clinical and pharmacokinetic evaluation for the replacement therapy of  $\alpha_1$ -protease-inhibitor in patients with congenital  $\alpha_1$ -protease-inhibitor deficiency and lung emphysema.  
Atemw.-Lungenkrkh. 15, 479-488 (1989).
58. H.G. Schaefer, D. Harrison, M.P. Hocking, J. Limberg, H. Derendorf  
Effect of truncal vagotomy and partial gastrectomy on the pharmacokinetics of propranolol enantiomers in dogs.  
J. Pharm. Sci. 79, 292-294 (1990).
59. H. Schreier, G. Hochhaus, R.J. Prankerd, H. Derendorf, M.E. Brewster, R.A. Baughman  
Pharmaceutical Biotechnology: A new graduate course at the University of Florida College of Pharmacy.  
Am. J. Pharm. Educ. 54, 46-50 (1990).
60. J. Limberg, M. LeBel, H. Derendorf  
Evaluation of free tissue concentrations of fleroxacin after oral administration.  
Pharm. Res. 7, 422-424 (1990).
61. E. Brunt, J. Limberg, H. Derendorf  
High performance liquid chromatographic-assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolon antibiotic.  
J. Pharm. Biomed. Anal. 8, 67-71 (1990).
62. H. Derendorf, H. Möllmann, J. Barth  
Comparative pharmacokinetic evaluation of glucocorticoids after intraarticular administration.  
Akt. Rheumatol. 15, 145-153 (1990).
63. F.F.T. Ververs, H.G. Schaefer, J.F. Lefevre, L.M. Lopez, H. Derendorf  
Simultaneous HPLC-assay of propranolol, diltiazem and diltiazem-metabolites in human plasma with application.  
J. Pharm. Biomed. Anal. 8, 535-539 (1990).

64. P. Adland-Davenport, M.P. Brown, J.D. Robinson, H. Derendorf  
Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis.  
Equine Vet. J. 22, 18-22 (1990).
65. H. Derendorf, H. Möllmann, G. Voortman, F.A. van den Ouweland, L.B.A. van de Putte, G. Gevers, J. Dequeker, E. van Vliet-Daskalopoulou  
Pharmacokinetics of rimexolone after intra-articular administration.  
J. Clin. Pharmacol. 30, 476-479 (1990).
66. K. Dietzel, V. Keuth, K.S. Estes, M.E. Brewster, R. Clemmons, R. Vistelle, N.S. Bodor, H. Derendorf  
A redox-based system that enhances delivery of estradiol to the brain: Pharmacokinetic evaluation in the dog.  
Pharm. Res. 7, 879-883 (1990).
67. H.G. Schaefer, H. Spahn, L.M. Lopez, H. Derendorf  
Simultaneous determination of propranolol and 4-hydroxypropranolol enantiomers after chiral derivatization using reversed phase high-performance liquid chromatography.  
J. Chromatogr. 527, 351-359 (1990).
68. J. Limberg, D. Harrison, M.P. Hocking, H. Derendorf  
Theophylline absorption and gastric emptying after partial gastrectomy in dogs.  
J. Pharm. Sci. 79, 968-969 (1990).
69. M. Kaltenbach, S.H. Curry, H. Derendorf  
Extent of drug absorption at the time of peak plasma concentration in an open one-compartment body model with first-order absorption.  
J. Pharm. Sci. 79, 462 (1990).
70. K. Dietzel, K.S. Estes, M.E. Brewster, N.S. Bodor, H. Derendorf  
The use of hydroxypropyl- $\beta$ -cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs.  
Int. J. Pharm. 59, 225-230 (1990).

71. J. Barth, H. Fett, M. Pörtner, B.E. Braun, H. Möllmann, P. Rohdewald, J. Krämer, H. Derendorf  
Exogenous and endogenous glucocorticoid levels after epidural administration of glucocorticoid crystal suspensions in different volumes.  
Orthop. Praxis 26, 729-736 (1990).
72. H. Möllmann, B. Armbruster, J. Barth, H. Derendorf, O.W. Flörke, G. Hochhaus, C.R. Möllmann, P. Rohdewald, E.W. Schmidt  
Distribution and aggregation of crystals in glucocorticoid suspensions.  
Akt. Rheumatol. 15, 101-124 (1990).
73. C.D. Hepler, L.M. Strand, H. Derendorf  
The pharmacist and pharmaceutical care - future opportunities and responsibility.  
Pharmazeutische Zeitung 135, 3087-3092 (1990).
74. K.S. Estes, V. Keuth, K. Dietzel, M.E. Brewster, N.S. Bodor, H. Derendorf  
A redox-based chemical delivery system that enhances estradiol to the brain: Disposition studies in the rat.  
Pharm. Res. 8, 1180-1185 (1991).
75. O. Makil, M. Kaltenbach, J. Limberg, D. Harrison, M.P. Hocking, H. Derendorf  
Pharmacokinetics of ranitidine after partial gastrectomy in dogs.  
J. Pharm. Sci. 80, 1034-1036 (1991).
76. H. Derendorf, H. Möllmann, J. Barth, C. Möllmann, S. Tunn, M. Krieg  
Pharmacokinetics and oral bioavailability of hydrocortisone.  
J. Clin. Pharmacol. 31, 473-476 (1991).
77. H. Möllmann, J. Barth, C. Möllmann, S. Tunn, M. Krieg, H. Derendorf  
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate.  
J. Pharm. Sci. 80, 835-836 (1991).

78. H. Derendorf, H. Möllmann, M. Krieg, S. Tunn, C. Möllmann, J. Barth, H.J. Röthig  
Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.  
Pharm. Res. 8, 263-268 (1991).
79. B. Wichert, H. Schreier, H. Derendorf  
Sensitive HPLC-assay for the determination of amikacin in human plasma.  
J. Pharm. Biomed. Anal. 9, 251-254(1991).
80. C.D. Page, M. Mautino, H. Derendorf, W. Mechlinski  
Multiple-dose pharmacokinetics of ketoconazole administered orally to gopher tortoises (*Gopherus polyphemus*).  
J. Zoo & Wildlife Med. 22, 191-198 (1991).
81. T. Loftsson, M.E. Brewster, H. Derendorf, N. Bodor  
2-Hydroxypropyl- $\beta$ -cyclodextrin: Properties and usage in pharmaceutical formulations.  
PZ Wissenschaft 4, 5-10 (1991).
82. C.D. Page, M. Mautino, H. Derendorf, J.P. Anhalt  
Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants.  
J. Zoo & Wildlife Med. 22, 409-416 (1991).
83. K.H. Rand, K. Gibbs, H. Derendorf, J. Graham-Pole  
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients.  
J. Clin. Pharmacol. 31, 1151-1154 (1991).
84. K.S. Estes, P. Dewland, M.E. Brewster, H. Derendorf, N. Bodor  
A redox-based chemical delivery system (CDS) applied to estradiol.  
PZ Wissenschaft 4, 153-158 (1991).
85. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth  
A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids.  
J. Pharm. Biomed. Anal. 9, 761-767 (1991).

86. M.A. Longer, H.G. Schaefer, H. Derendorf  
Fundamentals of assessing bioequivalence studies.  
PZ Wissenschaft 5, 15-22 (1992).
87. G. Hochhaus, L.S. Chen, A. Ratka, P. Druzgala, J. Howes, N. Bodor, H. Derendorf  
Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.  
J. Pharm. Sci. 81, 1210-1215 (1992).
88. H. Schreier, K.J. McNicol, M. Ausborn, D.M. Soucy, H. Derendorf, A.A. Stecenko, R.J. Gonzalez-Rothi  
Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep.  
Int. J. Pharmac. 87, 183-193 (1992).
89. S. Tunn, H. Möllmann, J. Barth, H. Derendorf, M. Krieg  
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration.  
Clin. Chem. 38, 1491-1494 (1992).
90. G. Hochhaus, R. Hochhaus, G. Werber, H. Derendorf, H. Möllmann  
A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids  
Biomedical Chromatography 6, 283-286 (1992).
91. H. Möllmann, H. Derendorf, J. Barth, C. Möllmann, S. Tunn, M. Krieg  
Bioavailability of hydrocortisone after rectal administration of hydrocortisone acetate foam.  
Med. Welt 43, 609-615 (1992).
92. H. Derendorf  
Choice of appropriate pharmacokinetic-pharmacodynamic models for predicting drug effects.  
Klin. Pharmakol. aktuell 3, 19-21 (1992).
93. J. Barth, M. Damoiseaux, H. Möllmann, K.H. Brandis, G. Hochhaus, H. Derendorf  
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration.  
Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 317-324 (1992).

94. S. Mohammed, M. Butschkau, H. Derendorf  
A reversed phase liquid chromatographic method for the determination of codeine in biological fluids with application.  
J. Liq. Chromatogr. 16, 2325-2334 (1993).
95. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth, M. Krieg, S. Tunn, C. Möllmann  
Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids.  
J. Clin. Pharmacol. 33, 115-123 (1993).
96. T. Wagner, J. Barth, A. Tromm, C. Bigalke, S. Tunn, M. Krieg, H. Derendorf, H. Möllmann, B. May, G. Hochhaus  
Bioavailability of hydrocortisone after single and multiple dosing of hydrocortisone acetate foam in patients with chronic distal inflammatory bowel disease and healthy controls  
Akt. Koloproktol. 10, 223-226 (1993).
97. S.S. Mohammed, M. Christopher, P. Mehta, A. Kedar, S. Gross, H. Derendorf  
Increased erythrocyte and protein binding of codeine in patients with sickle cell disease  
J. Pharm. Sci 82, 1112-1117 (1993).
98. S.S. Mohammed, M. Ayass, P. Mehta, A. Kedar, S. Gross, H. Derendorf  
Codeine disposition in sickle cell patients compared with healthy volunteers  
J. Clin. Pharmacol. 33, 811-815 (1993).
99. J. Barth, G. Hochhaus, H. Derendorf, K.H. Lehr, T. Hoehler, H. Möllmann  
Prednicarbate after different forms of administration: plasma levels of drug and metabolites and effects on endogenous cortisol levels in humans  
Curr. Probl. Dermatol. 21, 147-156 (1993).
100. J. Barth, K.H. Lehr, H. Derendorf, H. Möllmann, T. Höhler, G. Hochhaus  
Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration.  
Skin Pharmacol. 6, 179-186 (1993).

101. J. Barth, H. Möllmann, B. Armbruster, W. Flörke, G. Hochhaus, C. Möllmann, H. Derendorf  
Analysis of shape, particle size, distribution and aggregation of the crystals of sodium cromoglycate and nedocromil sodium  
Eur. J. Hosp. Pharm. 3, 20-28 (1993).
102. H. Möllmann, G. Hochhaus, A. Tromm, J. Barth, C. Bigalke, B. May, A. Möllmann, U. Schwegler, H. Derendorf, S. Tunn, M. Krieg  
Topical use of steroids in gastroenterology  
In "Inflammatory Bowel Diseases", ed. by J. Schölmerich, W. Kruis, H. Goebell, W. Hohenberger and V. Gross, pg. 343-349, Kluwer Academic Publishers, Dordrecht (1993).
103. M.L. Kaltenbach, S.S.Mohammed, G. Mullersmann, J.H. Perrin, H. Derendorf  
Pharmacokinetic evaluation of two ibuprofen-codeine combinations  
Int. J. Clin. Pharmacol. Ther. 32, 210-214 (1994).
104. G.N. Henderson, P.O. Whalen, R.A. Darr, S.H. Curry, H. Derendorf, T.G. Baumgartner, P.W. Stacpoole  
Development of an oral drug formulation for dichloroacetate and thiamine  
Drug Developm. Ind. Pharm. 20, 2425-2437 (1994).
105. H. Derendorf  
Pharmacokinetic/pharmacodynamic consequences of space flight  
J. Clin. Pharmacol. 34, 684-691 (1994).
106. H. Schreier, K.J. McNicol, D.B. Bennett, Z. Teitelbaum, H. Derendorf  
Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep  
Pharm. Res. 11, 1056-1059 (1994).
107. A. Nolting, H. Derendorf  
Pharmacokinetic Profile: Cefprozidime  
Antiinf. Drugs Chemoth. 12, 31-35 (1994).



108. R. Mies, J. van der Aa, C. Dixon, M. Kaltenbach, H. Derendorf, N. Gravenstein  
Computer-modulated patient-controlled analgesia:  
Preliminary evaluation of a prototype  
*Regional Anesthesia* 19, 270-276 (1994).
109. H. Derendorf  
Pharmacodynamic aspects of systemic drug delivery  
*Drug Developm. Ind. Pharm.* 20, 485-502 (1994).
110. J. Barth, H. Möllmann, T. Wagner, G. Hochhaus, H. Derendorf  
The validity of 'equivalent doses' in corticosteroid therapy - a comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone  
*Dtsch. Med. Wschr.* 119, 1671-1676 (1994).
111. H. Schreier, J. Engel, K.J. McNicol, H. Derendorf, K. Groot, A.V. Schally  
Systemic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep  
*Eur. J. Pharm. Sci.* 2, 303-306 (1994).
112. G. Hochhaus, R.J. Gonzalez-Rothi, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa  
Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats  
*Pharm. Res.* 12, 134-137 (1995).
113. H. Möllmann, S. Balbach, G. Hochhaus, J. Barth, H. Derendorf  
Pharmacokinetic-pharmacodynamic correlations of corticosteroids  
In "Handbook of pharmacokinetic-pharmacodynamic correlations", ed. by H. Derendorf and G. Hochhaus, CRC Press, Boca Raton, 323-362 (1995).
114. A. Nolting, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of antibiotics  
In "Handbook of pharmacokinetic-pharmacodynamic correlations", ed. by H. Derendorf and G. Hochhaus, CRC Press, Boca Raton, 363-388 (1995).

115. G. Hochhaus, H. Derendorf  
Dose optimization based on pharmacokinetic-  
pharmacodynamic modeling  
In "Handbook of pharmacokinetic-pharmacodynamic  
correlations", ed. by H. Derendorf and G. Hochhaus,  
CRC Press, Boca Raton, 79-120 (1995).
116. H. Derendorf, G. Hochhaus, S. Rohatagi, H. Möllmann,  
J. Barth, H. Sourgens, M. Erdmann  
Pharmacokinetics of triamcinolone acetonide after  
intravenous, oral and inhaled administration  
J. Clin. Pharmacol. 35, 302-305 (1995).
117. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H.  
Derendorf  
Pharmacokinetic/pharmacodynamic evaluation of  
deflazacort in comparison to methylprednisolone and  
prednisolone  
Pharm. Res. 12, 1096-1100 (1995).
118. L.B. Panton, G.J. Guillen, L. Williams, J.E. Graves,  
C. Vivas, M. Cediell, M.L. Pollock, L. Garzarella, J.  
Krumerman, H. Derendorf, D.T. Lowenthal  
The lack of effect of aerobic exercise training on  
propranolol pharmacokinetics in young and elderly  
adults  
J. Clin. Pharmacol. 35, 885-894 (1995).
119. A. Nolting, H. Derendorf  
Pharmacokinetic Profile: Ceftriaxone  
Antiinf. Drugs Chemoth. 13, 27-31 (1995).
120. S. Rohatagi, G. Hochhaus, H. Möllmann, J Barth and H.  
Derendorf  
Pharmacokinetic interaction between endogenous  
cortisol and exogenous corticosteroids  
Die Pharmazie, 50, 610-613 (1995).
121. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, E.  
Galia, M. Erdmann, H. Sourgens, H. Derendorf  
Pharmacokinetic/pharmacodynamic evaluation of  
triamcinolone acetonide after intravenous, oral and  
inhaled administration  
J. Clin. Pharmacol. 35, 1187-1193 (1995).

122. S. Rohatagi, U. Täuber, K. Richter, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of cortisol  
suppression after oral administration of fluocortolone  
J. Clin. Pharmacol. 36, 311-314 (1996).
123. S. Rohatagi, A. Bye, A. Mackie, H. Derendorf  
Mathematical modeling of cortisol circadian rhythm and  
cortisol suppression  
Eur. J. Pharm. Sci. 4, 341-350 (1996).
124. T. Dalla Costa, H. Derendorf  
AUC - a general target for the optimization of dosing  
regimens of antibiotics?  
Ann. Pharmacother. 30, 1024-1028 (1996).
125. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H.  
Derendorf, M. Krieg, H. Weisser, A. Möllmann  
Pharmacokinetics and pharmacodynamics of cloprednol  
Int. J. Clin. Pharmacol. Ther. 34, 1-5 (1996).
126. H. Möllmann, M. Wagner, J. Barth, H. Derendorf, M.  
Schulz  
Fluticasone, a new glucocorticoid for inhalation (in  
German)  
Pharm. Ztg. 141, 3662-3672 (1996).
127. A. Kovar, C. Schäfer, H. Derendorf  
Pharmacokinetic Profile: Cefepime  
Antiinf. Drugs Chemoth. 14, 95-103 (1996).
128. A. Nolting, T. Dalla Costa, R. Vistelle, K.H. Rand, H.  
Derendorf  
Determination of free extracellular concentrations of  
piperacillin by microdialysis  
J. Pharm. Sci. 85, 369-372 (1996).
129. A. Nolting, T. Dalla Costa, K.H. Rand, H. Derendorf  
Pharmacokinetic-pharmacodynamic modelling of the  
antibiotic effect of piperacillin  
Pharm. Res. 13, 91-96 (1996).
130. H. Derendorf, T. Dalla Costa  
Pharmacokinetics of piperacillin, tazobactam and its  
metabolite in renal impairment  
Int. J. Clin. Pharmacol. Ther. 34, 482-488 (1996).

131. H. Möllmann, J. Barth, G. Hochhaus, A. Möllmann, H. Derendorf, A. Tromm  
Concepts of corticosteroid therapy of chronic inflammatory bowel disease: topical vs. systemic administration (in German)  
In "Corticosteroid therapy of chronic inflammatory bowel disease", ed. by B. May and H. Möllmann, Falk Foundation, 69-90 (1996).
132. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R. Hochhaus  
Pharmacodynamic aspects of corticosteroid effects (in German)  
In "Corticosteroid therapy of chronic inflammatory bowel disease", ed. by B. May and H. Möllmann, Falk Foundation, 91-117 (1996).
133. H. Derendorf, H. Möllmann, G. Hochhaus, J. Barth  
Kinetic/dynamic interrelationships as basis for rational therapy (in German)  
In "Corticosteroid therapy of chronic inflammatory bowel disease", ed. by B. May and H. Möllmann, Falk Foundation, 119-135 (1996).
134. H. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A. Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth  
Pharmacokinetics and pharmacodynamics of budesonide-pH-modified release capsules (in German)  
In "Corticosteroid therapy of chronic inflammatory bowel disease", ed. by B. May and H. Möllmann, Falk Foundation, 149-167 (1996).
135. R. Gonzalez-Rothi, S. Suarez, G. Hochhaus, H. Schreier, A. Lukyanov, H. Derendorf, T. Dalla Costa  
Pulmonary targeting of liposomal triamcinolone acetonide phosphate  
Pharm. Res. 13, 1699-1703 (1996).
136. B.G. Danielson, T. Salmonson, H. Derendorf, P. Geisser  
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single i.v. dose in healthy volunteers  
Arzneimittelforschung (Drug Research) 46, 615-621 (1996).

137. A. Suri, M. Kaltenbach, B. Grundy, H. Derendorf  
Pharmacodynamic evaluation of codeine using tooth pulp  
evoked potentials  
J. Clin. Pharmacol. 36, 1126-1131 (1996).
138. S. Rohatagi, A. Bye, C. Falcoz, A. Mackie, B. Meibohm,  
H. Möllmann, H. Derendorf  
Dynamic modeling of cortisol reduction after inhaled  
administration of fluticasone propionate  
J. Clin. Pharmacol. 36, 938-941 (1996).
139. H. Möllmann, J. Barth, G. Hochhaus, A. Möllmann, H.  
Derendorf, A. Tromm  
Principles of topical versus systemic corticoid  
treatment in inflammatory bowel disease  
in 'Glucocorticoid Therapy in Chronic Inflammatory  
Bowel Disease', ed. by H. Möllmann and B. May, Kluwer,  
42-60 (1996).
140. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R.  
Hochhaus  
Pharmacodynamic aspects of glucocorticoid action  
in 'Glucocorticoid Therapy in Chronic Inflammatory  
Bowel Disease', ed. by H. Möllmann and B. May, Kluwer,  
61-79 (1996).
141. H. Derendorf, H. Möllmann, G. Hochhaus, J. Barth  
Kinetic/dynamic interrelationships as basis for  
rational therapy  
in 'Glucocorticoid Therapy in Chronic Inflammatory  
Bowel Disease', ed. by H. Möllmann and B. May, Kluwer,  
80-98 (1996).
142. H. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A.  
Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth  
Pharmacokinetics and pharmacodynamics of budesonide  
pH-modified release capsules  
in 'Glucocorticoid Therapy in Chronic Inflammatory  
Bowel Disease', ed. by H. Möllmann and B. May, Kluwer,  
107-120 (1996).
143. A. Suri, B. Grundy, H. Derendorf  
Pharmacokinetics and pharmacodynamics of enantiomers  
of ibuprofen and flurbiprofen after oral  
administration  
Int. J. Clin. Pharm. Ther. 35, 1-8 (1997).

144. H. Sourgens, H. Derendorf, H. Schifferer  
Pharmacokinetic profile of cefaclor  
Int. J. Clin. Pharmacol. Ther. 35, 374-380 (1997).
145. A. Suri, K.S. Estes, G. Geisslinger, H. Derendorf  
Pharmacokinetic-pharmacodynamic relationships for  
analgesics  
Int. J. Clin. Pharmacol. Ther. 35, 307-323 (1997).
146. M. Brewster, W. Anderson, A. Webb, L.M. Pablo, D.  
Meinsma, D. Moreno, H. Derendorf, N. Bodor, E. Pop  
Evaluation of a brain-targeting zidovudine chemical  
delivery system in dogs  
Antimicrob. Agents Chemother. 41, 122-128 (1997).
147. A. Kovar, A. Nolting, H. Derendorf  
Microdialysis for the determination of unbound tissue  
concentrations (in German)  
PharmUZ 26, 17-23 (1997).
148. A. Kovar, T. Dalla Costa, H. Derendorf  
Comparison of plasma and free tissue levels of  
ceftriaxone in rats using microdialysis  
J. Pharm. Sci. 86, 52-56 (1997).
149. G.N. Henderson, S.H. Curry, H. Derendorf, E.C. Wright,  
P.W. Stacpoole  
Pharmacokinetics of dichloroacetate in adult patients  
with lactic acidosis  
J. Clin. Pharmacol. 37, 416-425 (1997).
150. M.E. Brewster, W.R. Anderson, D. Meinsma, D. Moreno,  
A.I. Webb, L. Pablo, K.S. Estes, H. Derendorf, N.  
Bodor, R. Sawchuk, B. Cheung, E. Pop  
Intravenous and oral pharmacokinetic evaluation of a  
2-hydroxypropyl- $\beta$ -cyclodextrin-based formulation of  
carbamazepine in the dog: Comparison with commercially  
available tablets and suspensions  
J. Pharm. Sci. 86, 335-339 (1997).
151. B. Meibohm, H. Derendorf  
Basic concepts of pharmacokinetic/pharmacodynamic  
(PK/PD) modeling  
Int. J. Clin. Pharmacol. Ther. 35, 401-413 (1997).

152. T. Dalla Costa, A. Nolting, K. Rand, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of the in-  
vitro antiinfective effect of piperacillin-tazobactam  
combinations  
Int. J. Clin. Pharmacol. Ther. 35, 426-433 (1997).
153. H. Derendorf, H. Möllmann, G. Hochhaus, B. Meibohm, J.  
Barth  
Clinical PK/PD modeling as a tool in drug development  
of corticosteroids  
Int. J. Clin. Pharmacol. Ther. 35, 481-488 (1997).
154. B. Meibohm, G. Hochhaus, S. Rohatagi, H. Möllmann, J.  
Barth, M. Wagner, M. Krieg, R. Stöckmann, H. Derendorf  
Dependency of cortisol suppression on the  
administration time of inhaled corticosteroids  
J. Clin. Pharmacol. 37, 704-710 (1997).
155. S. Rohatagi, S. Kan, H. Derendorf  
Non-compartmental analysis of pharmacokinetic data  
after multiple intravenous and oral administration  
Pharmazie 52, 529-532 (1997).
156. G. Hochhaus, H. Möllmann, H. Derendorf, R.J. Gonzalez-  
Rothi  
Pharmacokinetic/pharmacodynamic aspects of aerosol  
therapy using glucocorticoids as a model  
J. Clin. Pharmacol. 37, 881-892 (1997).
157. H. Möllmann, H. Derendorf, J. Barth, B. Meibohm, M.  
Wagner, M. Krieg, H. Weisser, J. Knöllner, A. Möllmann,  
G. Hochhaus  
Pharmacokinetic/pharmacodynamic evaluation of systemic  
effects of flunisolide after inhalation  
J. Clin. Pharmacol. 37, 893-903 (1997).
158. A. Kovar, H. Derendorf  
Plasma and free tissue concentrations - significance  
for the evaluation of antibiotics (in German)  
Krankenhauspharmazie 18, 564-567 (1997).
159. S. Rohatagi, J. Barth, H. Möllmann, G. Hochhaus, A.  
Soldner, C. Möllmann, H. Derendorf  
Pharmacokinetics of methylprednisolone and  
prednisolone after single and multiple oral dosing  
J. Clin. Pharmacol. 37, 916-925 (1997).

160. M. Müller, B. Rohde, A. Kovar, A. Georgopoulos, H.G. Eichler, H. Derendorf  
Relationship between plasma and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis  
J. Clin. Pharmacol. 37, 1108-1113 (1997).
161. H. Derendorf  
Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety  
Resp. Med. 91A, 22-28 (1997).
162. G. Hochhaus, P. Froehlich, R. Hochhaus, A. Möllmann, H. Derendorf, H. Möllmann  
A selective HPLC/RIA for the determination of budesonide  
J. Pharm. Biomed. Anal. 17, 1235-1242 (1998).
163. H. Derendorf, G. Hochhaus  
Pharmacodynamic aspects of drug delivery  
Klin. Pharmakol. 15, 10-18 (1998).
164. H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, R. Stöckmann, M. Krieg, H. Weisser, C. Falcoz, H. Derendorf  
Pharmacokinetic and pharmacodynamic evaluation of fluticasone after inhaled administration  
Eur. J. Clin. Pharmacol. 53, 459-467 (1998).
165. D. Gravenstein, A. Suri, H. Derendorf, J. Koska  
Influence of plasma expansion on plasma protein binding of ketorolac  
J. Clin. Anesth. 10, 464-468 (1998).
166. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth  
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids  
J. Allergy Clin. Immunol. 101, S440-446 (1998).
167. E. Liang, H. Derendorf  
Pitfalls in pharmacokinetic multi-compartmental analysis  
J. Biopharm. Pharmacokin. 26, 247-260 (1998).



168. S.A. Lottenberg, D. Gianella-Neto, H. Derendorf, M. Rocha, A. Bosco, S.V. Carvalho, A.E. Moretti, A.C. Lerario, B.L. Wajchenberg  
Effect of fat distribution on the pharmacokinetics of cortisol in obesity  
Int. J. Clin. Pharm. Ther. 36, 501-505 (1998).
169. B. Meibohm, H. Möllmann, M. Wagner, G. Hochhaus, A. Möllmann, H. Derendorf  
The clinical pharmacology of fluticasone propionate  
Rev. Contemp. Pharmacother. 8, 535-549 (1998).
170. Hämmerlein, H. Derendorf, D. Lowenthal  
Pharmacokinetic and pharmacodynamic changes in the elderly - clinical implications  
Clin. Pharmacokin. 35, 49-64 (1998).
171. H. Sourgens, R. Hoerr, A. Biber, H. Steinbrede, H. Derendorf  
KA 672-HCl, a neuronal activator against dementia: Tolerability, safety and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers  
J. Clin. Pharm. 38, 373-381 (1998).
172. T. Dalla Costa, A. Nolting, A. Kovar, H. Derendorf  
Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis  
J. Antimicrob. Chemother. 42, 769-778 (1998).
173. H. Möllmann, M. Wagner, J. Barth, H. Derendorf, M. Schulz  
Broncholytics/Antiasthmatics - Fluticasone  
In "Offizin und Praxis 16/17", ed. by H. Morck, H. Liekfeld, L. Schneider, Govi-Verlag, 105-113 (1998).
174. S. Modric, A.I. Webb, H. Derendorf  
Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle, J. Vet. Pharmacol. Ther. 21, 444-452 (1998).
175. M. Wagner, R. Stöckmann, A.C. Möllmann, G. Hochhaus, H. Derendorf, J. Barth, H. Möllmann  
Fluticasone propionate: First long-acting inhaled corticosteroid  
Atemwegs- und Lungenerkrank. 25, 580-598 (1999).

176. A. de la Peña, H. Derendorf  
Pharmacokinetic properties of beta-lactamase inhibitors  
Int. J. Clin. Pharmacol. Ther. 37, 63-75 (1999).
177. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann, H. Derendorf  
A PK/PD approach to predict the cumulative cortisol suppression of inhaled corticosteroids  
J. Biopharm. Pharmacokin. 27, 127-147 (1999).
178. E.U. Graefe, H. Derendorf, M. Veit  
Pharmacokinetics and bioavailability of the flavonol quercetin in humans  
Int. J. Clin. Pharmacol. Ther. 37, 209-218 (1999).
179. I. Beierle, B. Meibohm, H. Derendorf  
Gender differences in pharmacokinetics and pharmacodynamics  
Int. J. Clin. Pharmacol. Ther. 37, 529-547 (1999).
180. B. Mayer, C. Mensik, S. Krishnaswami, H. Derendorf, H.G. Eichler, L. Schmetterer, M. Wolzt  
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans  
Br. J. Clin. Pharm. 47, 539-544 (1999).
181. B. Meibohm, H. Derendorf, H. Möllmann, P. Froehlich, A. Tromm, M. Wagner, S. Homrighausen, M. Krieg, G. Hochhaus  
Mechanism based PK/PD -model for the lymphocytopenia induced by endogenous and exogenous corticosteroids  
Int. J. Clin. Pharmacol. Ther. 37, 367-376 (1999).
182. H. Derendorf, B. Meibohm  
Modeling of pharmacokinetic/pharmacokinetic (PK/PD) relationships: Concepts and perspectives  
Pharm. Res. 16, 176-185 (1999).
183. C. Rojas, N.V. Nagaraja, H. Derendorf  
In vitro recovery of triamcinolone acetonide in microdialysis  
Pharmazie 55, 659-662 (2000).

184. D.H. Schweitzer, P.P.H. LeBrun, S. Krishnaswami, H. Derendorf  
Pharmacodynamic effects of an accidental triamcinolone acetonide overdose - a case study  
Neth. J. Med. 56, 12-16 (2000).
185. M. Schwahn, N.V. Nagaraja, H. Derendorf  
Population pharmacokinetic modeling of cetorelix, a novel LH-RH antagonist, and testosterone in rats and dogs  
Pharm. Res. 17, 328-335 (2000).
186. B. Pechstein, N.V. Nagaraja, R. Hermann, P. Romeis, M. Locher, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetorelix in healthy volunteers  
J. Clin. Pharmacol. 40, 266-274 (2000).
187. A. de la Peña, A. Gräbe, H. Derendorf  
Pharmacokinetics of beta-lactamase inhibitors in renal impairment (in German)  
Chemotherapy J. 9, 107-113 (2000).
188. S. Delacher, H. Derendorf, U. Hollenstein, M. Brunner, C. Joukhadar, S. Hofmann, A. Georgopoulos, H.G. Eichler, M. Müller  
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans  
J. Antimicrob. Chemother. 46, 733-739 (2000).
189. H. Derendorf, L. Lesko, P. Chaikin, W.A. Colburn, P. Lee, R. Miller, R. Powell, G. Rhodes, D. Stanski, J. Venitz  
Pharmacokinetic/pharmacodynamic modeling in drug research and development  
J. Clin. Pharmacol. 40, 1399-1418 (2000).
190. H. Derendorf, G. Hochhaus, S. Krishnaswami, B. Meibohm, H. Möllmann  
Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism  
Pharmazie 55, 223-227 (2000).

191. S. Krishnaswami, H. Möllmann, H. Derendorf, G. Hochhaus  
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma  
J. Pharm. Biomed. Anal. 22, 123-129 (2000).
192. N.V. Nagaraja, Y.J. Park, S. Jeon, C.D. Sands, H. Derendorf  
Population pharmacokinetics of digoxin in Korean patients  
Int. J. Clin. Pharmacol. Ther. 38, 291-297 (2000).
193. A. de la Peña, P. Liu, H. Derendorf  
Microdialysis in peripheral tissues  
Adv. Drug Deliv. Rev. 45, 189-216 (2000).
194. G. Hochhaus, J. Barrett, H. Derendorf  
Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20<sup>th</sup> century  
J. Clin. Pharmacol. 40, 908-917 (2000).
195. S. Krishnaswami, G. Hochhaus, H. Derendorf  
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy  
AAPS Pharmsci. (<http://www.pharmsci.org>) 2(3), article 22 (2000).
196. B. Meibohm, H. Derendorf  
Pharmacokinetics and pharmacodynamics of biotechnological drugs (in German)  
In "Pharmazeutische Biotechnologie", edited by O. Kayser and R.H. Müller, Wissenschaftliche Verlagsgesellschaft Stuttgart, p. 103-124 (2000).
197. N.V. Nagaraja, B. Pechstein, K. Erb, C. Klipping, R. Hermann, G. Niebch, H. Derendorf  
PK/PD modeling of cetorelix, a LH-RH antagonist, after subcutaneous administration in healthy postmenopausal women  
Clin. Pharm. Ther. 68, 617-625 (2000).
198. A. Kovar, T. Peters, N. Beier, H. Derendorf  
Pharmacokinetic/pharmacodynamic evaluation of eniporide  
J. Clin. Pharmacol. 41, 139-148 (2001).

199. G. Hochhaus, J. Barth, S. Al-Fayoumi, S. Suarez, H. Derendorf, H. Möllmann  
Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: A comparison with dexamethasone phosphate (DP)  
J. Clin. Pharmacol. 41, 425-434 (2001).
200. H. Derendorf, G. Hochhaus, H. Möllmann  
Evaluation of pulmonary absorption using pharmacokinetic methods  
J. Aerosol Med. 14, S9-S17 (2001).
201. S. Krishna, N.V. Nagaraja, T. Planche, T. Agbenyega, G. Bedo-Addo, D. Ansong, A. Owusu-Ofori, A. Shroads, G. Henderson, A. Hutson, H. Derendorf, P. Stacpoole  
Population pharmacokinetics of intramuscular quinine in children with severe malaria  
Antimicrob. Agents Chemother. 45, 1803-1809 (2001).
202. H. Möllmann, M. Wagner, S. Krishnaswami, H. Dimova, Y. Tang, C. Falcoz, P. Daley-Yates, M. Krieg, R. Stöckmann, J. Barth, C. Lawlor, A. Möllmann, H. Derendorf, G. Hochhaus  
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder  
J. Clin. Pharmacol. 41, 1329-1338 (2001).
203. H. Derendorf, P.T. Daley-Yates, J. Efthimiou  
Systemic bioavailability of inhaled steroids: The importance of appropriate and comparable methodology  
Eur. Resp. J. 17, 157-158 (2001).
204. E.U. Gräfe, J. Wittig, S. Müller, A.K. Riethling, B. Uehleke, B. Drewelow, H. Pforte, G. Jacobasch, H. Derendorf, M. Veit  
Pharmacokinetics and bioavailability of quercetin glycosides in humans  
J. Clin. Pharmacol. 41, 492-499 (2001).

205. A. Tromm, H. Möllmann, J. Barth, G. Hochhaus, M. Krieg, C. Bigalke, A. Möllmann, H. Derendorf  
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients  
J. Clin. Pharmacol. 41, 536-541 (2001).
206. C. Joukhadar, H. Derendorf, M. Müller  
Microdialysis - a novel tool for clinical studies of antiinfective agents  
Eur. J. Clin. Pharmacol. 57, 211-219 (2001).
207. M. Müller, U. Müller-Zellenberg, G. Hochhaus, H. Derendorf  
Current concepts in pharmacokinetics and their implications for clinical medicine  
Wien. Klin. Wochenschr. 15/16, 566-572 (2001).
208. A. de la Peña, T. Dalla Costa, J.D. Talton, E. Rehak, J. Gross, U. Thyroff-Friesinger, A.I. Webb, M. Müller, H. Derendorf  
Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats  
Pharm. Res. 18, 1310-1314 (2001).
209. H. Derendorf, S. Krishnaswami, G. Hochhaus, H. Möllmann  
Systemic disposition and effects of inhaled corticosteroids  
In 'Airway activity and selectivity of inhaled steroids in asthma', ed. by R. Schleimer, P. O'Byrne, S. Szefler, R. Brattsand, Dekker, Lung biology in health and disease, Vol. 163, pg. 247-272 (2001).
210. G. Hochhaus, H. Derendorf, J. Talton, H. Möllmann  
Factors involved in the pulmonary targeting of inhaled glucocorticoids  
In 'Airway activity and selectivity of inhaled steroids in asthma', ed. by R. Schleimer, P. O'Byrne, S. Szefler, R. Brattsand, Dekker, Lung biology in health and disease, Vol. 163, pg. 283-307 (2001).
211. B. Meibohm, H. Derendorf  
Pharmacokinetic/pharmacodynamic studies in drug product development  
J. Pharm. Sci. 91, 18-31 (2002).

212. H. Derendorf, P.T. Daley-Yates, L.N. Pierre, J. Efthimiou  
Bioavailability and metabolism of mometasone furoate -  
pharmacology versus methodology  
J. Clin. Pharmacol. 42, 383-387 (2002).
213. A. de la Peña, M. Brunner, H.-G. Eichler, E. Rehak, J. Gross, U. Thyroff-Friesinger, M. Müller, H. Derendorf  
Comparative target site pharmacokinetics of immediate  
and modified-release formulations of cefaclor in  
humans  
J. Clin. Pharmacol. 42, 403-411 (2002).
214. G. Hochhaus, S. Sahasranaman, H. Derendorf, H. Möllmann  
Intranasal glucocorticoid delivery: competition  
between local and systemic effects  
S.T.P. Pharma Sciences 12, 23-31 (2002).
215. A. Buchwald, H. Derendorf, F. Ji, N.V. Nagaraja, M.W. Wu, N. Bodor  
Soft cannabinoid analogues as potential anti-glaucoma  
agents  
Pharmazie 57, 108-114 (2002).
216. P. Liu, M. Müller, M. Grant, A. Webb, B. Obermann, H. Derendorf  
Interstitial tissue concentration of cefpodoxime  
J. Antimicrob. Chemother. 50, 19-22 (2002).
217. B. Meibohm, I. Beierle, H. Derendorf  
How important are gender differences in  
pharmacokinetics  
Clin. Pharmacokinet. 41, 329-342 (2002).
218. P. Liu, M. Müller, H. Derendorf  
Rational dosing of antibiotics: the use of plasma  
concentrations versus tissue concentrations  
Int. J. Antimicrob. Agents 19, 285-290 (2002).
219. J.W. Mouton, M.N. Dudley, O. Cars, H. Derendorf, G.L. Drusano  
Standardization of pharmacokinetic/pharmacodynamic  
(PK/PD) terminology for anti-infective drugs  
Int. J. Antimicrob. Agents 19, 355-358 (2002).

220. C. Kohlert, G. Schindler, R.W. März, G. Abel, B. Brinkhaus, H. Derendorf, E.U. Gräfe, M. Veit  
Systemic availability and pharmacokinetics of thymol in humans  
J. Clin. Pharmacol. 42, 731-737 (2002).
221. V.A. Bhattaram, E.U. Gräfe, C. Kohlert, M. Veit, H. Derendorf  
Pharmacokinetics and bioavailability of herbal medicinal products  
Phytomedicine 9 (Suppl. III), 1-36 (2002).
222. E.S. El Desoky, N.V. Nagaraja, H. Derendorf  
Population pharmacokinetics of digoxin in Egyptian pediatric patients: Impact of one data point utilization  
Am. J. Ther. 9, 492-498 (2002).
223. K. Erb, K. Junge, B. Pechstein, E. Schneider, H. Derendorf, R. Hermann  
Novel formulations of cetrorelix acetate in healthy men: Pharmacodynamic effects and noncompartmental pharmacokinetics  
J. Clin. Pharmacol. 42, 995-1001 (2002).
224. C. Rojas, N.V. Nagaraja, A.I. Webb, H. Derendorf  
Microdialysis of triamcinolone acetonide in rat muscle  
J. Pharm. Sci. 92, 394-397 (2003).
225. N.V. Nagaraja, B. Pechstein, K. Erb, C. Klipping, R. Hermann, M. Locher, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of Luteinizing Hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women  
J. Clin. Pharmacol. 43, 243-251 (2003).
226. A.M. Persky, M. Müller, H. Derendorf, M. Grant, G.A. Brazeau, G. Hochhaus  
Single- and multiple-dose pharmacokinetics of oral creatine  
J. Clin. Pharmacol. 43, 29-37 (2003).



227. H. Sourgens, J. Schmidt, H. Derendorf  
Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study  
Int. J. Clin. Pharmacol. Ther. 41, 22-29 (2003).
228. T. Agbenyega, T. Planche, G. Bedu-Addo, D. Ansong, A. Owusu-Ofori, V.A. Bhattaram, N.V. Nagaraja, A.L. Shroads, G.N. Henderson, A.D. Hutson, H. Derendorf, S. Krishna, P.W. Stacpoole  
Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children  
J. Clin. Pharmacol. 43, 386-396 (2003).
229. B. Meibohm, H. Derendorf  
Pharmacokinetics and pharmacodynamics of biotechnology products (in Polish)  
In "Biotechnologia Farmaceutyczna", edited by O. Kayser and R.H. Müller, Wydawnictwo Lekarskie PZWL Warszawa, p. 91-110 (2003).
230. D.B. Allen, L. Bielrory, H. Derendorf, R. Dluhy, G.L. Colice, S.J. Szeffler  
Inhaled corticosteroids: Past lessons and future issues  
Journal Allergy Clin. Immunol. 112, S1-40 (2003).
231. A.M. Persky, N.D. Eddington, H. Derendorf  
A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics  
Int. J. Clin. Pharmacol. Ther. 41, 504-516 (2003).
232. P. Liu, H. Derendorf  
Antimicrobial tissue concentrations  
Infect. Dis. Clin. N. Am. 17, 599-613 (2003).
233. S. Rohatagi, S. Appajoyula, H. Derendorf, S. Szeffler, R. Nave, K. Zech, D. Banerji  
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective  
J. Clin. Pharmacol. 44, 37-47 (2004).

234. A. de la Peña, A. Gräbe, K. Rand, E. Rehak, J. Gross, U. Thyroff-Friesinger, M. Müller, H. Derendorf  
PK-PD modeling of the effect of cefaclor on four different bacterial strains  
Int. J. Antimicrob. Agents 24, 218-225 (2004)
235. B. Meibohm, H. Derendorf  
Pharmacokinetics and pharmacodynamics of biotech drugs  
In "Pharmaceutical Biotechnology", edited by O. Kayser and R.H. Müller, Wiley-VCH, Weinheim, p. 147-172 (2004).
236. M. Müller, A. de la Pena, H. Derendorf  
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC  
Antimicrob. Agents Chemother. 48, 369-377 (2004).
237. R. Hermann, M. Locher, M. Siebert-Weigel, N. LaVallee, H. Derendorf, G. Hochhaus  
Intranasal loteprednol etabonate in healthy male subjects: Pharmacokinetics and effects on endogenous cortisol  
J. Clin. Pharmacol. 44, 510-519 (2004).
238. Q. Liu, K. Rand, H. Derendorf  
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations  
Int. J. Antimicrob. Agents 23, 494-497 (2004).
239. H. Derendorf  
Relevant pharmacokinetic parameters for determining efficacy and safety inhaled corticosteroids  
Eur. Respir. Rev. 13, 62-65 (2004).
240. A. Graebe, E.L. Schuck, P. Lensing, L. Putcha, H. Derendorf  
Physiological, pharmacokinetic and pharmacodynamic changes in space  
J. Clin. Pharmacol. 44, 837-853 (2004).
241. M. Müller, A. de la Pena, H. Derendorf  
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue  
Antimicrob. Agents Chemother. 48, 1441-1453 (2004).

242. J. Winkler, G. Hochhaus, H. Derendorf  
How the lung handles drugs: Pharmacokinetics and  
pharmacodynamics of inhaled corticosteroids  
Proc. Am. Thorac. Soc. 1, 356-363 (2004).
243. V.A. Schuck, I. Rinas, H. Derendorf  
In vitro microdialysis sampling of docetaxel  
J. Pharm. Biomed. Anal. 36, 807-813 (2004).
244. K. Kim, J.A. Johnson, H. Derendorf  
Differences in drug pharmacokinetics between East  
Asians and Caucasians and the role of genetic  
polymorphisms  
J. Clin. Pharmacol. 44, 1083-1105 (2004).
245. J. Barth, J. Winkler, R. Schumann, N.V. Nagaraja, R.  
Madabushi, S. Balbach, H. Derendorf, H. Möllmann, G.  
Möllenhoff  
Population pharmacokinetics of methylprednisolone in  
accident victims with spinal cord injury  
Int. J. Clin. Pharmacol Ther. 42, 504-511 (2004).
246. V. Butterweck, H. Derendorf, W. Gaus, A. Nahrstedt, V.  
Schulz, M. Unger  
Pharmacokinetic herb-drug interactions: Are preventive  
screenings necessary and appropriate?  
Planta Med. 70, 784-791 (2004).
247. H. Derendorf, S. Pedersen  
Choosing an inhaled corticosteroid for once-daily  
administration in asthma  
Resp. Dig. 6(2), 1-11 (2004).
248. S.M. Wittemer, M. Ploch, T. Windeck, S.C. Müller, B.  
Drewelow, H. Derendorf, M. Veit  
Bioavailability and pharmacokinetics of caffeoylquinic  
acids and flavonoids after oral administration of  
Artichoke leaf extracts in humans  
Phytomedicine 12, 28-38 (2005).
249. V.A. Bhattaram, N.V. Nagaraja, T. Peters, T. Machnig,  
S. Kroesser, A. Kovar, H. Derendorf  
Population pharmacokinetics of eniporide and its  
metabolite in healthy subjects and patients with acute  
myocardial infarction  
J. Clin. Pharmacol. 45, 631-639 (2005).

250. S. Krishnaswami, G. Hochhaus, H. Möllmann, H. Derendorf  
Interpretation of absorption rate data for fluticasone propionate obtained in compartmental pharmacokinetic modeling  
Int. J. Clin. Pharmacol. Ther. 43, 117-122 (2005).
251. C. Buck, N. Bertram, T. Ackermann, T. Sauerbruch, H. Derendorf, W.D. Paar  
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion  
Int. J. Antimicrob. Agents 25, 62-67 (2005).
252. O. Burkhardt, J. Majcher-Peszynska, K. Borner, R. Mundkowski, B. Drewelow, H. Derendorf, T. Welte  
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery  
J. Clin. Pharmacol. 45, 659-665 (2005).
253. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form  
Infection 33 Suppl. 2, 22-28 (2005).
254. J. Mouton, M.N. Dudley, O. Cars, H. Derendorf, G.L. Drusano  
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update  
J. Antimicrob. Chemother. 55, 601-607 (2005).
255. P. Liu, K.H. Rand, B. Obermann, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models  
Int. J. Antimicrob. Agents 25, 120-129 (2005).
256. P. Liu, R. Fuhrherr, A.I. Webb, B. Obermann, H. Derendorf  
Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats  
Eur. J. Pharm. Sci. 25, 439-444 (2005).
257. P. Liu, M. Müller, M. Grant, B. Obermann, H. Derendorf  
Tissue penetration of cefpodoxime and cefixime in healthy subjects  
J. Clin. Pharmacol. 45, 564-569 (2005).

258. W.R. Heizmann, H. Derendorf  
Criteria for comparison of the combinations  
piperacillin/tazobactam and piperacillin/sulbactam  
Z Herz- Thorax- Gefäßschir. 19, 89-99 (2005).
259. H. Derendorf, G. Hochhaus  
What is the best marker for inhaled corticosteroid  
safety?  
Allergy Asthma Proceed. 26, 89-94 (2005).
260. E.L. Schuck, M. Grant, H. Derendorf  
Effect of simulated microgravity on the disposition  
and tissue penetration of ciprofloxacin in healthy  
volunteers  
J. Clin. Pharmacol. 45, 822-831 (2005).
261. H. Derendorf, C.P. Van der Maelen, R.S. Brickel, T.R,  
MacGregor, W. Eisert  
Dipyridamole bioavailability in subjects with reduced  
gastric acidity  
J. Clin. Pharmacol. 45, 845-850 (2005).
262. R.P.E. Yanong, E.W. Curtis, V.A. Bhattaram, M.  
Gopalakrishnan, N. Ketabi, N.V. Nagaraja, H. Derendorf  
Pharmacokinetic studies of florfenicol in Koi Carp and  
Threespot Gourami Trichogaster trichopterus after oral  
and intramuscular treatment  
J. Aquat. Anim. Health 17, 129-137 (2005).
263. E.L. Schuck, H. Derendorf  
Pharmacokinetic/pharmacodynamic evaluation of anti-  
infective drugs  
Expert Rev. Antiinfect. Ther. 3, 361-373 (2005).
264. M. Hübner, G. Hochhaus, H. Derendorf  
Comparative pharmacology, bioavailability,  
pharmacokinetics and pharmacodynamics of inhaled  
glucocorticoids  
Immunol. Allergy Clin. N. Am. 25, 469-488 (2005).
265. M. Brunner, H. Derendorf, M. Müller  
Microdialysis for in vivo pharmacokinetic/  
pharmacodynamic characterization of anti-infective  
drugs  
Curr. Opin. Pharmacol. 5, 1-5 (2005).

266. H. Derendorf  
Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy  
Allergy Asthma Proceed. 26, 327-335 (2005).
267. E. ElDesoky, R. Madabushi, Sel D. Amry, V.A. Bhattaram, H. Derendorf  
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense?  
Am. J. Ther. 12, 320-327 (2005).
268. W.V. De Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, H. Derendorf  
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies  
J. Agric. Food Chem. 11, 249-255 (2006).
269. E. ElDesoky, H. Derendorf, U. Klotz  
Variability in response to cardiovascular drugs  
Curr. Clin. Pharmacol. 1, 35-46 (2006).
270. O. Burkhardt, H. Derendorf, T. Welte  
Achieving eradication of MRSA colonization in patients. Therapeutic options  
Med. Monatsschr. Pharm. 29, 17-21 (2006).
271. O. Burkhardt, H. Derendorf, T. Welte  
New antibiotics for the treatment of MRSA infections  
Med. Monatsschr. Pharm. 29, 56-62 (2006).
272. S.U. Mertens-Talcott, I. Zadezensky, W.V. De Castro, V. Butterweck, H. Derendorf  
Drug interactions of grapefruit and other citrus - what have we learned?  
In Y.W.F. Lam, S.M. Huang, S. Hall (Ed.), Herbal Supplements-Drug Interactions, Marcel Dekker, p.147-190 (2006).
273. R. Madabushi, B. Frank, B. Drewelow, H. Derendorf, V. Butterweck  
Hyperforin in St. John's wort drug interactions  
Eur. J. Clin. Pharmacokin. 62, 225-233 (2006).

274. J.G. Stark, S. Werner, S. Homrighausen, Y. Tang, M. Krieg, H. Derendorf, H. Möllmann, G. Hochhaus  
Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide  
J. Pharmacokinet. Pharmacodyn. 33, 441-459 (2006).
275. M.J. Salvador, E.O. Ferreira, S.U. Mertens-Talcott, W.V. De Castro, V. Butterweck, H. Derendorf, D.A. Dias  
Isolation and HPLC quantitative analysis of antioxidant flavonoids from *Alternanthera tenella* Colla  
Z. Naturforsch. 61, 19-25 (2006).
276. L.A. Boothby, R. Madabushi, V. Kumar, B.D. Bredland, R.C. Hatton, P.L. Doering, H. Derendorf  
Extended stability of oxytocin in Ringer's Lactate Solution at 4° and 25°C  
Hospital Pharmacy 41, 437-441 (2006).
277. Y. Li, J. Peris, L. Zhong, H. Derendorf  
Microdialysis as a tool in local pharmacodynamics  
AAPS Journal 8, E222-235 (2006).
278. M. Brunner, H. Derendorf  
Clinical microdialysis: Current applications and potential use in drug development  
Trends in Analytical Chemistry 25, 674-680 (2006).
279. V. Kumar, R. Madabushi, L.A. Boothby, B.D. Breland, R.C. Hatton, P.L. Doering, H. Derendorf  
Development and validation of an HPLC method for oxytocin in Ringer's lactate and its application in stability analysis  
J. Liq. Chromatog. Rel. Technol. 29, 2353-2365 (2006).
280. O. Burkhardt, C. Lehmann, R. Madabushi, V. Kumar, H. Derendorf, T. Welte  
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistant development?  
J. Antimicrob. Chemother. 58, 822-829 (2006).

281. O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, H. Derendorf  
Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by microdialysis  
*J. Antimicrob. Chemother.* 58, 632-636 (2006).
282. U. Theuretzbacher, F. Ihle, H. Derendorf  
Pharmacokinetic/pharmacodynamic profile of voriconazole  
*Clin. Pharmacokin.* 45, 649-663 (2006).
283. C.J. Clancy, H. Huang, S. Cheng, H. Derendorf, M.H. Nguyen  
Characterizing the effects of caspofungin on *Candida albicans*, *Candida parapsilosis*, and *Candida glabrata* isolates by simultaneous time-kill and postantifungal-effect experiments  
*Antimicrob. Agents Chemother.* 50, 2569-2572 (2006).
284. V.A. Bhattaram, R. Madabushi, H. Derendorf  
Role of Food and Drug Administration in drug development  
in K.C. M. Campbell, *Pharmacology and Ototoxicity for Audiologists*, Thomson Delmar Learning, Clifton Park NY, pg. 33-45 (2006)
285. V. Butterweck, H. Derendorf  
Pharmacokinetics of botanical products  
In Y.W.F. Lam, S.M. Huang, S. Hall (Ed.), *Herbal Supplements-Drug Interactions*, Marcel Dekker, p.205-244 (2006).
286. S.U. Mertens-Talcott, P. Jilma-Stohlawetz, J. Rios, L. Hingorani, H. Derendorf  
Absorption, metabolism, and antioxidant effects of pomegranate (*Punica granatum* L.) polyphenols after ingestion of a standardized extract in healthy human volunteers  
*J. Agric. Food Chem.* 54, 8956-8961 (2006).
287. W.V. De Castro, M.A. Pires, C.D. Vianna-Soares, E.A. Nunan, G.A. Pianetti, L.M. Moreira-Campos, S.U. Mertens-Talcott, H. Derendorf  
The influence of formulation on the dissolution profile of diclofenac sodium tablets  
*Drug Dev. Ind. Pharm.* 32, 1103-1109 (2006).



288. O. Burkhardt, H. Derendorf, D. Jäger, V. Kumar, R. Madabushi, K. Rohl, J. Barth  
Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis  
Scand. J. Infect. Dis. 38, 904-908 (2006).
289. E.O. Meltzer, H. Derendorf  
The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide  
Ann Allergy Asthma Immunol. 97, 149-157 (2006).
290. H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, W. Wurst  
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma  
Eur. Respir. J. 28, 1042-1050 (2006).
291. S.U. Mertens-Talcott, I. Zadezensky, W.V. De Castro, H. Derendorf, V. Butterweck  
Grapefruit-Drug Interactions: Can Interactions with drugs be avoided?  
J. Clin. Pharmacol. 46, 1390-1416 (2006).
292. V. Kumar, S. Mostafa, M.W. Kayo, E.P. Goldberg, H. Derendorf  
HPLC Determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents  
Pharmazie 61, 908-911 (2006).
293. J.A. Manthey, K Myung, S. Mertens-Talcott, H. Derendorf, V. Butterweck, W.W. Widmer  
The isolation of minor-occurring furanocoumarins in grapefruit and analysis of their inhibition of CYP3A4 and P-glycoprotein transport of talinolol from Caco-2 cells  
Proc. Fla. State Hort. Soc. 119, 361-366 (2006).
294. O. Burkhardt, V. Kumar, D. Katterwe, J. Majcher-Peszynska, B. Drewelow, H. Derendorf, T. Welte  
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration on the free drug concentration  
J. Antimicrob. Chemother. 59, 277-284 (2007).

295. W. Treyaprasert, S.Schmidt, K.H. Rand, U. Suvanakoot, H.Derendorf  
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains  
Int. J. Antimicrob. Agents 29, 263-270 (2007).
296. M. Vogt, H. Derendorf, J. Kramer, H.E. Junginger, K.K. Midha, V.P. Shah, S. Stavchansky, J.B. Dressman, D.M. Barends  
Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone  
J. Pharm. Sci. 96, 27-37 (2007).
297. O. Burkhardt, H. Derendorf, T. Welte  
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice  
Expert Opin Pharmacother. 8, 237-56 (2007).
298. H. Derendorf  
Clinical trials and dipyridamole formulation selection  
Cerebrovasc Dis. 23, 72-73 (2007).
299. J. Xu, J. Winkler, H. Derendorf  
A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma  
J Pharmacokinet. Pharmacodyn. 34, 355-372(2007).
300. H. Derendorf, M. Hübner, B. Drewelow, U. Fuhr, C.H. Gleiter, B. Lemmer, G. Mikus, I. Roots, A. Ziegler, D. Ukena  
Pharmacokinetics and pharmacodynamics of ciclesonide,  
Arzneimitteltherapie 25, 89-94 (2007).
301. C.S.Chaurasia, M. Müller, E.D. Bashaw, E. Benfeldt, J. Bolinder, R. Bullock, P.M. Bungay, E.C.M. DeLange, H. Derendorf, W.F. Elmquist, M. Hammarlund-Udenaes, C. Joukhadar, D.L. Kellogg, C.E. Lunte, C.H. Nordstrom, H. Rollema, R.J. Sawchuk, B.W.Y. Cheung, V.P. Shah, L. Stahle, U. Ungerstedt, D.F. Welty, H. Yeo  
AAPS-FDA workshop white paper: Microdialysis principles, application and regulatory perspectives  
J. Clin. Pharmacol. 47, 589-603 (2007).

302. H. Derendorf  
Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide  
J. Clin. Pharmacol. 47, 782-789 (2007).
303. S. Schmidt, E. Schuck, V. Kumar, O. Burkhardt, H. Derendorf  
Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents - minimum inhibitory concentrations vs. kill curves  
Expert Opin. Drug Discov. 2, 849-860 (2007).
304. S.U. Mertens-Talcott, W.V. De Castro, J.A. Manthey, H. Derendorf, V. Butterweck  
Polymethoxylated flavones and other phenolic derivatives from Citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells  
J. Agric. Food Chem. 55, 2563-2568 (2007).
305. M. Vogt, H. Derendorf, J. Krämer, H.E. Junginger, K.K. Midha, V.P. Shah, S. Stavchansky, J.B. Dressman, D.M. Barends  
Biowaiver monographs for immediate release solid oral dosage forms: prednisone  
J. Pharm. Sci. 96, 1480-1489 (2007).
306. W.V. De Castro, S.U. Mertens-Talcott, H. Derendorf, V. Butterweck  
Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells  
J. Pharm. Sci. 96, 2808-2817 (2007).
307. Y. Li, H. Nguyen, H. Derendorf, S. Cheng, C.J. Clancy  
Measurement of voriconazole activity against *Candida albicans*, *C. glabrata*, and *C. parapsilosis* isolates using time-kill methods validated by high-performance liquid chromatography  
Antimicrob. Agents Chemother. 51, 2985-2987 (2007).
308. M. Lobmeyer, S. Schmidt, H. Derendorf  
Pharmacogenetics and personalized medicine  
Deutsche Apotheker Zeitung 07/50, (2007).

309. H. Derendorf, K.S. Estes  
The significance of optimized formulation for  
dipyridamole in stroke risk reduction  
European Neurological Disease 2007 (II), 21-23 (2007).
310. O. Burkhardt, H. Derendorf  
Grundlage der Pharmakotherapie beim kritisch Kranken  
In "Intensivmedizin", edited by H. Van Aken, K.  
Reinhart, M. Zimpfer, T. Welte, Thieme, pg. 476-486  
(2007).
311. Y. Li, M.H. Nguyen, S. Cheng, S. Schmidt, L. Zhong, H.  
Derendorf, C.J. Clancy  
A pharmacokinetic/pharmacodynamic mathematical model  
accurately describes the activity of voriconazole  
against *Candida* spp. in vitro  
Int. J. Antimicrob. Agents 31, 369-374(2008).
312. J.W. Mouton, U. Theuretzbacher, W.A. Craig, P.M.M.  
Tulkens, H. Derendorf, O. Cars  
Tissue concentrations: Do we ever learn?  
J Antimicrob. Chemother. 61, 235-237 (2008).
313. F.B. Mayr, A.O. Spiel, J.M. Leitner, C. Firbas, T.  
Kliegel, P. Jilma-Stohlawetz, H. Derendorf, B. Jilma  
Duffy antigen modifies the chemokine response in human  
endotoxemia  
Crit Care Med. 36, 159-165 (2008).
314. S. Schmidt, R. Banks, V. Kumar, K.H. Rand, H.  
Derendorf  
Clinical microdialysis in skin and soft tissues: an  
update.  
J Clin Pharmacol. 48, 351-364 (2008).
315. B. Meibohm, H. Derendorf  
Pharmacokinetics and pharmacodynamics of biotech drugs  
In "Pharmacology - From Drug Development to Gene  
Therapy", edited by R.A. Meyers, pg. 107-136, Wiley-  
VCH, Weinheim (2008).
316. J. Xu, J. Winkler, S.N. Sabarinath, H. Derendorf  
Assessment of the impact of dosing time on the  
pharmacokinetics/pharmacodynamics of prednisolone  
The AAPS Journal 10, 331-341(2008).

317. C. Scheerans, H. Derendorf, C. Kloft  
Proposal for a standardized identification of the mono-exponential terminal phase for orally administered drugs  
Biopharm. Drug. Dispos. 29, 145-157 (2008).
318. V. Butterweck, H. Derendorf  
Potential of pharmacokinetic profiling for detecting herbal interactions with drugs  
Clin. Pharmacokin. 47, 383-397 (2008).
319. S. Schmidt, A. Barbour, M. Sahre, K.H. Rand, H. Derendorf  
PK/PD: new insights for antibacterial and antiviral applications  
Curr. Opinion Pharmacol. 8, 549-556 (2008).
320. K. Blake, R. Madabushi, H. Derendorf, J. Lima  
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma  
Chest 134, 981-989 (2008).
321. W.V. de Castro, S. Mertens-Talcott, H. Derendorf, V. Butterweck  
Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats  
J. Agric. Food Chem. 56, 4840-4845 (2008).
322. H. Derendorf, E.O. Meltzer  
Molecular and clinical pharmacology of intranasal corticosteroids: Clinical and therapeutic implications  
Allergy 63, 1292-1300(2008).
323. H. Badrane, M.H. Nguyen, S. Cheng, V. Kumar, H. Derendorf, K.A. Iczkowski, C.J. Clancy  
The *Candida albicans* phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence  
Microbiology 154, 3296-3308 (2008).

324. S. Schmidt, K. Röck, M. Sahre, O. Burkhardt, M. Brunner, M.T. Lobmeyer, H. Derendorf  
Effect of protein binding on the pharmacological activity of highly bound antibiotics  
Antimicrob. Agents Chemother. 52, 3994-4000 (2008).
325. S.U. Mertens-Talcott, J. Rios, P. Jilma-Stohlawetz, L.A. Pacheco-Palencia, B. Meibohm, S.T. Talcott, H. Derendorf  
Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (*Euterpe oleracea* Mart.) in human healthy volunteers  
J Agric Food Chem. 56, 7796-802 (2008).
326. J. Liu, H. Pan, M.S. Gold, H. Derendorf, A.W. Bruijnzeel  
Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats  
Neuropharmacology 55, 812-818 (2008).
327. S. Sarawek, H. Derendorf, V. Butterweck  
Pharmacokinetics of luteolin and metabolites in rats  
Natural Product Communications 3, 2029-2036 (2008).
328. E.S. ElDesoky, V. Kumar, M.S. Alorainy, M.M. Hamdi, H. Derendorf  
Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach.  
Int. J. Clin. Pharmacol. Ther. 46, 617-626 (2008).
329. J. Xu, S.N. Sabarinath, H. Derendorf  
Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children  
Eur. J. Pharm. Sci. 36, 110-121 (2009).
330. O.G. Ghobrial, H. Derendorf, J.D. Hillman  
Pharmacodynamic activity of the lantibiotic MU1140  
Int. J. Antimicrob. Agents 33, 70-74 (2009).
331. O.G. Ghobrial, H. Derendorf, J.D. Hillman  
Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma  
J. Pharm. Biomed. Anal. 49, 970-975 (2009).

332. A. Barbour, S. Schmidt, K.H. Rand, H. Derendorf  
Ceftobiprole: a novel cephalosporin with activity  
against Gram-positive and Gram-negative pathogens,  
including methicillin-resistant *Staphylococcus aureus*  
(MRSA)  
Int. J Antimicrob. Agents 34, 1-7 (2009).
333. A. Barbour, S. Schmidt, W.R. Rout, K. Ben-David, O.  
Burkhardt, H. Derendorf  
Soft tissue penetration of cefuroxime determined by  
clinical microdialysis in morbidly obese patients  
undergoing abdominal surgery  
Int. J Antimicrob. Agents 34, 231-235 (2009).
334. A. Barbour, S. Schmidt, S.N. Sabarinath, M. Grant, C.  
Seubert, D. Skee, B. Murthy, H. Derendorf  
Soft-tissue penetration of ceftobiprole in healthy  
volunteers determined by in vivo microdialysis  
Antimicrob. Agents Chemother. 53, 2773-2776 (2009).
335. V. Butterweck, I. Zdrojewski, C. Galloway, R. Freye,  
H. Derendorf  
Toxicological and Pharmacokinetic Evaluation of  
Concomitant Intake of Grapefruit Juice and Simvastatin  
in Rats after Repeated Treatment over 28 Days  
Planta Med. 75, 1196-202 (2009).
336. Y. Li, M.H. Nguyen, S. Schmidt, L. Zhong, H.  
Derendorf, C.J. Clancy  
Pharmacokinetic/pharmacodynamic modelling and in vitro  
simulation of dynamic voriconazole-*Candida*  
interactions  
Int. J Antimicrob. Agents 34, 240-245 (2009).
337. K. Woelkart, R.F. Frye, H. Derendorf, R. Bauer, V.  
Butterweck  
Pharmacokinetics and Tissue Distribution of Dodeca-  
2E,4E,8E,10E/Z-tetraenoic Acid Isobutylamides after  
Oral Administration in Rats  
Planta Med. 75,1306-13 (2009).
338. A. Barbour, S. Schmidt, B. Ma, L. Schiefelbein, K.H.  
Rand, O. Burkhardt, H. Derendorf  
Clinical pharmacokinetics and pharmacodynamics of  
tigecycline  
Clin. Pharmacokin. 48, 575-584 (2009).

339. S. Schmidt, S. N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, S. Sha, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of the in vitro activity of oxazolidinone antimicrobial agents against methicillin-resistant *Staphylococcus aureus*  
*Antimicrob. Agents Chemother.* 53, 5039-5045(2009).
340. F.B. Mayr FB, A.O. Spiel, J.M. Leitner, C. Firbas, J. Schnee, J. Hilbert, H. Derendorf, B. Jilma  
Influence of the duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo  
*Int J Immunopathol Pharmacol.* 22, 615-625 (2009).
341. D.Gonzalez, H. Derendorf  
Ciclosenide in the management of asthma  
*Clinical Medicine: Therapeutics* 1, 1437-1449 (2009).
342. O. Burkhardt, V. Kumar, S. Schmidt, J.T. Kielstein, T. Welte, H. Derendorf  
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations.  
*International Journal of Antimicrobial Agents* 35, 96-97 (2010).
343. H. Yamada, M. Bishnoi, K. Keijzers, I. Van Tuijl, E. Small, H. Shah, R. Bauzo, F. Kobeissy, S. Sabarinath, H. Derendorf, A. Bruijnzeel  
Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats.  
*Pharmacol Biochem Behav.* 95, 401-409 (2010).
344. A. Barbour, F. Scaglione, H. Derendorf  
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices.  
*Int J Antimicrob Agents.* 35, 431-438 (2010).
345. S. Schmidt, D. Gonzalez, H. Derendorf  
Significance of protein binding in pharmacokinetics and pharmacodynamics.  
*J. Pharm. Sci.* 99, 1107-1122 (2010).
346. J. Xu J, R. Nave, G. Lahu, E. Derom, H. Derendorf  
Population Pharmacokinetics and Pharmacodynamics of



- Inhaled Ciclesonide and Fluticasone Propionate in Patients With Persistent Asthma.  
J. Clin. Pharmacol. 50, 1118-1127 (2010).
347. O. Ghobrial, H. Derendorf, J.D.Hillman  
Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140.  
J Pharm Sci. 99, 2521-2528 (2010).
348. J. Gloede, C. Scheerans, H. Derendorf, C. Kloft  
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.  
J Antimicrob Chemother. 65, 186-201 (2010).
349. B. Wu, H. Derendorf  
Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure  
Pharmazie 65, 417-420(2010).
350. T.E. Morey, J.H. Modell, J.E. Garcia, M. Bewernitz, H. Derendorf, M. Varshney, N. Gravenstein, D.O. Shah, D.M. Dennis  
Thromboelastographic and Pharmacokinetic Profiles of Micro- and Macro-emulsions of Propofol in Swine  
Biopharm. Drug Dispos. 31, 269-277 (2010).
351. Y. Li, U. Theuretzbacher, C.J. Clancy, M.H. Nguyen, H. Derendorf  
Pharmacokinetic/pharmacodynamic profile of posaconazole  
Clin. Pharmacokinet. 49, 379-396 (2010).
352. S.N. Sabarinath, R.P. Singh, H. Derendorf  
PK-PD approaches - Antibiotic drug development  
In: "Clinical Pharmacology: Current Topics and Case Studies", ed. by M. Müller, pg. 143-155, Springer (2010).
353. D.J. Conrado, D. Gonzalez, H. Derendorf  
Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke  
Ann.N.Y.Acad.Sci. 1207, 134-142 (2010).
354. A. Barbour, H. Derendorf  
Resistance and the management of complicated skin and

- skin structure infections: the role of ceftobiprole  
Ther.Clin.Risk Managem. 6, 485-495 (2010).
355. M.L.T. Viera, R.P. Singh, H. Derendorf  
Simultaneous HPLC analysis of triamcinolone acetonide  
and budesonide in microdialysate and rat plasma:  
Application to a pharmacokinetic study  
J.Chromatogr. 878, 2967-2973 (2010).
356. K. Romero, B. Corrigan, C.W. Tornoe, J.V. Gobburu, M.  
Danhof, W.R. Gillespie, M.R. Gastonguay, B. Meibohm,  
H. Derendorf  
Pharmacometrics as a discipline is entering its  
'industrialization' phase: standards, automation,  
knowledge sharing, and training are critical for  
future success  
J.Clin.Pharmacol. 50(Suppl.), 9S-19S (2010).
357. J. Liu, H. Derendorf  
Clinical pharmacology of addicting drugs  
In 'Addictive Disorders in Medical Populations', ed.  
by N.S. Miller and M.S. Gold, pg. 107-124, Wiley-  
Blackwell (2010).
358. O. Ghobrial, H. Derendorf, J. Hillman  
Human serum binding and its effect on the  
pharmacodynamics of the lantibiotic MU1140  
Eur. J. Pharm. Sci. 41, 658-664 (2010).
359. R. Shi, H. Derendorf  
Pediatric dosing and body size in biotherapeutics  
Pharmaceutics 2, 389-418 (2010).
360. B. Drewelow, H. Derendorf, F. Sörgel. J. Majcher-  
Peszynska, C. Lebert  
Pharmacokinetics and Pharmacodynamics  
In 'Guidelines for the calculated parenteral initial  
therapy of bacterial infections in adults' by K.F.  
Bodmann, B. Grabein and the PEG Expert Committee  
Chemother. J. 19, 179-255 (2010).
361. K.S. Estes, H. Derendorf  
Comparison of the pharmacokinetic properties of  
vancomycin, linezolid, tigecyclin, and daptomycin  
Eur. J. Med. Res. 15, 533-543 (2010).

362. E. Small, H.P. Shah, J.J. Davenport, J.E. Geier, K.R. Yavarovich, H. Yamada, S.N. Sabarinath, H. Derendorf, J.R. Pauly, M.S. Gold, A.W. Bruijnzeel  
Tobacco smoke exposure induces nicotine dependence in rats  
*Psychopharmacol.* 208, 143-58(2010).
363. V. Kumar, R. Madabushi, M.B.B. Lucchesi, H. Derendorf  
Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs  
*J.Vet.Pharm.Ther.* 34, 130-135 (2011).
364. E. Potocka, R.A. Baughman, H. Derendorf  
Population pharmacokinetic model of human insulin following different routes of administration  
*J. Clin. Pharmacol.* 51, 1015-1024(2011).
365. Z. Ahmad, C.A. Peloquin, R.P. Singh, H. Derendorf, S. Tyagi, A. Ginsberg, J.H. Grosset, E. Nuernberger  
PA-824 exhibits time-dependent activity in a murine model of tuberculosis  
*Antimicrob. Agents Chemother.* 55, 239-245 (2011).
366. R. Shi, H. Derendorf  
Theoretical models for dermatokinetics of therapeutic agents  
In "Dermatokinetics of Therapeutic Agents", ed. by S.N. Murthy, pg. 25-66, Taylor & Francis (2011).
367. R. P. Singh, H. Derendorf, E. A. Ross  
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis  
*Clin. J. Am. Soc. Nephrol.* 6, 1155-1159 (2011).
368. S.N. Sabarinath, B. Wu, C.A. Peloquin, H. Derendorf  
Pharmacometrics in dose finding or dose optimization of anti-retroviral and anti-tubercular drugs  
*Infect. Disord. Drug Targets* 11, 157-166 (2011).
369. B.M. Wu, S.N. Sabarinath, K. Rand, J. Johnson, H. Derendorf  
Suppression of ciprofloxacin-induced resistant *Pseudomonas aeruginosa* in a dynamic kill curve system  
*Int. J. Antimicrob. Agents* 37, 519-524 (2011).

370. P. Reddy, D. Ellington, Y. Zhu, I. Zdrojewski, S.J. Parent, J.S. Harmatz, H. Derendorf, D.J. Greenblatt, K. Browne  
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily  
Br. J. Clin. Pharmacol. 72, 434-441 (2011).
371. L. Zhuang, J. Gao, Y. Zeng, F. Yu, B. Zhang, M. Li, H. Derendorf, C. Liu  
HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats  
Eur. J. Drug Metab. Pharmacokinet. 36, 61-69 (2011).
372. M. Zeitlinger, H. Derendorf, J.W. Mouton, O. Cars, W.A. Craig, D. Andes, U. Theuretzbacher  
Protein binding: Do we ever learn?  
Antimicrob. Agents Chemother. 55, 3067-3074 (2011).
373. D. O'Connor, W.P. Adams, M.L. Chen, P. Daley-Yates, J. Davis, H. Derendorf, M.P. Ducharme, A. Fuglsang, M. Herrle, G. Hochhaus, S.M. Holmes, S.L. Lee, B.V. Li, S. Lyapustina, S. Newman, M. Oliver, B. Patterson, J. Peart, G. Poochikian, P. Roy, T. Shah, G.J. Singh, S.S. Sharp  
Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report  
J. Aerosol Med. Pulm. Drug Deliv. 24, 119-135 (2011).
374. D. Gonzalez, D.J. Conrardo, U. Theuretzbacher, H. Derendorf  
The effect of critical illness on drug distribution  
Curr. Pharm. Biotechnol. 12, 2030-2036 (2011).
375. A.W. Bruijnzeel, G. Rodrick, R.P. Singh, H. Derendorf, R.M. Bauzo  
Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats  
Pharmacol. Biochem. Behav. 100, 109-118 (2011).
376. K. Ardjomand-Wölkart, M. Kollroser, C. Magnes, F. Sinner, R.F. Frye, H. Derendorf, R. Bauer, V. Butterweck  
Absolute/relative bioavailability and metabolism of

- dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides  
(tetraenes) after intravenous and oral single doses to  
rats  
Planta Medica 77, 1794-1799 (2011).
377. K. Ardjomand-Wölkart, M. Kollroser, L. Li, H.  
Derendorf, V. Butterweck, R. Bauer  
Development and validation of a LC-MS/MS method based  
on a new 96-well hybrid-SPE-precipitation technique  
for quantification of CYP450 substrates/metabolites in  
rat plasma  
Anal. Bioanal. Chem. 400, 2371-2381 (2011).
378. K. Ikawa, A. Nakashima, N. Morikawa, K. Ikeda, Y.  
Murakami, H. Ohge, H. Derendorf, T. Sueda  
Clinical pharmacokinetics of meropenem and biapenem in  
bile and dosing considerations for biliary tract  
infections based on site-specific pharmacodynamic  
target attainment  
Antimicrob. Agents Chemother. 55, 5609-5615 (2011).
379. M. Alter, P. Doering, H. Derendorf  
Medication Therapy Monitoring - Model for Germany?  
Deutsch. Apoth. Ztg. 151, 4560-71 (2011).
380. M. Sahre, R. Naik, H. Derendorf  
Clinical microdialysis in skin and soft tissues  
In "Applications of Microdialysis in Pharmaceutical  
Sciences", ed. by Tung-Hu Tsai, pg. 313-334, Wiley  
(2011).
381. E.S. El Desoky, S.N. Sabarinath, M.M. Hamdi, M.  
Bewernitz, H. Derendorf  
Population pharmacokinetics of steady-state  
carbamazepine in Egyptian epilepsy patients  
J. Clin. Pharm. Ther. 37, 352-355(2012).
382. A. Barbour, H. Derendorf  
Applications of pharmacokinetic/pharmacodynamics  
models for the development of antimicrobial agents  
In "Antibiotic Discovery and Development", ed. by T.J.  
Dougherty and M.J. Pucci, pg. 1055-1070, Springer  
(2012).
383. C. Sampath, K. Haug, S. Thanel, H. Derendorf, R. Frye,  
V. Butterweck  
Pharmacokinetics of valerenic acid in rats after

- intravenous and oral administration  
Planta Med. 78, 575-581 (2012).
384. M. Bewernitz, H. Derendorf  
Electroencephalogram-based pharmacodynamics measures:  
a review  
Int. J. Clin. Pharm. Ther. 50, 162-184 (2012).
385. S. Wright, R.P. Singh, S. Retlich, U. Graefe-Mody, H. Derendorf  
The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety  
Int. J. Clin. Pharmacol. Ther. 50, 323-330 (2012).
386. H. Derendorf, U. Munzel, U. Petzold, J. Maus, H. Mascher, R. Hermann, H. Derendorf  
Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray  
Br. J. Clin. Pharmacol. 74, 125-133 (2012).
387. M. Zeitlinger, S. Marchand, W. Couet, A. Barth, H. Derendorf  
Microdialysis in antibiotic research  
In "Microdialysis in Drug Development", ed. by M. Müller, Springer, pg. 103-126 (2012).
388. K. Chooluck, R.P. Singh, K. Sathirakul, H. Derendorf  
Dermal pharmacokinetics of terpinen-4-ol following topical administration of *Zingiber cassumunar* (plai) oil  
Planta Medica 78, 1761-1766 (2012).
389. C. Lebert, H. Derendorf  
Therapeutic drug monitoring of vancomycin in adults - retrospective analysis of plasma level data of 1122 patients  
Chemother. J. 21, 101-108 (2012).
390. M. Sahre, S. Sabarinath, M. Grant, C. Seubert, C. Deanda, P. Prokocimer, H. Derendorf  
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers  
Int. J. Antimicrob. Agents 40, 51-54 (2012).

391. H. Derendorf  
Model-based drug approval - the rubber hits the road  
Int. J. Clin. Pharmacol. Ther. 50, 621 (2012).
392. V. Butterweck, H. Derendorf  
Herb-drug interactions  
Planta Med. 78, 13 (2012).
393. T.E. Morey, S. Wasdo, J. Wishin, B. Quinn, A. van der Straten, M. Booth, D. Gonzalez, H. Derendorf, R.J. Melker, D.M. Dennis  
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels  
J. Clin. Pharm. 53, 103-111 (2013).
394. K. Chooluck, R.P. Singh, K. Sathirakul, H. Derendorf  
Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration  
Pharmazie 68, 135-140 (2013).
395. S.K.B. Sy, R.P. Singh, S. Shilbayeh, R. Zmeili, D. Conrado, H. Derendorf  
Influence of CYP3A5 6986A>G and ABCB1 3435C>T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients  
Clin. Pharmacol. Drug Dev. 2, 67-78 (2013).
396. H. Mückter, H. Derendorf, B. Fichtl  
Toxicokinetics  
In "Toxikologie", ed. by H. Marquardt, S. Schäfer, H. Barth, Wissenschaftliche Verlagsgesellschaft, pg. 41-88 (2013).
397. M. Ibarra, M. Vazquez, P. Fagiolino, H. Derendorf  
Sex related differences on valproic acid pharmacokinetics after oral single dose  
J. Pharmacokinet. Pharmacodyn. 40, 479-486 (2013).
398. P. Brossard, H. Derendorf, J. Xu, H. Maatouk, A. Halabi, J. Dingemans  
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P<sub>1</sub> receptor modulator, in the first-in-human study  
Br. J. Clin. Pharmacol. 76, 888-896(2013).

399. T.E. Morey, M. Booth, S. Wasdo, J. Wishin, B. Quinn, D. Gonzalez, H. Derendorf, S.P. McGorray, J. Simoni, R.J. Melker, D.M. Dennis  
Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy  
AIDS Behav. 17, 298-306 (2013).
400. H. Derendorf, K. Rübsamen, L. Clarke, A. Schäffler, J.R. Kirwan  
Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis  
J. Clin. Pharmacol. 53, 326-333 (2013).
401. A. van der Straten, H. Cheng, S. Wasdo, L. Montgomery, K. Smith-McCune, M. Booth, D. Gonzalez, H. Derendorf, T.E. Morey, D.M. Dennis  
A novel breath test to directly measure use of vaginal gel and condoms  
AIDS Behav. 17, 2211-2221 (2013).
402. D.J. Greenblatt, H. Derendorf  
Grapefruit-medication interactions  
CMAJ 185, 507 (2013).
403. D. Gonzalez, S. Schmidt, H. Derendorf  
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents  
Clin. Microbiol. Rev. 26, 274-88 (2013).
404. J. Heuberger, S. Schmidt, H. Derendorf  
When is protein binding important?  
J. Pharm. Sci. 102, 3458-3467 (2013).
405. L. Li, A.R. Han, A.D. Kinghorn, R.F. Frye, H. Derendorf, V. Butterweck  
Pharmacokinetic properties of pure xanthenes in comparison to a mangosteen fruit extract in rats  
Planta Med. 79, 646-653 (2013).
406. D.J. Conrado, M. Bewernitz, M. Ding, J. Cibula, C. Seubert, S.K. Sy, S. Eisenschenk, H. Derendorf  
Electroencephalogram effects of armodafinil: Comparison with behavioral alertness  
J. Clin. Pharmacol. 53, 1058-1071 (2013).



407. E.S. El Desoky, M.H. Ghazal, R.P. Singh, O.N. Abdelhamid, H. Derendorf  
Population pharmacokinetics of methotrexate in Egyptian children with lymphoblastic leukemia  
*Pharmacology & Pharmacy* 4, 139-145 (2013).
408. S.K.B. Sy, J. Heuberger, S. Shilbayeh, D.J. Conrado, H. Derendorf  
A Markov Chain Model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation  
*AAPS Journal* 15, 1189-1199(2013).
409. S.K.B. Sy, S. Innes, H. Derendorf, M.F. Cotton, B. Rosenkranz  
Estimation of intracellular concentration of stavudine-triphosphate in HIV-infected children given the reduced dose of 0.5 milligrams per kilogram twice daily  
*Antimicrob. Agents Chemother.* 58, 1084-1091 (2014).
410. B. Wu, S.K. B. Sy, H. Derendorf  
Principles of Applied Pharmacokinetic-pharmacodynamic modeling  
In 'Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics', ed. by A.A. Vinks, H. Derendorf, J.W. Mouton, Springer, New York, pp. 63-80 (2014).
411. J. Michael, A. Barth, C. Kloft, H. Derendorf  
Pharmacodynamic in-vitro models to determine the effect of antibiotics  
In 'Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics', ed. by A.A. Vinks, H. Derendorf, J.W. Mouton, Springer, New York, pp. 81-112 (2014).
412. F. Hurtado, B. Weber, H. Derendorf, G. Hochhaus, T. Dalla Costa  
Population pharmacokinetic modeling of the unbound levofloxacin concentrations in plasma and prostate tissue measured by microdialysis in rats  
*Antimicrob. Agents Chemother.* 58, 678-686 (2014).
413. E. Folzer, D. Gonzalez, R. Singh, H. Derendorf  
Comparison of skin permeability for three diclofenac topical formulations: An in vitro study  
*Die Pharmazie* 69, 27-31 (2014).

414. F. V. Büdingen, D. Gonzalez, A.N. Tucker, H. Derendorf  
Relevance of liver failure for anti-infective agents:  
From pharmacokinetic alterations to dosage adjustments  
Ther. Advan. Inf. Dis. 2, 17-41 (2014).
415. A.M. Barbour, S. Schmidt, L. Zhuang, K. Rand, H.  
Derendorf  
Application of pharmacokinetic/pharmacodynamic  
modelling and simulation for the prediction of target  
attainment of ceftobiprole against meticillin-  
resistant Staphylococcus aureus using minimum  
inhibitory concentration and time-kill curve based  
approaches.  
Int J Antimicrob Agents. 43, 60-7 (2014).
416. K. Ikawa, E. Kikuchi, J. Kikuchi, M. Nishimura, H.  
Derendorf, N. Morikawa  
Pharmacokinetic modeling of serum and bronchial  
concentrations for clarithromycin and telithromycin,  
and site-specific pharmacodynamic simulation for their  
dosages  
J. Clin. Pharm. Ther. 39, 411-417 (2014).
417. F. J. Azeredo, T. Dalla Costa, H. Derendorf  
Role of microdialysis in pharmacokinetics and  
pharmacodynamics: Current status and future directions  
Clin. Pharmacokin. 53, 205-212 (2014).
418. O. Burkhardt, H. Derendorf  
Grundlage der Pharmakotherapie beim kritisch Kranken  
In "Intensivmedizin", edited by H. Van Aken, K.  
Reinhart, T. Welte, M. Weigand, Thieme, pg. 353-361  
(2014).
419. H. Derendorf  
Pharmacodynamic evaluation of inhaled corticosteroids  
Respiratory Drug Delivery, Vol. 1-2014, 173-182  
(2014).
420. M. Zühlsdorf, V.A. Bhattaram, M. Campioni, S. Krösser,  
H. Derendorf, A. Kovar  
Population pharmacokinetics of cilengitide in adult  
and pediatric cancer patients from a nonlinear mixed-  
effects analysis  
J. Clin. Pharmacol. 54, 1391-1399 (2014).

421. E.F. Egelund, M. Weiner, R.P. Singh, T.J. Prihoda, J.A. Gelfond, H. Derendorf, W.R. Mac Kenzie, C.A. Peloquin  
Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. *Antimicrob. Agents Chemother.* 58, 4904-4910 (2014).
422. M. Yu, L.A. Salvador, S.K. Sy, Y. Tang, R.S. Singh, Q.Y. Chen, Y. Liu, J. Hong, H. Derendorf, H. Luesch  
Largazole pharmacokinetics in rats by LC-MS/MS. *Mar. Drugs* 12, 1623-1640 (2014).
423. J.K. Mukker, R.P. Singh, H. Derendorf  
Determination of atypical nonlinear plasma-protein-binding behavior of tigecycline using an in vitro microdialysis technique. *J. Pharm. Sci.* 103, 1013-1019 (2014).
424. H. Derendorf, E.O. Meltzer, R. Hermann, G.W. Canonica  
Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate. *Drugs Today* 50, 15-31 (2014).
425. M. Zeitlinger, S. Marchand, W. Couet, A. Barth, H. Derendorf  
Microdialysis in antibiotic research (in Chinese)  
In "Microdialysis in Drug Development", ed. by M. Müller, Springer, pg. 75-90 (2014).
426. A.N. Deitchman, H. Derendorf  
Measuring drug distribution in the critically ill patient  
*Adv. Drug Deliv. Rev.* 77, 22-26 (2014).
427. F. Hurtado, J.V. Laureano, G. de A Lock, H. Derendorf, T. Dalla Costa  
Enhanced penetration of moxifloxacin into rat prostate tissue evidenced by microdialysis  
*Int. J. Antimicrob. Agents.* 44, 327-333 (2014).
428. S.K. Sy, E. Asin-Prieto, H. Derendorf, E. Samara  
Predicting pediatric age-matched weight and body mass index  
*AAPS Journal* 16, 1372-1379 (2014).

429. S.K.B. Sy, X. Wang, H. Derendorf  
Introduction to pharmacometrics and quantitative pharmacology with an emphasis on physiologically based pharmacokinetics  
In 'Applied Pharmacometrics', ed. by S. Schmidt and H. Derendorf, Springer, New York, pp. 1-64 (2014).
430. S.K.B. Sy, H. Derendorf  
Pharmacometrics in bacterial infections  
In 'Applied Pharmacometrics', ed. by S. Schmidt and H. Derendorf, Springer, New York, pp. 229-258 (2014).
431. L. de Kock, S.K. Sy, B. Rosenkranz, A.H. Diacon, K. Prescott, K.R. Hernandez, M. Yu, H. Derendorf, P.R. Donald  
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis  
Antimicrob. Agents Chemother. 58, 6242-6250 (2014).
432. C. Scheerans, S.G. Wicha, J. Michael, H. Derendorf, C. Kloft  
Concentration-response studies and modelling of the pharmacodynamics of linezolid: Staphylococcus aureus versus Enterococcus faecium  
Int. J. Antimicrob. Agents, 45, 54-60 (2015).
433. G.A. Buqui, D.R. Gouvea, S.K. Sy, A. Voelkner, R.S. Singh, D.B. da Silva, E. Kimura, H. Derendorf, N.P. Lopes, A. Diniz  
Pharmacokinetic evaluation of avicularin Using a model-based development approach  
Planta Med. 81, 373-381 (2015).
434. R.R. Kempker, A.B. Barth, S. Vashakidze, K. Nikolaishvili, I. Sabulua, N. Tukvadze, N. Bablishvili, S. Gogishvili, R.S. Singh, J. Guarner, H. Derendorf, C.A. Peloquin, H.M. Blumberg  
Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis  
Antimicrob. Agents Chemother. 59, 3159-3155 (2015).
435. J.K. Mukker, R.S. Singh, H. Derendorf  
Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy

- Adv. Drug Deliv. Rev. 85, 57-64(2015).
436. S.K. Sy, R. Malmberg, A. Matsushima, E. Asin-Prieto, B. Rosenkranz, M.F. Cotton, H. Derendorf, S. Innes  
Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model  
Int. J. Antimicrob. Agents 45, 413-419 (2015).
437. F. Wei, R.S. Singh, M. Fueth, S. Swarts, P. Okunieff, H. Derendorf  
Development and validation of a HPLC-MS/MS method for the determination of phytolaccagenin in rat plasma and application to a pharmacokinetic study  
J. Pharm. Biomed. Anal. 107, 82-88 (2015).
438. L. Zhuang, S.K. Sy, H. Xia, R.P. Singh, M.B. Mulder, C. Liu, H. Derendorf  
Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model  
Int J Antimicrob Agents 45, 151-160 (2015).
439. F.J. Azeredo, S.E. Hass, P. Sansone, H. Derendorf, T. Dalla Costa, B.V. De Araujo  
Does the anesthetic urethane influence the pharmacokinetics of antifungal drugs? A population pharmacokinetic investigation in rats  
J. Pharm. Sci. 104, 3314-3318(2015).
440. G. An, J.K. Mukker, H. Derendorf, R.F. Frye  
Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea  
J. Clin. Pharmacol. 55, 1313-1331 (2015).
441. S.A.R. Shilbayeh, S.K. Sy, M. Melhem, R. Zmeili, H. Derendorf  
Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment  
Clin. Pharmacol. Drug Dev. 4, 387-394(2015).
442. R.P. Singh, J.K. Mukker, H. Derendorf  
Physiologically-based pharmacokinetic (PBPK) modeling: Impact on nano-based drug delivery  
In 'NanoBioMedicine, Vol. 2 (NanoPharmaceuticals)', ed. by B. Singh, K.K. Singh, G.S. Rekhi, Studium Press, p. 201-222 (2015).

443. U. Theuretzbacher, P.G. Ambrose, A.P. MacGowan, D.R. Andes, F. Sörgel, H. Derendorf, J.W. Mouton, G.L. Drusano, P.M. Tulkens, M.N. Dudley, O. Cars, R.L. Nation  
In memoriam: William A. Craig  
Antimicrob Agents Chemother. 59, 2971 (2015).
444. L. Zhuang, H. Xia, Y. Gu, H. Derendorf, Y. Li, C. Liu  
Theory and application of microdialysis in pharmacokinetic studies  
Curr Drug Metab. 16, 919-931 (2015).
445. L. Lachi-Silva, S.K. Sy, A. Voelkner, J.P. de Sousa, J.L. Lopes, D.B. Silva, N.P. Lopes, E. Kimura, H. Derendorf, A. Diniz  
Simultaneous characterization of intravenous and oral pharmacokinetics of lychnopholide in rats by transit compartment model  
Planta Med. 81, 1121-1127 (2015).
446. P. Augustijns, T. Loftsson, M. Davies M, H. Derendorf, J. Mesens, G. Verreck  
A tribute to Dr. Marcus E. Brewster: October 14, 1957-September 15, 2014  
J. Pharm. Sci. 105, 2466-2467 (2016).
447. J.K. Mukker, R.P. Singh, H. Derendorf  
Methodologies for protein binding determination in anti-infective agents  
In 'Antibiotic Pharmacodynamics', ed. by J.C. Rothschafer, D.R. Andes, K.A. Rodvold, Humana Press, p. 109-125 (2016).
448. S. Lampotang, D.E. Lizdas, H. Derendorf, N. Gravenstein, B. Lok, J.P. Quarles  
Race-specific pharmacodynamic model of propofol-induced loss of consciousness  
J. Clin. Pharmacol. 56, 1141-1150(2016).
449. L. Zhuang, Y. He, H. Xia, Y. Liu, S.K. Sy, H. Derendorf  
Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model  
J. Antimicrob. Chemother. 71, 1012-1021 (2016).

450. S.K. Sy, L. Zhuang, H. Derendorf  
Pharmacokinetics and pharmacodynamics in antibiotic dose optimization  
Expert Opin Drug Metab Toxicol. 12, 93-114 (2016).
451. S.K. Sy, H. Derendorf  
Pharmacokinetics I: PK-PD approach, the case of antibiotic drug development  
In 'Clinical Pharmacology: Current Topics and Case Studies', ed. By M. Müller, Springer, p. 185-217 (2016).
452. S.K. Sy, M. Beaudoin, L. Zhuang, K. Löblein, C. Lux, M. Kissel, R. Tremmel, C. Frank, S. Strasser, J. Heuberger, M. Mulder, V.A. Schuck, H. Derendorf  
In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms  
J. Antimicrob. Chemother. 71, 1866-1880 (2016).
453. J.K. Mukker, R.S. Singh, H. Derendorf  
Ciclesonide: A pro-soft drug approach for mitigation of side effects of inhaled corticosteroids  
J. Pharm. Sci. 105, 2509-2514(2016).
454. A. Deitchman, D. de Jong, A. Barbour, H. Derendorf  
Ceftobiprole medocaril (BAL-5788) for the treatment of complicated skin infections  
Expert Rev Anti Infect Ther. (2016).
455. R.S. Singh, J.K. Mukker, A. Deitchman, S. Drescher, H. Derendorf  
Role of divalent metal ions in atypical nonlinear plasma protein binding behavior of tigecycline  
J. Pharm Sci. 105, 3409-3414 (2016).
456. S.B. Jadhav, V. Khaowroongrueng, H. Derendorf  
Microdialysis of large molecules  
J. Pharm Sci. 105, 3233-3242 (2016).

**Series Clinical Pharmacy POP (Patient-oriented Pharmacy, in German)**

1. M. Alter, I. Waltering, O. Rose, H. Derendorf  
MTM für Arzt und Patient  
Deutsche Apotheker Zeitung 152, 1996-2002 (2012).
2. O. Rose, H. Derendorf  
Ein Patient mit Hyperlipidämie  
Deutsche Apotheker Zeitung 152, 2004-2012 (2012).
3. M. Zieglmeier, H. Derendorf, R. Hermann  
Eine Schmerzpatientin  
Deutsche Apotheker Zeitung 152, 2478-2486 (2012).
4. A.N. Förster, H. Derendorf, R. Hermann  
Eine Hypertonie-Patientin  
Deutsche Apotheker Zeitung 152, 3088-3095 (2012).
5. M. Zieglmeier, H. Derendorf, R. Hermann  
Eine Parkinson-Patientin mit Sturzneigung  
Deutsche Apotheker Zeitung 152, 3570-3575 (2012).
6. A.N. Förster, R. Hermann, H. Derendorf  
Ein junger Asthmapatient  
Deutsche Apotheker Zeitung 152, 3992-4000 (2012).
7. O. Rose, D. Hage, H. Derendorf  
Eine depressive Patientin  
Deutsche Apotheker Zeitung 152, 4578-4588 (2012).
8. A.N. Förster, H. Derendorf, R. Hermann  
Ein jugendlicher Diabetiker  
Deutsche Apotheker Zeitung 152, 4980-4988 (2012).
9. O. Rose, T. Liebig, D. Maintz, H. Derendorf  
Ein Schlaganfall-Patient  
Deutsche Apotheker Zeitung 152, 5646-5655 (2012).
10. I. Waltering, J. Rech, H. Derendorf  
Eine junge Rheumapatientin  
Deutsche Apotheker Zeitung 152, 6092-6103 (2012).
11. M. Weißenborn, E. Schmitz, M. Kissel, H. Derendorf  
Körperkonzentrationen - Wichtige Grundlagen der  
Pharmakokinetik



- Deutsche Apotheker Zeitung 152, 6108-6115 (2012).
12. M. Dircks, F. Fuchs, K. Leuner, F. Dörje, H. Derendorf  
Ein Patient mit COPD  
Deutsche Apotheker Zeitung 153, 162-172 (2013).
  13. E. Schmitz, M. Weißenborn, M. Kissel, H. Derendorf  
Der Weg durch den Körper - Resorption, Verteilung, Abbau  
und Ausscheidung von Arzneistoffen  
Deutsche Apotheker Zeitung 153, 277-287 (2013).
  14. M. Hahn, H. Derendorf, S. Roll  
Ein Patient mit bipolarer Störung  
Deutsche Apotheker Zeitung 153, 722-731 (2013).
  15. M. Weissenborn, E. Schmitz, M. Kissel, H. Derendorf  
Drug-Level-Monitoring - Voraussetzung für die optimale  
Dosierung bestimmter Arzneistoffe  
Deutsche Apotheker Zeitung 153, 736-740 (2013).
  16. G. Baumgärtner, M. Ziegelmeier, R. Hermann, H.  
Derendorf  
Eine Patientin mit Juckreiz und Ödemen  
Deutsche Apotheker Zeitung 153, 1056-1064 (2013).
  17. M. Weißenborn, E. Schmitz, M. Kissel, H. Derendorf  
Gewicht, Alter, Genom - Individuelle Einflussfaktoren auf  
die Pharmakokinetik  
Deutsche Apotheker Zeitung 153, 1070-1073 (2013).
  18. I. Richling, R. Hermann, H. Derendorf  
Eine Patientin mit Verhütungswunsch  
Deutsche Apotheker Zeitung 153, 1734-1740(2013).
  19. O. Rose, H. Omran, A. Dübbers, H. Derendorf  
Ein Patient mit cystischer Fibrose  
Deutsche Apotheker Zeitung 153, 2052-2060 (2013).
  20. I. Waltering, T. Fey, R. Hermann, H. Derendorf  
Ein Alzheimer-Patient  
Deutsche Apotheker Zeitung 153, 2552-2562 (2013).
  21. O. Rose, C. Fechtrup, H. Derendorf  
Ein Patient mit Herzinsuffizienz  
Deutsche Apotheker-Zeitung 153, 2990-2997 (2013).

22. N. Förster, R. Hermann, H. Derendorf  
Eine Patientin mit Herzrhythmusstörungen  
Deutsche Apotheker-Zeitung 153, 3392-3399 (2013).
23. N. Förster, R. Hermann, H. Derendorf  
Eine Patientin mit Epilepsie  
Deutsche Apotheker-Zeitung 153, 3790-3799 (2013).
24. H. Derendorf, C. Kloft, U. Jaehde  
Patientenorientierte Pharmazie – Gedanken zum Leitbild  
und zur Ausbildung des Apothekers  
Deutsche Apotheker-Zeitung 153, 3930-3933 (2013).
25. O. Rose, D. Maintz, H. Derendorf  
Eine Patientin mit fortgeschrittenem Parkinson-Syndrom  
Deutsche Apotheker-Zeitung 153, 4410-4416 (2013).
26. C. John, J. Meier, H. Derendorf  
Eine Patientin mit Gestationsdiabetes  
Deutsche Apotheker-Zeitung 153, 4986-4999 (2013).
27. D. Mertens-Keller, D. Maintz, H. Derendorf  
Eine junge Patientin mit multipler Sklerose  
Deutsche Apotheker-Zeitung 153, 5462-5471 (2013).
28. M. Ziegelmeier, R. Hermann, H. Derendorf  
Ein Diabetiker mit Erysipel  
Deutsche Apotheker-Zeitung 153, 163-168 (2014).
29. O. Rose, I. Richling, D. Maintz, H. Derendorf  
Ein Patient mit Prostatakarzinom  
Deutsche Apotheker-Zeitung 153, 634-642 (2014).
30. I. Richling, O. Rose, D. Maintz, H. Derendorf  
Ein Patient mit akutem Gichtanfall  
Deutsche Apotheker-Zeitung 153, 1074-1082 (2014).
31. I. Waltering, J. Rech, H. Derendorf  
Eine Patientin mit Arthrose  
Deutsche Apotheker-Zeitung 153, 1546-1555 (2014).
32. O. Rose, F. Horst, H. Derendorf  
Eine multimorbide Patientin mit Osteoporose  
Deutsche Apotheker-Zeitung 154, 2147-2155 (2014).
33. C. John, D. Hage, O. Rose, H. Derendorf  
Ein Kind mit ADHS

- Deutsche Apotheker-Zeitung 154, 2650-2662 (2014).
34. D. Mertens-Keller, M. Hoffmann, O. Rose, H. Derendorf  
Eine Patientin mit Morbus Crohn  
Deutsche Apotheker-Zeitung 154, 3112-3125 (2014).
35. I. Richling, I. Waltering, T.J. Hellmann, H. Derendorf  
Ein Patient mit koronarer Herzkrankheit  
Deutsche Apotheker-Zeitung 154, 3504-3512 (2014).
36. C. Remi, D. Bauer, J. Rosenbruch, H. Derendorf  
Ein Palliativ-Patient  
Deutsche Apotheker-Zeitung 154, 4064-4077 (2014).
37. M. Dircks, T. Grömer, J. Kornhuber, O. Rose, H. Derendorf, F. Dörje, K. Friedland  
Eine Patientin mit Zwangserkrankung  
Deutsche Apotheker-Zeitung 154, 4540-4549 (2014).
38. I. Waltering, O. Rose, D. Durstewitz-Knierim, H. Derendorf  
Ein Patient mit Rückenschmerzen  
Deutsche Apotheker-Zeitung 154, 5078-5086 (2014).
39. N. Kraft, K. Römer, O. Rose, H. Derendorf  
Ein Patient mit HIV-Infektion  
Deutsche Apotheker-Zeitung 154, 5532-5542 (2014).
40. O. Rose, C. Fechtrup, H. Derendorf  
Eine Patientin nach Herzinfarkt  
Deutsche Apotheker-Zeitung 155, 158-165 (2015).
41. I. Richling, F. Richling, O. Rose, H. Derendorf  
Ein Asthma-Patient mit Analgetika-Intoleranz  
Deutsche Apotheker-Zeitung 155, 644-652 (2015).
42. O. Rose, D. Hage, H. Derendorf  
Eine Schizophrenie-Patientin  
Deutsche Apotheker-Zeitung 155, 1206-1212 (2015).
43. M. Hahn, C. Fechtrup, O. Rose, H. Derendorf  
Ein Patient mit Hypertonie  
Deutsche Apotheker-Zeitung 155, 1610-1618 (2015).
44. K. Dahse, J. Lerner, O. Rose, H. Derendorf  
Ein Patient mit Harnwegsinfekt

- Deutsche Apotheker-Zeitung 155, 2026-2035 (2015).
45. I. Waltering, S. Koling, O. Rose, H. Derendorf  
Ein Jugendlicher nach Nierentransplantation  
Deutsche Apotheker-Zeitung 155, 2442-2451 (2015).
46. O. Rose, C. Fehtrup, H. Derendorf  
Eine ältere Patientin unter Polymedikation  
Deutsche Apotheker-Zeitung 155, 2926-2933 (2015).
47. M. Dircks, O. Strahl, O. Rose, M.W. Beckmann, F.  
Dörje, H. Derendorf  
Eine Patientin mit Mammakarzinom  
Deutsche Apotheker-Zeitung 155, 3310-3317 (2015).
48. O. Rose, M. Lautenschläger, C. Fehtrup, H. Derendorf  
Ein älterer Patient mit Typ-2-Diabetes und metabolischem  
Syndrom  
Deutsche Apotheker-Zeitung 155, 3716-3723 (2015).
49. I. Richling, O. Rose, C. Fehtrup, H. Derendorf  
Eine Patientin mit pulmonaler arterieller Hypertonie  
Deutsche Apotheker-Zeitung 155, 4330-4339 (2015).
50. I. Richling, F. Richling, O. Rose, H. Derendorf  
Eine Patientin mit Schlafstörungen  
Deutsche Apotheker-Zeitung 155, 4776-4788 (2015).
51. D.C. Dartsch, O. Rose, C. Fehtrup, H. Derendorf  
Eine multimorbide Patientin mit Herzinsuffizienz  
Deutsche Apotheker-Zeitung 155, 5224-5231 (2015).
52. D. Mertens-Keller, T. Warnecke, O. Rose, H. Derendorf  
Eine Patientin mit Restless-Leg-Syndrom  
Deutsche Apotheker-Zeitung 156, 214-222 (2016).
53. C. John, M. Steckstor, O. Rose, H. Derendorf  
Eine Patientin mit Ulcus Ventriculi  
Deutsche Apotheker-Zeitung 156, 592-603 (2016).
54. I. Waltering, J. rech, O. Rose, H. Derendorf  
Ein Patient mit Spondylitis ankylosans  
Deutsche Apotheker-Zeitung 156, 1010-1017 (2016).
55. E. Pfister, C. Hohmann, T. Neumann-HAefelin, O. Rose,  
H. Derendorf  
Ein Patient mit kardio-embolischem Schlaganfall

Deutsche Apotheker-Zeitung 156, 1810-1818 (2016).

56. A. Edalat, B. Besemer, O. Rose, H. Derendorf  
Ein Patient mit multiplem Myelom  
Deutsche Apotheker-Zeitung 156, 2790-2798 (2016).

57. O. Rose, C. Fechtrup, H. Derendorf  
Spannungsfeld Deprescribing - Eine Patientin mit  
Polymedikation  
Deutsche Apotheker-Zeitung 156, 3544-3553 (2016).

## List of Papers Presented at Meetings

1. H. Derendorf, P. Rohdewald  
Measurement of the analgesic action by subjective and objective parameters.  
4th Meeting on the Pain Society of Germany, Austria and Switzerland, Munich,  
October 1979
2. P. Rohdewald, H. Derendorf, C.E. Elger, O. Knoll  
Evoked potentials as objective parameters of the analgesic response of weak  
analgesics.  
Clinical Applications of Evoked Potentials in Neurology, Lyon, October 1980
3. H. Derendorf, E.R. Garrett  
HPLC of methadone, its major metabolite and cocaine using a post-column extraction  
of a fluorescent ion-pair.  
31st National Meeting of the American Pharmaceutical Association Academy of  
Pharmaceutical Sciences, Orlando, November 1981
4. H. Derendorf, E.R. Garrett  
Determination of morphine-antagonists in biological fluids using HPLC with  
electrochemical detection.  
31st National Meeting of the American Pharmaceutical Association Academy of  
Pharmaceutical Sciences, Orlando, November 1981
5. H. Derendorf, G. Drehsen, P. Rohdewald  
Relative potency of over-the-counter analgesics estimated by somatosensory evoked  
potentials.  
83rd Annual Meeting of the American Society of Clinical Pharmacology and  
Therapeutics, Lake Buena Vista, March 1982
6. H. Derendorf, G. Drehsen, P. Rohdewald  
Drug release, saliva levels and efficacy of weak analgesics.  
1st General Conference on Pharmaceutical Sciences, Munich, April 1983
7. P. Rohdewald, H. Möllmann, E.W. Schmidt, G. Drehsen, H. Derendorf  
Influences of high doses of water-soluble glucocorticoids on the cortisol-level in  
humans.  
1st General Conference on Pharmaceutical Sciences Munich, April 1983
8. H. Derendorf, A.A. El-Koussi, E.R. Garrett  
Electrochemical determination of erythrocyte partitioning and protein binding of  
naloxone and naltrexone.  
1st General Conference on Pharmaceutical Sciences, Munich, April 1983
9. P. Rohdewald, H. Derendorf, G. Drehsen, C.E. Elger, O. Knoll  
Attenuation of pain by over-the-counter analgesics.  
Serturmer-Symposium, Paderborn, June 1983
10. H. Derendorf, G. Hochhaus, H. Möllmann, P. Rohdewald  
Determination of glucocorticoids and their water soluble esters in biological  
fluids.  
35rd National Meeting of the American Pharmaceutical Association Academy of  
Pharmaceutical Sciences, Miami, November 1983
11. H. Derendorf, G. Drehsen, P. Rohdewald  
Analgesic activity of antipyrine in humans.  
85th Annual Meeting of the American Society for Clinical Pharmacology and  
Therapeutics, Atlanta, March 1984
12. H. Derendorf, H. Möllmann, P. Rohdewald  
Pharmacokinetics and pharmacodynamics of methylprednisolone and its hemisuccinate  
ester.  
131st Annual Meeting of the American Pharmaceutical Association, Montreal, May  
1984
13. P. Rohdewald, H. Derendorf, H. Möllmann, J. Rehder, E.W. Schmidt  
Pharmacokinetics of water soluble glucocorticoids.  
Annual Meeting of the German Pharmaceutical Association, Dusseldorf, September  
1984

14. H. Derendorf, R.L. Yost  
Determination of cephalosporins and their metabolites in biological fluids.  
37th National Meeting of the American Pharmaceutical Association Academy of  
Pharmaceutical Sciences, Philadelphia, October 1984
15. H. Derendorf, H. Möllmann, P. Rohdewald  
Pharmacokinetics of glucocorticoids following the application of high doses of  
water soluble glucocorticoids.  
7th European Workshop on Inflammation, Capri, April 1985
16. R.L. Yost, H. Derendorf, M.B. Affrime  
Pharmacokinetics of cefotaxime and its metabolite in normal and morbidly obese  
subjects.  
Annual meeting of the American College of Clinical Pharmacy, Orlando, July 1985
17. H. Derendorf, H. Möllmann, P. Rohdewald  
Pharmacokinetics of high dose glucocorticoids  
45th International Congress of Pharmaceutical Sciences of F.I.P., Montreal,  
September 1985
18. H. Derendorf, M. Kaltenbach  
Coulometric HPLC analysis of morphine in biological fluids.  
International Symposium on Drug Analysis, Ottawa, September 1985
19. R. Townsend, J.H. Perrin, H. Derendorf  
HPLC - Determination of free and conjugated estrogens in tablets.  
133rd Annual Meeting of the American Pharmaceutical Association, San Francisco,  
March 1986
20. H. Derendorf, H. Möllmann, P. Rohdewald, G. Gyselby  
Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after  
intraarticular administration.  
133rd Annual Meeting of the American Pharmaceutical Association, San Francisco,  
March 1986
21. H. Derendorf  
Pharmacokinetics and pharmacodynamics of high-dose glucocorticoids.  
19th Annual Higuchi Research Seminar, Lake Ozark, March 1986
22. H. Derendorf, M. Kaltenbach, G. von der Lippe  
Coulometric HPLC-analysis of morphine-surrogates in biological fluids.  
2nd International Symposium on Drug Analysis, Brussels, May 1986
23. G. Mullersman, V.P. Gotz, W.L. Russell, H. Derendorf  
In vitro and in vivo interactions between ranitidine and sucralfate.  
Annual Meeting of the American College of Clinical Pharmacy, Chicago, July 1986
24. G. Mullersman, H. Möllmann, A. Gruner, H. Derendorf  
Influence of triamcinolone acetate on the pharmacokinetics of diclofenac after  
i.m. - administration.  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986
25. G. Mullersman, V. Gotz, H. Derendorf  
In vitro and in vivo interaction between ranitidine and sucralfate.  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986
26. G. Mullersman, S. Toufflin, H. Derendorf  
Coulometric HPLC-Analysis of buprenorphine  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986
27. M. Butschkau, J.H. Perrin, H. Derendorf  
HPLC - determination, erythrocyte binding and relative bioavailability of codeine.  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986

28. H. Derendorf, R. Townsend, K. Embil  
HPLC - determination of conjugated estrogens.  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986
29. H. Derendorf, G. Mullersman, M.E. Brewster, K.S. Estes, N.S. Bodor  
Pharmacokinetics and pharmacodynamics of a brain-specific estradiol chemical  
delivery system.  
Meeting of the Austrian and German Pharmaceutical Association, Innsbruck,  
September 1986
30. H. Derendorf, M. Butschkau, J.H. Perrin  
HPLC-assay, erythrocyte binding and relative bioavailability of codeine.  
Annual Meeting of the American Association of Pharmaceutical Scientists,  
Washington, November 1986
31. G. Mullersman, V. Gotz, H. Derendorf  
In vitro and in vivo interactions between ranitidine and sucralfate.  
Annual Meeting of the American Association of Pharmaceutical Scientists,  
Washington, November 1986
32. G. Mullersman, H. Möllmann, A. Grüner, H. Derendorf  
Pharmacokinetics of diclofenac after intramuscular administration in combination  
with triamcinolone acetate.  
Annual Meeting of the American Association of Pharmaceutical Scientists,  
Washington, November 1986
33. G. Mullersman, S. Toufflin, H. Derendorf  
Coulometric HPLC-Analysis of buprenorphine.  
Annual Meeting of the American Association of Pharmaceutical Scientists,  
Washington, November 1986
34. S.A. Stout, D. Worthington-White, C.M. Riley, H. Derendorf  
Comparison of a short term assay and a clonogenic assay for the determination of  
anticancer drug effects.  
88th Annual Meeting of the American Society of Clinical Pharmacology and  
Therapeutics, Orlando, March 1987
35. H. Derendorf, H. Möllmann, P. Rohdewald  
Pharmacokinetics and pharmacodynamics of high-dose glucocorticoid esters.  
88th Annual Meeting of the American Society of Clinical Pharmacology and  
Therapeutics, Orlando, March 1987
36. H. Derendorf  
Pharmacokinetics and pharmacodynamics of a chemical delivery system for estradiol.  
20th Annual Higuchi Research Seminar, Lake Ozark, March 1987
37. H. Derendorf  
Pharmacokinetics of glucocorticoids.  
Workshop on Glucocorticoids in Rheumatology and Orthopedics, Rottach-Egern, April  
1987
38. S. A. Stout, C. M. Riley, H. Derendorf  
The correlation between the pharmacokinetics of melphalan and the pharmacodynamic  
response of neuroblastoma cells treated in vitro.  
3rd European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, April  
1987
39. H. Derendorf  
Pharmacokinetic evaluation of cefotaxime in normal and obese subjects.  
3rd European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, April  
1987
40. S.A. Stout, C.M. Riley, H. Derendorf  
In vitro pharmacokinetics and pharmacodynamics of melphalan.  
Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies,  
Munich, April 1987



41. H. Derendorf  
Estimation of free tissue levels for the pharmacokinetic evaluation of antibiotics.  
Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Munich, April 1987
42. H. Derendorf  
Pharmacokinetic significance of free tissue levels.  
Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October 1987
43. H. Derendorf  
Pharmacokinetic criteria for the evaluation of beta-lactam antibiotics.  
American Association of Pharmaceutical Scientists Western Regional Meeting, Reno, February 1988
44. H. Derendorf, H. Möllmann, P. Rohdewald  
Pharmacokinetics and pharmacodynamics of methylprednisolone phosphate and hemisuccinate.  
89th Annual Meetings of the American Society of Clinical Pharmacology and Therapeutics, San Diego, March 1988
45. H. Derendorf  
Estimation of free tissue levels of antibiotics.  
21st Annual Higuchi Research Seminar, Lake Ozark, March 1988
46. M.E. Brewster, K.S. Estes, T. Loftsson, G. Mullersman,  
H. Derendorf, R. Perchalski, N. Bodor  
Chemical and biological properties of a 2-hydroxy-propyl- $\beta$ -cyclodextrin complex of an estradiol chemical delivery system.  
4th International Symposium on Cyclodextrins, Munich, April 1988
47. K.S. Estes, H. Derendorf, M.E. Brewster, N. Bodor  
Buccal administration of a brain-targeted redox-based chemical delivery system for estradiol in rats.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
48. H. Derendorf, H. Möllmann, P. Rohdewald, C. Möllmann, J. Barth  
Clinical pharmacodynamics of methylprednisolone phosphate.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
49. J. Barth, A. Fett, M. Pörtner, B.E. Braun, H.W. Möllmann, J. Krämer, P. Rohdewald, H. Derendorf  
Pharmacokinetics of two glucocorticoid suspensions after epidural administration.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
50. H. Derendorf, K.S. Estes, R. Vistelle, M.E. Brewster, R. Clemmons, N. Bodor  
Pharmacokinetics of an estradiol chemical delivery system in dogs.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
51. H. Möllmann, P. Rohdewald, J. Barth, C. Möllmann, H. Derendorf  
Comparison of pharmacokinetic and pharmacodynamic properties of high doses of methylprednisolone prodrugs.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
52. E. Brunt, J. Limberg, H. Derendorf  
HPLC-assay, protein binding and red blood cell partitioning of fleroxacin.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988
53. H. Derendorf, H. Möllmann, P. Rohdewald, D. Stroband  
Comparison of pharmacokinetic properties of several glucocorticoids after intraarticular administration.  
Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1988

54. C.J. Betlach, A. Cohen, W. Huang, H. Derendorf, M.A. Gonzalez  
The multiple dose pharmacokinetics of two 24 hour theophylline tablets in normal subjects.  
45th Annual Congress of the American College of Allergy and Immunology, Los Angeles, November 1988
55. H. Möllmann, H. Derendorf, G. Hochhaus, J. Barth  
Biopharmaceutical and pharmacological aspects of locally and systemically administered glucocorticoids.  
4th Annual Meeting of the German Society for Osteology, Göttingen, February 1989
56. H. Möllmann, H. Derendorf, G. Hochhaus, J. Barth  
Pharmacodynamic and mechanic interactions of locally administered glucocorticoid crystal suspensions.  
4th Annual Meeting of the German Society for Osteology, Göttingen, February 1989
57. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus  
Pharmacodynamic interactions of systemic glucocorticoid therapy.  
4th Annual Meeting of the German Society for Osteology, Göttingen, February 1989
58. H. Derendorf, H. Möllmann, P. Rohdewald, D. Stroband, J. Barth, G. Hochhaus  
Pharmacokinetic aspects of intraarticular administration of glucocorticoids.  
4th Annual Meeting of the German Society for Osteology, Göttingen, February 1989
59. H. Derendorf  
Pharmacokinetics and pharmacodynamics of glucocorticoids.  
22nd Annual Higuchi Research Seminar, Lake Ozark, March 1989
60. H. Derendorf, J. Limberg, E. Brunt  
Erythrocyte uptake and protein binding of fleroxacin.  
4th European Congress of Clinical Microbiology, Nice, April 1989
61. H. Derendorf, H. Möllmann, P. Rohdewald, C. Möllmann, M. Krieg, S. Tunn, J. Barth, H.J. Röthig  
Clinical pharmacokinetics and pharmacodynamics of methylprednisolone phosphate.  
4th World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, July 1989
62. G. Hochhaus, H. Derendorf, H. Möllmann, C. Möllmann, M. Krieg, S. Tunn, J. Barth, H.J. Röthig  
Comparison of the clinical pharmacodynamics of dexamethasone, methylprednisolone and triamcinolone acetonide.  
4th World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, July 1989
63. H. Möllmann, J. Barth, H. Derendorf, G. Hochhaus  
Time course of bronchospasmolytic effects after injection of different water-soluble glucocorticoids.  
4th World Conference on Clinical Pharmacology and Therapeutics, Mannheim-Heidelberg, July 1989
64. F.F.T. Ververs, L. Lopez, H.G. Schaefer, S. Freyer, H. Derendorf  
Simultaneous HPLC-assay of propranolol, diltiazem and diltiazem-metabolites in human plasma with applications.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989
65. H. Derendorf, Y.L. Kan, J. Perrin  
Effect of lovastatin on the pharmacokinetics of glipizide.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989
66. J. Limberg, J. Sastry, N. Bodor, H. Derendorf  
Analysis, stability and receptor binding studies on a chemical delivery system for enkephalins.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989

67. K.S. Estes, K. Dietzel, M.E. Brewster, N. Bodor, H. Derendorf  
Improved bioavailability of dexamethasone administered intravenously as a water soluble cyclodextrin inclusion complex.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989
68. K. Dietzel, V. Keuth, K.S. Estes, M. Brewster, N. Bodor, H. Derendorf  
Pharmacokinetics of a chemical delivery system for estradiol in dogs.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989
69. H.G. Schaefer, H. Spahn, J. Limberg, H. Derendorf  
Effects of partial gastrectomy on the pharmacokinetics of propranolol-enantiomers.  
49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, September 1989
70. H. Derendorf, H. Möllmann  
Clinical pharmacokinetics and pharmacodynamics of methylprednisolone phosphate.  
Annual Meeting of the Southeastern Chapter of the American College of Clinical Pharmacology, Augusta, September 1989.
71. K. Dietzel, K.S. Estes, M.E. Brewster, N.S. Bodor, H. Derendorf  
Dose linearity testing for a chemical delivery system for estradiol in dogs.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
72. K. Dietzel, K.S. Estes, M.E. Brewster, N.S. Bodor, H. Derendorf  
Pharmacokinetics of dexamethasone after intravenous administration of an inclusion complex in  $\beta$ -hydroxypropylcyclodextrin.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
73. H. Derendorf, J. Limberg, J. Sastry, N. Bodor  
Stability and receptor binding of chemical delivery systems for enkephalins.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
74. H. Derendorf, H.G. Schaefer, J. Limberg, D. Harrison, M.P. Hocking  
Effects of partial gastrectomy on the pharmacokinetics of propranolol-enantiomers and theophylline in dogs.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
75. H. Möllmann, J. Barth, E.W. Schmidt, P. Rohdewald, H. Derendorf, G. Hochhaus  
Bronchospasmolytic activity of methylprednisolone in patients with severe pulmonary obstruction.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
76. E.W. Schmidt, B. Rasche, H. Möllmann, J. Barth, W.T. Ulmer, H. Derendorf  
Plasma-levels of  $\alpha_1$ -protease inhibitor, trypsin inhibitor and elastase-inhibitor in patients with lung emphysema.  
Fourth Annual Meeting of the American Association of Pharmaceutical Scientists, Atlanta, October 1989.
77. H. Derendorf  
Dose optimization based on pharmacokinetic/pharmacodynamic modelling.  
23rd Annual Higuchi Research Seminar, Lake Ozark, March 1990.
78. H. Derendorf  
The role of pharmacokinetics in clinical trials.  
7th Symposium on Chemotherapeutics, Munich, March 1990.
79. B. Wichert, H. Derendorf, R.J. Gonzalez-Rothi, H. Schreier  
Anti-TB drug liposome aerosols: formulation, characterization, stability and uptake by pulmonary alveolar macrophages (AM) in vitro.  
36th Annual Congress of the International Association for Pharmaceutical Technology (APV), Kiel, March 1990.

80. H. Derendorf  
Estimation of free tissue levels as predictors of antibiotic activity.  
Symposium on Antibiotic Policies, Vienna, March 1990.
81. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus  
Pharmacokinetic-pharmacodynamic optimization of systemic glucocorticoid therapy of colitis.  
Ulmer Symposium on Colitis, Ulm, March 1990.
82. H. Möllmann, J. Barth, H. Derendorf, G. Hochhaus  
Clinical significance of pharmacokinetics, intrinsic activity and biopharmaceutical properties of glucocorticoids after oral and intravenous administration.  
Ulmer Symposium on Colitis, Ulm, March 1990.
83. H. Möllmann, J. Barth, D. Hüppe, H. Derendorf, G. Hochhaus  
Clinical pharmacology of rectally administered glucocorticoids for Crohn's Disease and colitis ulcerosa.  
Ulmer Symposium on Colitis, Ulm, March 1990.
84. H. Möllmann, J. Barth, S. Tunn, M. Krieg, H. Derendorf, C.R. Möllmann  
Pharmacokinetics and bioavailability of hydrocortisone after rectal administration of hydrocortisone acetate foam in comparison to oral or intravenous administration of hydrocortisone.  
Ulmer Symposium on Colitis, Ulm, March 1990.
85. H. Derendorf, H. Möllmann, G. Hochhaus  
Free peripheral compartment levels as interface between pharmacokinetics and pharmacodynamics of glucocorticoids.  
3rd Symposium Frontiers of Pharmacokinetics and Pharmacodynamics, Baltimore, April 1990.
86. H. Derendorf, H. Möllmann, J. Barth, G. Hochhaus  
Dose optimization of glucocorticoids based on pharmacokinetic-pharmacodynamic modelling.  
Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijk, June 1990.
87. J. Barth, H. Möllmann, H. Derendorf, C. Möllmann, G. Hochhaus, K.H. Lehr, T. Höhler  
Systemic absorption of prednicarbate after dermal, oral and pulmonary administration.  
11th International Congress of Pharmacology, Amsterdam, July 1990.
88. K.S. Estes, K. Dietzel, M.E. Brewster, G. Ellison, N. Bodor, H. Derendorf  
The oxidized metabolite of a redox-based chemical delivery system for estradiol is rapidly eliminated in bile and urine of dogs.  
Gordon Conference on Drug Carriers in Medicine and Biology, Tilton, July 1990.
89. K.S. Estes, K. Dietzel, M.E. Brewster, N. Bodor, H. Derendorf  
Dexamethasone administered intravenously as a water soluble cyclodextrin inclusion complex.  
APhA End of Summer Meeting, Arlington, September 1990.
90. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Dose optimization of corticosteroids.  
Annual Meeting of the Southeastern Chapter of the American College of Clinical Pharmacology, Johnson City, September 1990.
91. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Prediction of clinical potency of corticosteroids by pharmacokinetic-pharmacodynamic modelling.  
Nineteenth Annual Meeting of the American College of Clinical Pharmacology, Las Vegas, November 1990.
92. P. LaBelle, P.D. Ronca, R.V. Zupkis, S. Schwartz, J. Perrin, H. Derendorf, Y.L. Kan  
The short-term effects of lovastatin on glipizide pharmacokinetics and glycemic control in hypercholesterolemic diabetics.  
Nineteenth Annual Meeting of the American College of Clinical Pharmacology, Las Vegas, November 1990.

93. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Area under the effect-time-curve as measure of cumulative drug effects.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
94. G. Hochhaus, L.S. Chen, H. Derendorf, P. Druzgala  
Loteprednol etabonate: Tissue distribution and receptor binding.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
95. H.G. Schäfer, S. Freyer, J. Urciola, H. Schmidt, L. Lopez, H. Derendorf  
Pharmacokinetic interaction of diltiazem and propranolol enantiomers.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
96. S.S. Mohamed, H. Derendorf  
Binding of codeine to healthy and sickle erythrocytes.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
97. H. Derendorf, H. Möllmann, J. Barth, S. Tunn, M. Krieg  
Saliva levels as predictors for free corticosteroid levels in plasma.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
98. K.S. Estes, K. Dietzel, M.E. Brewster, G. Ellison, N. Bodor, H. Derendorf  
Rapid biliary elimination of the oxidized metabolite of a redox-based chemical delivery system for estradiol in dogs.  
Fifth Annual Meeting of the American Association of Pharmaceutical Scientists, Las Vegas, November 1990.
99. H. Derendorf  
The role of the pharmacist today and tomorrow.  
21st International Pharmaceutical Continuing Education Week, Davos, January 1991.
100. H. Derendorf  
Pharmacokinetic aspects of drug evaluation.  
5th Symposium of the Section Pharmaceutical Chemistry of the German Pharmaceutical Society, Münster, March 1991.
101. H. Derendorf, H. Möllmann, J. Barth  
Treatment of pulmonary diseases with corticosteroids on the basis of pharmacokinetic-pharmacodynamic relationships.  
Pulmonology Symposium, Braunschweig, March 1991.
102. H. Derendorf  
Dose optimization of corticosteroids based on pharmacokinetic-pharmacodynamic modelling.  
International Workshop on Differential Corticosteroid Therapy of Chronically Inflamed Bowel Diseases, Köln, March 1991.
103. H. Derendorf  
Twin peaks - stereoselective pharmacokinetics of propranolol.  
24th Annual Higuchi Research Seminar, Lake Ozark, March 1991.
104. G. Hochhaus, R. Hochhaus, H. Möllmann, C. Barmeyer, H. Derendorf  
A sensitive assay for the simultaneous measurement of dexamethasone and dexamethasone-21-isonicotinate.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.
105. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Prediction of clinical potency of corticosteroids by pharmacokinetic-pharmacodynamic modelling.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.

106. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Area under the effect-time-curve as measure of cumulative drug effects.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.
107. S. Freyer, L. Lopez, H. Derendorf  
Pharmacokinetic interaction of diltiazem and propranolol enantiomers.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.
108. M.L. Kaltenbach, A.P. Mauderli, F. Bauman, B.L. Grundy, H. Derendorf  
Tooth-pulp evoked potentials in human pain research: Methods and apparatus.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.
109. S.S. Mohamed, P. Mehta, S. Gross, A. Kedar, M. Ayass, B. Tomlinson, H. Derendorf  
Pharmacokinetics of codeine in sickle cell patients and healthy controls.  
1991 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Charleston, April 1991.
110. K.H. Rand, K. Gibbs, H. Derendorf, J. Graham-Pole  
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients.  
Fifth International Conference on Immunopharmacology, Tampa, May 1991.
111. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Lymphocyte depression as a pharmacodynamic parameter for clinical corticosteroid activity.  
Fifth International Conference on Immunopharmacology, Tampa, May 1991.
112. H. Derendorf  
Relevant pharmacokinetic parameters for antibiotics.  
17th International Congress of Chemotherapy, Berlin, June 1991.
113. K.S. Estes, M.E. Brewster, H. Derendorf, R.M. Clemmons, N. Bodor  
Sustained estradiol in CSF with a chemical delivery system.  
Controlled Release Society, Amsterdam, July 1991.
114. J. Barth, H. Möllmann, S. Tunn, T. Wagner, H. Derendorf, G. Hochhaus  
Systemic absorption from hydrocortisone acetate rectal foam after single and multiple administration in healthy volunteers and patients with ulcerative colitis  
11th Congress of the European Association of Internal Medicine, Lissabon, September 1991
115. H. Derendorf  
Significance of pharmacokinetic parameters for drug evaluation.  
First Pharmacy Congress of the South Cone, Gramado, September 1991.
116. H. Derendorf  
Drug level monitoring in pharmacy practice.  
First Pharmacy Congress of the South Cone, Gramado, September 1991.
117. H. Möllmann, J. Barth, I. Wagner, S. Tunn, M. Krieg, C. Möllmann, H. Derendorf  
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration.  
20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta, October 1991.
118. S. Freyer, L. Lopez, H. Derendorf  
Pharmacokinetic interaction of diltiazem and propranolol enantiomers.  
20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta, October 1991.
119. H. Möllmann, J. Barth, U. Bötzel, G. Hochhaus, H. Derendorf, T. Wagner  
Ultra-high doses of methylprednisolone in acute spinal cord injury: pharmacokinetic considerations.  
20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta, October 1991.

120. G. Hochhaus, H. Derendorf, E.W. Schmidt, H. Möllmann  
Effects versus side-effects: dose optimization based on an integrated pharmacokinetic/dynamic approach.  
20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta, October 1991.
121. S.S. Mohamed, P. Mehta, S. Gross, A. Kedar, M. Ayass, B. Tomlinson, H. Derendorf  
Pharmacokinetics of codeine in sickle cell patients and healthy controls.  
20th Annual Meeting of the American College of Clinical Pharmacology, Atlanta, October 1991.
122. H. Derendorf  
Choice of appropriate pharmacokinetic-pharmacodynamic models for predicting drug effects.  
First Annual Meeting of the Society for Clinical Pharmacology, Kloster Arnsburg, October 1991.
123. K. Rand, K. Gibbs, H. Derendorf, J. Graham-Pole  
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
124. C.D. Page, M. Mautino, H. Derendorf, J.P. Anhalt  
Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
125. M. Kaltenbach, A. Mauderli, B.L. Grundy, H. Derendorf  
Tooth-pulp evoked potentials in human pain research: application to the study of the analgesic effect of codeine and ibuprofen.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
126. S.S. Mohamed, P. Mehta, S. Gross, A. Kedar, M. Ayass, B. Tomlinson, H. Derendorf  
Pharmacokinetics of codeine in sickle cell patients and healthy controls.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
127. J. Barth, H. Möllmann, J. Armbruster, O.W. Flörke, G. Hochhaus, H. Derendorf  
Biopharmaceutical characterization of crystals in glucocorticoid suspensions.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
128. G. Hochhaus, R. Hochhaus, H. Möllmann, C. Barmeyer, H. Derendorf  
A sensitive assay for the simultaneous measurement of dexamethasone and dexamethasone-21-isonicotinate.  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
129. G. Hochhaus, H. Derendorf, H. Möllmann, E. Schmidt  
Is there a dose with an optimal effect/side effect ratio ?  
Sixth Annual Meeting of the American Association of Pharmaceutical Scientists, Washington, November 1991.
130. J. Barth, H. Möllmann, S. Tunn, T. Wagner, H. Derendorf, G. Hochhaus  
Systemic absorption from hydrocortisone acetate rectal foam after single and multiple administration in healthy volunteers and patients with ulcerative colitis.  
11th Congress of the European Association of Internal Medicine, Lisbon, November 1991.
131. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Comparative pharmacokinetics and pharmacodynamics of intravenously administered prodrugs for corticosteroids.  
Japanese-U.S.-Symposium on Drug Delivery, Maui, December 1991.
132. H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Pulmonary delivery of lipophilic and water-soluble glucocorticoids: pharmacokinetic evaluation.  
Japanese-U.S.-Symposium on Drug Delivery, Maui, December 1991.

133. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus  
Glucocorticoid suspensions for sustained release delivery in orthopedics and rheumatology: factors modulating bioavailability  
Japanese-U.S.-Symposium on Drug Delivery, Maui, December 1991.
134. H. Möllmann, U. Bötzel, J. Barth, C. Möllmann, G. Hochhaus, H. Derendorf  
Acute treatment of spinal trauma.  
Symposium on Treatment of Spinal Cord Injuries, Erfurt, March 1992.
135. H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf, E. van Winden  
Pharmacokinetic/dynamic investigations during therapeutic use of mega-dose methylprednisolone in patients with acute spinal trauma.  
International Workshop on Neurological Recovery after Spinal Cord Injuries, Heidelberg, March 1992.
136. H. Derendorf  
Hard-linked pharmacokinetic-pharmacodynamic models.  
25th Annual Higuchi Research Seminar, Lake Ozark, March 1992
137. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Receptor based pharmacokinetic-pharmacodynamic model for corticosteroids.  
Ninety-third Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, March 1992.
138. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Comparative pharmacokinetics and pharmacodynamics of intravenously administered prodrugs for corticosteroids.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
139. H. Derendorf, H. Möllmann, J. Barth, S. Tunn, M. Krieg  
Saliva levels as predictors for free corticosteroid levels in plasma.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
140. K. Rand, H. Derendorf, K. Gibbs, J. Graham-Pole  
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
141. C.D. Page, M. Mautino, H. Derendorf, J.P. Anhalt  
Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
142. H. Möllmann, J. Barth, I. Wagner, S. Tunn, M. Krieg, C. Möllmann, H. Derendorf  
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration to healthy volunteers and patients.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
143. S. Balbach, H. Möllmann, U. Boetzel, J. Barth, T. Wagner, G. Hochhaus, E. van Winden, H. Derendorf  
CSF/plasma concentrations of methylprednisolone after ultra-high doses in acute spinal cord injury.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
144. A. Nolting, J. Limberg, M. Lebel, H. Derendorf  
Free tissue levels as predictors of antibiotic activity  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.
145. S.S. Mohamed, P. Mehta, S. Gross, A. Kedar, M. Ayass, B. Tomlinson, H. Derendorf  
Pharmacokinetics of codeine in sickle cell patients and healthy controls.  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Wilmington, April 1992.



146. K.S. Estes, M.E. Brewster, H. Derendorf, R.M. Clemmons, N. Bodor  
A chemical delivery system (CDS) enhances estradiol (E<sub>2</sub>) in CSF vs. plasma  
1992 Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Wilmington, April 1992.
147. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus  
Morphological properties, pharmacokinetics and local availability of  
intraarticularly administered glucocorticoid crystal suspensions.  
98th Conference of the German Society of Internal Medicine, Wiesbaden, April 1992.
148. K. McNicol, M. Ausborn, H. Derendorf, R. Gonzalez-Rothi, D. Soucy, A. Stecenko, H.  
Schreier  
Pharmacokinetics of pulmonary delivery of amikacin liposomes and liposome toxicity  
in sheep.  
International Conference of the American Lung Association / American Thoracic  
Society, Miami Beach, May 1992.
149. H. Derendorf  
Pharmacokinetic/pharmacodynamic consequences of space flight.  
Twelfth Frontiers of Pharmacology Symposium on Pharmacology Beyond Earth's  
Boundaries, Houston, May 1992.
150. G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Molecular pharmacological aspects of glucocorticoid therapy  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
151. H. Möllmann, J. Barth, H. Derendorf, G. Hochhaus  
Fundamentals of corticosteroid therapy  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
152. H. Derendorf, H. Möllmann, J. Barth, G. Hochhaus  
Rational dose optimization in corticosteroid therapy  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
153. J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf  
Pharmacodynamic interaction of corticosteroids with immunological and inflammatory  
processes  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
154. H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Comparison of the pharmacokinetics of water- and lipid-soluble corticosteroids in  
various dosage forms after intrabronchial administration and inhalation  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
155. H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf, E. van Winden, U. Bötzel  
Pharmacokinetic-pharmacodynamic investigations after therapeutic use of mega-high  
doses of methylprednisolone in patients with acute spinal injury.  
Current Concepts of Glucocorticoid Therapy, Darmstadt, May 1992.
156. J. Barth, T. Wagner, S. Tunn, A. Tromm, H. Derendorf, M. Krieg, H. Möllmann, G.  
Hochhaus  
Bioavailability of hydrocortisone after rectal administration in healthy  
volunteers  
Inflammatory Bowel Diseases - Pathophysiology and Therapy, Regensburg, June 1992.
157. T. Wagner, J. Barth, A. Tromm, S. Tunn, M. Krieg, H. Derendorf, H. Möllmann  
Systemic absorption from hydrocortisone acetate rectal foam after single and  
multiple administration in healthy volunteers  
Inflammatory Bowel Diseases - Pathophysiology and Therapy, Regensburg, June 1992.
158. H. Möllmann, J. Barth, A. Tromm, C. Bigalke, T. Wagner, U. Schwegler, S. Tunn, H.  
Derendorf, M. Krieg, B. May, G. Hochhaus  
Pharmacokinetics and bioavailability of hydrocortisone after single and multiple  
rectal administration of hydrocortisone acetate foam in patients with distal  
chronic and inflammatory bowel diseases in comparison to healthy volunteers  
Inflammatory Bowel Diseases - Pathophysiology and Therapy, Regensburg, June 1992.
159. H. Derendorf  
What exactly is "tissue concentration"?  
4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies,  
Prague, August 1992.

160. A. Nolting, J. Limberg, M. Lebel, H. Derendorf  
Free tissue concentrations as predictors of antibiotic activity  
4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies,  
Prague, August 1992.
161. K. Rand, H. Derendorf, K. Gibbs, J. Graham-Pole  
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients  
4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies,  
Prague, August 1992.
162. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Evaluation of pharmacokinetic interactions between prednisolone and hydrocortisone  
21st Annual Meeting of the American College of Clinical Pharmacology, Washington,  
September 1992.
163. A. Suri, H. Derendorf, R.J.M. Mies, M. Kaltenbach, J. van der Aa, N. Gravenstein  
Use of a spreadsheet program for the determination of variable infusion rates to  
produce stepwise changes of morphine steady state levels  
21st Annual Meeting of the American College of Clinical Pharmacology, Washington,  
September 1992.
164. H. Möllmann, M. Damoiseaux, J. Barth, K.H. Brandis, G. Hochhaus, H. Derendorf  
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral  
administration  
21st Annual Meeting of the American College of Clinical Pharmacology, Washington,  
September 1992.
165. H. Derendorf  
Clinical significance of pharmacokinetic-pharmacodynamic models  
21st Annual Meeting of the American College of Clinical Pharmacology, Washington,  
September 1992.
166. K.S. Estes, M. Brewster, H. Derendorf, R.M. Clemmons, N. Bodor  
A chemical delivery system (CDS) enhances estradiol in CSF vs. plasma of dogs  
7th Annual Meeting of the American Association of Pharmaceutical Scientists, San  
Antonio, November 1992.
167. C. Vivas, L. Panton, M. Gonzalez, D. Lowenthal, J. Graves, H. Derendorf  
Analysis of propranolol in human plasma by reversed phase liquid chromatography  
1993 Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Research Triangle Park, April 1993.
168. A. Nolting, H. Derendorf  
Determination of piperacillin in broth solution by high performance liquid  
chromatography  
1993 Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Research Triangle Park, April 1993.
169. S. Rohatagi, H. Möllmann, J. Barth, A. Soldner, G. Hochhaus, H. Derendorf  
Analysis of hydrocortisone, prednisolone and methylprednisolone in biological  
fluids using normal phase chromatography  
1993 Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Research Triangle Park, April 1993.
170. A. Suri, V. Srinivasan, M. Kaltenbach, B. Grundy, H. Derendorf  
Pharmacodynamic evaluation of codeine using tooth pulp evoked potentials  
1993 Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Research Triangle Park, April 1993.
171. H. Möllmann, A. Tromm, U. Schwegler, B. May, J. Barth, T. Wagner, H. Derendorf, G.  
Hochhaus  
Pharmacokinetics and pharmacodynamics of budesonide after rectal application  
9th Annual Meeting of the American Gastroenterological Association, Boston, May  
1993.

172. A. Tromm, H. Möllmann, U. Schwegler, B. May, J. Barth, H. Derendorf, G. Hochhaus  
Pharmacokinetics and pharmacodynamics of budesonide after oral topical administration  
Pharmacokinetics and pharmacodynamics of budesonide after rectal application  
9th Annual Meeting of the American Gastroenterological Association, Boston, May 1993.
173. H. Derendorf  
The significance of free tissue analysis for the pharmacokinetic evaluation of antibiotics  
Hungarian Society for Chemotherapy, Debrecen, June 1993.
174. H. Derendorf  
Prospects for controlled drug delivery systems: Impact on drug therapy  
Florida Pharmacy Association, Marco Island, July 1993.
175. H. Derendorf, J. Barth, G. Hochhaus, H. Möllmann  
Kinetic/dynamic interrelationships as basis for rational therapy  
Conference on Corticosteroids for Inflammatory Bowel Diseases, Strassburg, September 1993.
176. H. Derendorf, H. Möllmann, A. Tromm  
Optimization of therapy by development of disease-related specific dose regimens  
Conference on Corticosteroids for Inflammatory Bowel Diseases, Strassburg, September 1993.
177. H.W. Ecker, H. Möllmann, A. Tromm, W. Lindemann, J. Barth, H. Derendorf, G. Hochhaus, B. May  
Comparison of pharmacodynamic effects of 3 mg budesonide in healthy volunteers and patients with inflammatory bowel disease after ileostomy  
IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg, September 1993.
178. H. Möllmann, A. Tromm, U. Schwengler, B. May, J. Barth, A. Wagner, S. Tunn, M. Krieg, H. Derendorf, G. Hochhaus  
Pharmacodynamics of budesonide after rectal application in healthy volunteers: evidence for low systemic side effects  
IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg, September 1993.
179. H. Möllmann, A. Tromm, J. Barth, S. Tunn, M. Krieg, U. Schwengler, B. May, H. Derendorf, G. Hochhaus  
Plasma levels of budesonide after multiple oral administration of budesonide in healthy volunteers  
IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg, September 1993.
180. J. Barth, H. Möllmann, A. Tromm, S. Tunn, M. Krieg, U. Schwengler, B. May, H. Derendorf, G. Hochhaus  
Systemic effects of orally administered budesonide: comparison of a single and divided dose regimen  
IV. International Symposium on Chronic Inflammatory Bowel Diseases, Strassburg, September 1993.
181. U. Bötel, E. Gläser, J. Barth, R. Schumann, G. Hochhaus, H. Derendorf, S. Tunn, M. Krieg, C. Möllmann, H. Möllmann  
Pharmacokinetics and metabolic interactions of ultra-high dosed methylprednisolone in patients with acute spinal cord injury  
3rd Scientific Meeting of the Scandinavian Medical Society of Paraplegia, Lahti, September 1993.
182. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth  
Clinical significance of pharmacokinetic-pharmacodynamic modeling of corticosteroids  
World Congress of Pharmacy and Pharmaceutical Sciences FIP '93, Tokyo, September 1993.
183. H. Derendorf  
Pharmacodynamic aspects of oral, buccal and nasal systemic drug delivery  
FIP Taipei Post-Congress Symposium, Taipei, September 1993.

184. A. Tromm, H. Möllmann, U. Schwengler, B. May, J. Barth, H. Derendorf, G. Hochhaus  
Orla treatment with budesonide in healthy volunteers: evidence of low systemic side effects  
22nd Annual Meeting of the American College of Clinical Pharmacology, Boston, November 1993.
185. H. Möllmann, A. Tromm, U. Schwegler, B. May, J. Barth, T. Wagner, H. Derendorf, G. Hochhaus  
Pharmacodynamics of budesonide after rectal application in healthy volunteers  
22nd Annual Meeting of the American College of Clinical Pharmacology, Boston, November 1993.
186. G. Henderson, P. Whalen, R. Darr, S. Curry, H. Derendorf, T. Baumgatner, P. Stacpoole  
Development and stability of an oral drug formulation for dichloroacetate and thiamine  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
187. A. Nolting, H. Derendorf, K. Rand  
An in vitro pharmacokinetic-pharmacodynamic model for piperacillin  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
188. S. Rohatagi, H. Möllmann, J. Barth, A. Soldner, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of multiple dosing regimens of methylprednisolone and prednisolone  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
189. A. Tromm, H. Möllmann, U. Schwengler, B. May, J. Barth, H. Derendorf, G. Hochhaus  
Oral treatment with budesonide: results of a pharmacodynamic study in healthy volunteers  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
190. A. Suri, V. Srinivasan, M. Kaltenbach, B. Grundy, H. Derendorf  
Somatosensory evoked potentials for measuring the analgesic effect of codeine  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
191. H. Möllmann, A. Tromm, U. Schwengler, B. May, J. Barth, T. Wagner, H. Derendorf, G. Hochhaus  
Budesonide enemas and suppositories in healthy volunteers: evidence for low systemic side effects  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
192. J. Barth, G. Hochhaus, H. Derendorf, K.H. Lehr, T. Hoehler, H. Möllmann  
Pharmacokinetics of prednicarbate in humans after oral, pulmonary and cutaneous administration  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
193. J. Barth, G. Hochhaus, R. Hochhaus, H. Derendorf, H. Möllmann  
Pharmacokinetics and pharmacodynamics of dexamethasone sulfobenzoate and dexamethasone phosphate  
8th Annual Meeting of the American Association of Pharmaceutical Scientists, Orlando, November 1993.
194. L. Williams, L.B. Panton, G.J. Guillen, J.E. Graves, C. Vivas, M. Gonzalez, H. Derendorf, M.L. Pollock, D.T. Lowenthal  
Effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults  
Ninety-fifth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, New Orleans, March 1994.
195. L. Panton, D. Lowenthal, G. Guillen, L. Williams, J. Graves, H. Derendorf, L. Garzarella, C. Vivas, M. Pollock  
Effect of aerobic exercise training on resting hepatic blood flow and propranolol

- kinetics in young and elderly adults  
Annual Meeting of the American Geriatrics Society, Los Angeles, March 1994.
196. A. Nolting, T. Dalla Costa, H. Derendorf, K. Rand  
An in vitro pharmacokinetic-pharmacodynamic model for piperacillin  
1994 AAPS Southeast Regional Meeting, Durham, April 1994
197. S. Rohatagi, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of triamcinolone acetonide after intravenous, oral and pulmonary administration  
1994 AAPS Southeast Regional Meeting, Durham, April 1994
198. E. Galia, S. Rohatagi, G. Hochhaus, H. Derendorf  
Hydrocortisone suppression after triamcinolone acetonide administration by various routes  
1994 AAPS Southeast Regional Meeting, Durham, April 1994
199. S. Rohatagi, G. Hochhaus, H. Derendorf  
Oral and pulmonary bioavailability of triamcinolone acetonide  
1994 AAPS Southeast Regional Meeting, Durham, April 1994
200. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of triamcinolone acetonide after intravenous, oral and pulmonary administration  
5th Symposium: Frontiers in Pharmacokinetics and Pharmacodynamics, Baltimore, April 1994.
201. H. Derendorf  
Pharmacokinetic-pharmacodynamic models  
Forum on current therapeutic concepts and rational use of corticosteroids for lung and intestinal diseases, Dresden, June 1994.
202. H. Derendorf  
Pharmacokinetic/pharmacodynamic analysis of corticosteroids - implications for clinical use.  
International Workshop on Corticosteroids, Göttingen, September 1994.
203. H. Derendorf, G. Hochhaus, S. Rohatagi, J. Barth, H. Möllmann  
Receptor-based PK/PD model for corticosteroids  
Second European Congress of Pharmaceutical Sciences, Berlin, September 1994.
204. G. Hochhaus, R. Gonzalez-Rothi, E.W. Schmidt, H. Möllmann, H. Derendorf, T. Dalla Costa, H. Schreier  
PK/PD characterization of pulmonary targeting  
Second European Congress of Pharmaceutical Sciences, Berlin, September 1994.
205. G. Hochhaus, P. Froehlich, H. Derendorf, H. Möllmann  
Selective HPLC/RIA assay for budesonide in biological fluids  
Second European Congress of Pharmaceutical Sciences, Berlin, September 1994.
206. H. Derendorf  
Pharmaceutical education in the U.S.A.  
ABDA Symposium on Pharmaceutical Care, Frankfurt, October 1994.
207. H. Derendorf  
Influence of systemic delivery on pharmacodynamics  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.
208. A. Suri, M. Kaltenbach, B. Grundy, H. Derendorf  
Pharmacodynamic evaluation of codeine using tooth pulp evoked potentials  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.
209. A. Nolting, T. Dalla Costa, R. Vistelle, H. Derendorf  
Free tissue levels of piperacillin, measured by microdialysis, as indicators of antibacterial activity  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.

210. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf  
Influence of endogenous hydrocortisone on pharmacokinetics and pharmacodynamics of exogenous corticosteroids  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.
211. S. Rohatagi, A. Soldner, J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modelling of oral multiple dosing of methylprednisolone  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.
212. P. Froehlich, H. Derendorf, H. Möllmann, G. Hochhaus  
A novel method for analysis of budesonide and its metabolites in biological fluids  
23rd Annual Meeting of the American College of Clinical Pharmacology, Orlando, October 1994.
213. A. Suri, H. Derendorf  
Determination of ibuprofen enantiomers by reversed phase HPLC using a derivatization technique  
9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, November 1994.
214. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf  
Influence of endogenous hydrocortisone on pharmacokinetics and pharmacodynamics of exogenous corticosteroids  
9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, November 1994.
215. S. Rohatagi, A. Soldner, J. Barth, H. Möllmann, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of oral multiple dosing of methylprednisolone  
9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, November 1994.
216. S. Rohatagi, E. Galia, G. Hochhaus, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of triamcinolone acetonide after intravenous, oral and pulmonary administration  
9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, November 1994.
217. A. Nolting, T. Dalla Costa, R. Vistelle, H. Derendorf  
Free tissue levels of piperacillin measured by microdialysis as indicators of antibacterial activity  
9th Annual Meeting of the American Association of Pharmaceutical Scientists, San Diego, November 1994.
218. H. Derendorf  
Introduction to PK/PD modelling  
1st Pharmacokinetic Experts Meeting, Wuppertal, January 1995.
219. H. Derendorf  
Tissue pharmacokinetics  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
220. H. Derendorf  
Combination of pharmacokinetics and pharmacodynamics  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
221. P. Froehlich, H. Derendorf, H. Möllmann, G. Hochhaus  
A novel method for analysis of budesonide and its metabolites in biological fluids  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
222. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, M. Erdmann, H. Sourgens, H. Derendorf  
Oral and pulmonary bioavailability of triamcinolone acetonide  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.

223. S. Rohatagi, E. Galia, G. Hochhaus, H. Möllmann, J. Barth, M. Erdmann, H. Sourgens, H. Derendorf  
Pharmacokinetic and pharmacodynamic modelling of triamcinolone acetate after intravenous, oral and pulmonary administration  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
224. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Evaluation of the pharmacokinetic interaction between prednisolone and hydrocortisone  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
225. A. Tromm, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Plasma levels and pharmacodynamic effects of budesonide tablets and pH-modified-release capsules. Results of a comparative study in healthy volunteers  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
226. J. Barth, G. Hochhaus, R. Hochhaus, H. Derendorf, H. Möllmann  
Pharmacokinetics and pharmacodynamics of the water-soluble dexamethasone-21-sulfobenzoate and dexamethasone phosphate  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
227. H. Möllmann, J. Barth, M. Krieg, T. Wagner, H. Derendorf, G. Hochhaus  
Absorption from hydrocortisone after single and multiple rectal administrations of a hydrocortisone acetate foam preparation  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
228. J. Barth, H. Möllmann, H. Derendorf, C. Möllmann, G. Hochhaus, K.H. Lehr, T. Höhler  
Pharmacokinetics and metabolism of prednicarbate after different routes of administration  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
229. A. Möllmann, H. Möllmann, A. Tromm, G. Hochhaus, J. Barth, C. Bigalke, H. Derendorf, B. May  
Plasma levels and systemic effects after administration of budesonide enemas and foams  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
230. J. Barth, H. Möllmann, H. Derendorf, G. Hochhaus  
Glucocorticoid crystal suspensions for intra-articular administration: crystal morphology, pharmacokinetics and local drug concentrations  
4th Annual Meeting of the Association for Applied Human Pharmacology, Neuss, January 1995.
231. H. Derendorf  
Dose optimization of corticosteroids based on PK/PD-modeling  
PhRMA Foundation Annual Awardee Meeting, Washington, February 1995.
232. H. Derendorf  
Dose optimization of anti-infective drugs using microdialysis  
28th Annual Higuchi Research Seminar, Lake Ozark, March 1995.
233. H. Derendorf  
New developments in the field of pharmacokinetics  
25 Anos do Curso de Pós-Graduação em Ciências Farmacêuticas da UFRGS, Porto Alegre, March 1995.
234. A. Tromm, H. Möllmann, J. Barth, B. May, G. Hochhaus, H. Derendorf  
Budesonide plasma levels and quantitative pharmacodynamic effects after oral administration of pH-modified release tablets and capsules  
4th Conference of Gastroenterology, Bonn, March 1995.

235. H. Derendorf  
Ambulatory intravenous anti-infective therapy  
Symposium on Effective Antibiotic Therapy, Rostock, June 1995.
236. H. Derendorf  
Clinical Pharmacokinetics of Antibiotics  
Symposium on Effective Antibiotic Therapy, Rostock, June 1995.
237. S. Rohatagi, G. Hochhaus, H. Derendorf  
Correlation of in vitro and in vivo corticosteroid receptor affinity  
Eastern Regional Meeting of the American Association of Pharmaceutical Scientists,  
New Brunswick, June 1995.
238. A. Suri, H. Derendorf  
Pharmacodynamic-pharmacokinetic modeling of the analgesic effect of ibuprofen and  
flurbiprofen  
Eastern Regional Meeting of the American Association of Pharmaceutical Scientists,  
New Brunswick, June 1995.
239. S. Rohatagi, A. Bye, A. Mackie, H. Derendorf  
Mathematical modeling of cortisol circadian rhythm and cortisol suppression  
Eastern Regional Meeting of the American Association of Pharmaceutical Scientists,  
New Brunswick, June 1995.
240. S. Rohatagi, H. Derendorf  
Correlation of in vitro and in vivo corticosteroid receptor affinity  
GRASP Meeting, New York, June 1995
241. S. Rohatagi, H. Derendorf  
Mathematical modeling of cortisol circadian rhythm and cortisol suppression  
GRASP Meeting, New York, June 1995
242. T. Dalla Costa, H. Derendorf, A. Nolting, A. Kovar  
Microdialysis determination of free tissue concentrations of tazobactam and  
piperacillin administered alone and in combination  
GRASP Meeting, New York, June 1995
243. S. Suarez, G. Hochhaus, R. Gonzalez-Rothi, A. Lukyanov, H. Derendorf, H. Schreier,  
T. Dalla Costa  
Liposomes as a targeted delivery system to the lung  
GRASP Meeting, New York, June 1995
244. A. Suri, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of the analgesic effect of ibuprofen and  
flurbiprofen  
GRASP Meeting, New York, June 1995
245. A. Kovar, T. Dalla Costa, H. Derendorf  
Determination of plasma and free tissue levels of ceftriaxone in rats using  
microdialysis  
Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Morrisville, June 1995
246. T. Dalla Costa, A. Nolting, A. Kovar, H. Derendorf  
Microdialysis determination of free tissue concentrations of tazobactam and  
piperacillin administered alone and in combination  
Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Morrisville, June 1995
247. A. Suri, B.L. Grundy, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of analgesic effects of ibuprofen and  
flurbiprofen  
Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Morrisville, June 1995
248. R. Gonzalez-Rothi, S. Suarez, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla  
Costa, G. Hochhaus  
Liposomes as a targeted drug delivery system to the lungs  
Southeast Regional Meeting of the American Association of Pharmaceutical  
Scientists, Morrisville, June 1995



249. S. Rohatagi, A. Bye, A. Mackie, H. Derendorf  
Mathematical modeling of cortisol circadian rhythm and cortisol suppression  
Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, June 1995
250. S. Rohatagi, G. Hochhaus, H. Derendorf  
Optimizing dosing time of systemic corticosteroid administration using PK/PD modeling  
Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, June 1995
251. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Receptor based integrated pharmacokinetic modeling of corticosteroids  
Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, June 1995
252. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Pharmacokinetics and pharmacodynamics of cloprednol  
Southeast Regional Meeting of the American Association of Pharmaceutical Scientists, Morrisville, June 1995
253. H. Derendorf, A. Nolting, T. Dalla Costa, K. Rand  
Application of an  $E_{max}$ -model to evaluate the pharmacodynamics of antimicrobials  
Satellite Symposium on Pharmacodynamics of Antimicrobials, Quebec City, July 1995.
254. A. Suri, B. Grundy, H. Derendorf  
Intra- and interindividual variability in pharmacokinetics and pharmacodynamics of flurbiprofen and ibuprofen  
24th Annual Meeting of the American College of Clinical Pharmacology, Washington, September 1995.
255. S. Rohatagi, Y.L. Kan, H. Derendorf  
Noncompartmental analysis of pharmacokinetic data after oral and intravenous administration  
24th Annual Meeting of the American College of Clinical Pharmacology, Washington, September 1995.
256. S. Rohatagi, U. Täuber, H. Derendorf  
Pharmacokinetic and pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone  
24th Annual Meeting of the American College of Clinical Pharmacology, Washington, September 1995.
257. T. Dalla Costa, H. Derendorf  
AUC - a general target for the optimization of dosing regimens of antibiotics?  
24th Annual Meeting of the American College of Clinical Pharmacology, Washington, September 1995.
258. H. Derendorf  
Pharmacokinetics - today  
Conference on Safe and Rational Use of Broad-Spectrum Antibiotics, San Francisco, September 1995.
259. R. Gonzalez-Rothi, S. Suarez, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa, G. Hochhaus  
Liposomes as a targeted drug delivery system to the lungs  
10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, November 1995.
260. A. Kovar, T. Dalla Costa, H. Derendorf  
Determination of plasma and free tissue levels of ceftriaxone in rats using microdialysis  
10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, November 1995.
261. T. Dalla Costa, A. Nolting, A. Kovar, H. Derendorf  
Microdialysis determination of free tissue concentrations of tazobactam and piperacillin administered alone and in combination  
10th Annual Meeting of the American Association of Pharmaceutical Scientists, Miami, November 1995.

262. S. Rohatagi, A. Bye, A. Mackie, H. Derendorf  
Mathematical modeling of cortisol circadian rhythm and cortisol suppression  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
263. S. Rohatagi, G. Hochhaus, H. Derendorf  
Optimizing dosing time of systemic corticosteroid administration using PK/PD  
modeling  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
264. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Receptor based integrated pharmacokinetic and pharmacodynamic modeling of  
corticosteroids after single and multiple administration  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
265. A. Suri, B.L. Grundy, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of analgesic effect of ibuprofen and  
flurbiprofen  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
266. S. Rohatagi, H. Möllmann, J. Barth, G. Hochhaus, H. Derendorf  
Pharmacokinetics and pharmacodynamics of cloprednol  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
267. A. Nolting, T. Dalla Costa, K. Rand, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of the antibacterial effects of  
piperacillin  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
268. P. Fröhlich, H. Möllmann, H. Derendorf, G. Hochhaus  
Pharmacokinetic and pharmacodynamic modeling of budesonide after single and  
multiple oral administration  
10th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Miami, November 1995.
269. H. Derendorf  
Tissue pharmacokinetics of beta-lactam antibiotics  
Conference on Comparison of Beta-lactam Antibiotics, Munich, November 1995.
270. H. Derendorf, A. Nolting, T. Dalla Costa, K. Rand  
Pharmacokinetic-pharmacodynamic modeling of the antibacterial effect of  
piperacillin in vitro  
IBC International Conference on Pharmacokinetic/Pharmacodynamic Analysis,  
Washington, February 1996.
271. G. Hochhaus, S. Suarez, R. Gonzalez-Rothi, H. Derendorf, T. Dalla Costa  
PK/PD based characterization of pulmonary targeting of glucocorticoids  
IBC International Conference on Pharmacokinetic/Pharmacodynamic Analysis,  
Washington, February 1996.
272. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Disposition and blood cell effects of prednisolone and methylprednisolone  
97th Annual Meeting of the American Society for Clinical Pharmacology and  
Therapeutics, Orlando, March 1996.
273. H. Derendorf, T. Dalla Costa, A. Kovar, A. Nolting  
Pharmacokinetic aspects of antiinfective therapy  
6th Biennial Conference on Antiinfective Agents and Chemotherapy, Leipzig, May  
1996.
274. H. Derendorf, A. Kovar  
Significance of tissue concentrations of macrolides  
6th Biennial Conference on Antiinfective Agents and Chemotherapy, Leipzig, May  
1996.

275. H. Derendorf  
Pharmacokinetic-pharmacodynamic (PK/PD) relationships for anti-infective therapy  
6th Biennial Conference on Anti-infective Agents and Chemotherapy, Leipzig, May 1996.
276. T. Dalla Costa, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of piperacillin-tazobactam combinations  
6th Biennial Conference on Anti-infective Agents and Chemotherapy, Leipzig, May 1996.
277. A. Kovar, T. Dalla Costa, H. Derendorf  
Comparison of plasma and free tissue levels of ceftriaxone in rats using microdialysis  
6th Biennial Conference on Anti-infective Agents and Chemotherapy, Leipzig, May 1996.
278. H. Derendorf  
Renal impairment and PK/PD relationships  
Nephropharmacology 1996, Berlin, June 1996.
279. A. Kovar, T. Dalla Costa, A. Nolting, H. Derendorf  
Comparison of plasma and free tissue levels of  $\beta$ -lactam antibiotics in rats using microdialysis  
2nd International Symposium on Infection Models in Antimicrobial Chemotherapy, Reykjavik, July 1996.
280. H. Derendorf, A. Kovar, T. Dalla Costa, A. Nolting, K.H. Rand  
Comparison of pharmacodynamic models to describe the activity of anti-infective drugs  
2nd International Symposium on Infection Models in Antimicrobial Chemotherapy, Reykjavik, July 1996.
281. H. Derendorf, T. Dalla Costa  
Effect of impaired renal function on the pharmacokinetics of piperacillin, tazobactam and its metabolite  
VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, August 1996.
282. H. Derendorf, S. Rohatagi, G. Hochhaus, J. Barth, H. Möllmann  
Receptor-based integrated pharmacokinetic and pharmacodynamic evaluation of corticosteroids  
VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, August 1996.
283. J. Barth, H. Möllmann, A. Möllmann, M. Krieg, U. Bötzel, G. Hochhaus, H. Derendorf  
Ultra-high dosed methylprednisolone in acute spinal cord injury (SCI) - pharmacokinetics and effects on cortisol, potassium, glucose and blood cells  
VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, August 1996.
284. T. Dalla Costa, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of piperacillin-tazobactam combinations  
VI World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, August 1996.
285. H. Derendorf  
Pharmacokinetic and pharmacodynamic evaluation of anti-infective agents  
Workshop on Anti-infective Therapy, German Society of Hospital Pharmacy, Göppingen, September 1996.
286. H. Derendorf  
Pharmacodynamic aspects of drug absorption  
6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, September 1996.
287. J. Barth, H. Möllmann, G. Lehr, T. Höhler, H. Derendorf, G. Hochhaus  
Pharmacokinetics of prednicarbate after dermal, oral and pulmonary administration and monitoring of potential side effects  
6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, September 1996.

288. G. Hochhaus, R. Gonzalez-Rothi, H. Derendorf, H. Schreier, H. Möllmann  
Pharmacokinetic/pharmacodynamic relationships relevant for optimizing the  
effect/risk ratios after topical administration - Pulmonary delivery as an example  
6th Annual Meeting of the German Society for Clinical Pharmacology and  
Therapeutics, Dresden, September 1996.
289. H. Möllmann, G. Hochhaus, A. Tromm, A. Möllmann, H. Derendorf, J. Barth, P.  
Fröhlich, K.W. Ecker, A. Lindemann, M. Krieg  
Serum and ileostoma liquid pharmacokinetics and the influence of food after oral  
administration of pH-modified-release capsules in healthy volunteers and ileostoma  
patients  
6th Annual Meeting of the German Society for Clinical Pharmacology and  
Therapeutics, Dresden, September 1996.
290. A. Tromm, H. Möllmann, S. v. Heymann, J. Barth, B. May, G. Hochhaus, H. Derendorf  
Pharmacokinetics and -dynamics after application of budesonide pH-modified-release  
capsules in patients with Crohn's disease and healthy volunteers  
6th Annual Meeting of the German Society for Clinical Pharmacology and  
Therapeutics, Dresden, September 1996.
291. H. Derendorf, A. Kovar, T. Dalla Costa  
Pharmacokinetic/pharmacodynamic modelling of anti-infective activity  
Third European Congress of Pharmaceutical Sciences, Edinburgh, September 1996.
292. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Modulation of lymphocyte count in blood by the circadian rhythm of endogenous  
cortisol  
25th Annual Meeting of the American College of Clinical Pharmacology,  
Philadelphia, September 1996.
293. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Cumulative cortisol suppression as a measure of the systemic effect of inhaled  
corticosteroids  
25th Annual Meeting of the American College of Clinical Pharmacology,  
Philadelphia, September 1996.
294. G. Hochhaus, H. Möllmann, M. Krieg, A. Möllmann, A. Tromm, H. Derendorf, J. Barth  
Pharmacokinetic/pharmacodynamic evaluation of budesonide after oral delivery  
25th Annual Meeting of the American College of Clinical Pharmacology,  
Philadelphia, September 1996.
295. H. Derendorf  
PK-PD modeling in drug development  
11th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Seattle, October 1996.
296. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Circadian rhythm of lymphocytes in blood and its interrelation to endogenous  
cortisol  
11th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Seattle, October 1996.
297. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Quantification of cortisol suppression as a measure for the cumulative systemic  
effect of corticosteroids  
11th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Seattle, October 1996.
298. S. Rohatagi, H. Derendorf  
Relationship of mean residence time and effective half life after oral and  
intravenous administration  
11th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Seattle, October 1996.
299. T. Dalla Costa, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of piperacillin-tazobactam combinations  
11th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Seattle, October 1996.
300. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth  
Pharmacokinetics of inhaled glucocorticoids

- Workshop on Inhaled Glucocorticosteroids, Brussels, January 1997.
301. H. Derendorf  
PK/PD modeling of anti-infective drugs: Why MIC is poison for the mind  
6<sup>th</sup> Annual Meeting of the Association for Applied Human Pharmacology, Neu-Ulm, February 1997.
  302. H. Derendorf  
Clinical PK/PD modeling as a tool in drug development of corticosteroids  
6<sup>th</sup> Annual Meeting of the Association for Applied Human Pharmacology, Neu-Ulm, February 1997.
  303. H. Derendorf  
Changes in Pharmacy  
ABDA Symposium, Königswinter, February 1997.
  304. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth  
Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids  
Landmark Symposium, London, February 1997.
  305. B. Meibohm, G. Hochhaus, H. Derendorf  
Time dependency of the pharmacologic response to glucocorticoids  
98<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, February 1997.
  306. H. Derendorf  
Pitfalls in tissue pharmacokinetics  
Thirtieth Annual Higuchi Research Seminar, Lake Ozark, March 1997
  307. M. Schwahn, P. Romeis, H. Derendorf, M. Herbst  
Absolute bioavailability and dose proportionality of cetrorelix, a novel LH-RH-antagonist, in male and female albino Wistar rats  
Annual Meeting of the German Pharmacological Society, Mainz, March 1997
  308. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth  
Pharmacokinetics and pharmacodynamics of soft corticosteroids for inhalation  
1<sup>st</sup> Drug Optimization via Retrometabolism Conference, Amelia Island, May 1997.
  309. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
PK/PD-modeling of the circadian rhythm of the lymphocyte count in blood modulated by endogenous cortisol  
1<sup>st</sup> Drug Optimization via Retrometabolism Conference, Amelia Island, May 1997.
  310. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
A PK/PD-approach to assess the systemic activity of inhaled corticosteroids as cumulative cortisol suppression  
1<sup>st</sup> Drug Optimization via Retrometabolism Conference, Amelia Island, May 1997.
  311. K.S. Estes, K. Dietzel, M.E. Brewster, N. Bodor, H. Derendorf  
Rapid renal and biliary elimination of a redox-based chemical delivery system for estradiol in dogs  
1<sup>st</sup> Drug Optimization via Retrometabolism Conference, Amelia Island, May 1997.
  312. B. Meibohm, G. Hochhaus, H. Möllmann, J, Barth, H. Derendorf  
Pharmacokinetic/pharmacodynamic (PK/PD) modeling of inhaled corticosteroids  
17<sup>th</sup> Annual Meeting of the Graduate Research Association of Students in Pharmaceutics, Gainesville, June 1997.
  313. E. Liang, H. Derendorf  
A pitfall in the pharmacokinetics of oral multicompartment analysis  
17<sup>th</sup> Annual Meeting of the Graduate Research Association of Students in Pharmaceutics, Gainesville, June 1997.
  314. H. Derendorf  
Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety  
Workshop on Targeting Drugs to the Lung, Bagshot, June 1997
  315. H. Derendorf  
Influence of drug absorption and protein binding on drug disposition and

- pharmacodynamics  
Residential School on Medicinal Chemistry 'Designing Drugs with Optimal In-Vivo Activity After Oral Administration', Princeton, July 1997.
316. H. Derendorf  
Pharmacokinetics in neonates and geriatric patients  
1<sup>st</sup> Uruguyan Congress of Biochemistry, Montevideo, September 1997.
317. S. Rohatagi, G. Hochhaus, A. Kovar, H. Derendorf  
Algebraic solutions for nonlinear protein binding interactions  
26<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix, October 1997.
318. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Advanced PK/PD-model for the modulation of lymphocyte count by glucocorticoids and endogenous cortisol  
26<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix, October 1997.
319. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Predictive Power of PK/PD-modeling for inhaled corticosteroids  
26<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix, October 1997.
320. J. Knoeller, K. Schiffer, H. Derendorf  
Determination of salbutamol in human plasma using LC/MS/Ms  
26<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix, October 1997.
321. M. Wagner, G. Hochhaus, R. Stöckmann, H. Derendorf, J. Barth, B. Meibohm, M. Krieg, H. Möllmann  
Pharmacokinetics and pharmacodynamics after inhaled administration of flunisolide  
XVI International Congress of Allergology & Clinical Immunology, Cancun, October 1997.
322. H. Möllmann, M. Wagner, R. Stöckmann, H. Derendorf, G. Hochhaus, B. Meibohm, J. Barth, M. Krieg  
pharmacokinetic/pharmacodynamic evaluation after single-dose inhaled fluticasone propionate  
XVI International Congress of Allergology & Clinical Immunology, Cancun, October 1997.
323. H. Möllmann, H. Derendorf, J. Barth, B. Meibohm, M. Wagner, M. Krieg, J. Knoeller, A. Möllmann, G. Hochhaus  
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
324. G. Hochhaus, H. Derendorf, B. Meibohm  
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of inhaled glucocorticoids  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
325. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Chronopharmacology of cortisol suppression during inhaled corticosteroid therapy  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
326. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Absorption profiles of inhaled corticosteroids  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
327. E. Liang, H. Derendorf  
Pitfalls in pharmacokinetic multi-compartment analysis  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.

328. S. Rohatagi, H. Derendorf  
Mathematical description of diurnal cortisol variation using a modified exponential model and characterization of cortisol suppression following corticosteroid administration using an induction model  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
329. U. Graefe, H. Derendorf, M. Veit  
Urinary metabolites of flavonoids in humans after application of a crude extract from Equisetum arvense  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
330. D. Gravenstein, A. Suri, J. Koska, H. Derendorf  
Influence of plasma expansion on plasma protein binding of ketorolac  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
331. G. Hochhaus, B. Meibohm, H. Möllmann, H. Derendorf, J. Barth, M. Wagner, M. Krieg, J. Knoeller  
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of budesonide after oral delivery  
12th Annual Meeting of the American Association of Pharmaceutical Scientists, Boston, November 1997.
332. H. Derendorf  
The role of pharmacokinetics and pharmacodynamics in drug discovery and development - future challenges for kineticists and applied mathematicians  
1997 Biomedical Kinetics Workshop, Orlando, November 1997.
333. H. Derendorf  
Pharmacokinetic-pharmacodynamic evaluation of inhalation products  
Thirty-first Annual Higuchi Research Seminar, Lake Ozark, March 1998
334. H. Derendorf, R. Hermann, P. Romeis, M. Locher, Y. Schnaars, H. Riethmüller-Winzen, B. Pechstein  
PK-PD modeling of cetrorelix effects on circadian testosterone production  
99<sup>th</sup> Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, New Orleans, March 1998.
335. B. Meibohm, H. Derendorf, H. Möllmann, M. Wagner, P. Froehlich, G. Hochhaus  
Physiologically based PK/PD-model for the interaction between endogenous and exogenous corticosteroids and lymphocytes  
99<sup>th</sup> Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, New Orleans, March 1998.
336. H. Derendorf  
Local pharmacokinetics of drugs in the lung  
Respiratory Challenges '98, Madrid, March 1998.
337. H. Derendorf, T. Dalla Costa, A. de la Peña  
Tissue microdialysis of antibiotics  
1<sup>st</sup> International Symposium on Microdialysis in Drug Research and Development, Noordwijkerhout, March 1998.
338. H. Derendorf  
Pharmacokinetic-pharmacodynamic relationships of antibiotics  
2<sup>nd</sup> European Congress of Chemotherapy, Hamburg, May 1998.
339. H. Derendorf  
Pharmacists and Physicians - A joint way into the future  
Meeting of the German Society of Hospital Pharmacists, Hannover, May 1998.
340. H. Derendorf  
Pharmacokinetics/pharmacodynamics in drug development and drug registration  
German Drug Regulatory Agency (BfArM), Berlin, May 1998.
341. H. Derendorf, B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann  
Pharmacokinetic/pharmacodynamic modeling of cumulative cortisol suppression by inhaled corticosteroids

- 2<sup>nd</sup> World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Paris, May 1998.
342. G. Hochhaus, H. Derendorf, B. Meibohm  
Effect of clearance and volume of distribution on pulmonary targeting of inhaled corticosteroids  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
343. G. Hochhaus, B. Meibohm, J. Stark, H. Möllmann, H. Derendorf, M. Wagner  
Interaction between endogenous and exogenous corticosteroids and blood lymphocytes: the buffering capacity of cortisol suppression  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
344. B. Meibohm, H. Derendorf, H. Möllmann, M. Wagner, G. Hochhaus  
Mechanism-based PK/PD-model for the interaction between endogenous and exogenous corticosteroids and blood lymphocytes  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
345. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, H. Derendorf  
Chronopharmacological aspects in cortisol suppression during inhaled corticosteroid therapy  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
346. A. Nolting, T. Dalla Costa, K. Rand, H. Derendorf  
Pharmacokinetic-pharmacodynamic model of the antibacterial effects of piperacillin  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
347. T. Dalla Costa, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of piperacillin-tazobactam combinations  
3<sup>rd</sup> International Symposium on Measurements and Kinetics of In Vivo Drug Effects, Noordwijkerhout, May 1998.
348. H. Derendorf  
Evaluation and optimization of inhaled corticosteroids  
Asthma & Allergy Conference, Baltimore, June 1998.
349. H. Derendorf  
Pharmacokinetics of inhaled corticosteroids  
Workshop on Asthma and Inflammation, Hamburg, June 1998.
350. H. Derendorf  
Linked Pharmacokinetic-pharmacodynamic models  
4<sup>th</sup> International Workshop on the Pharmacodynamics of Anticancer Agents, Dunkeld, August 1998.
351. H. Derendorf  
Pharmacokinetics of second-generation antihistamines  
57<sup>th</sup> Annual Meeting of the American Academy of Otolaryngic Allergy, San Antonio, September 1998.
352. G. Hochhaus, B. Meibohm, A. Tromm, H. Derendorf, J. Stark, J. Barth, H. Möllmann, M. Wagner, M. Krieg, S. Homrighausen, A. Möllmann  
Interaction between endogenous and exogenous corticosteroids and blood lymphocytes: the buffering capacity of cortisol suppression  
27<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Toronto, October 1998.
353. H. Derendorf  
Applied pharmacokinetics in intensive care patients  
German Surgical Society, Frankfurt, October 1998.
354. H. Derendorf  
Perspectives of Clinical Pharmacy in Research and Practice  
Annual Meeting of the German Pharmaceutical Society, Tübingen, November 1998.



315. H. Derendorf  
The role of the pharmacist in the OTC market: A comparison of Germany and the USA  
12<sup>th</sup> Annual Pharmacy Management Conference, Munich, November 1998.
316. H. Derendorf  
The role of pharmacokinetic-pharmacodynamic modeling in drug development  
Wolfgang A. Ritschel Symposium, Cincinnati, November 1998.
317. N.V. Nagaraja, B. Pechstein, R. Herrmann, P. Romeis, M. Locher, Y. Schnaars, H. Riethmüller-Winzen, H. Derendorf  
PK-PD modeling of cetrorelix effects on circadian rhythm of testosterone release  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
358. T. Dalla Costa, A. de la Peña, A. Nolting, A. Kovar, H. Derendorf  
Determination of unbound tissue concentrations of antibiotics by microdialysis  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
359. H. Derendorf, A. de la Peña, T. Dalla Costa  
PK/PD approaches in antibiotic drug evaluation  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
360. A. de la Peña, H. Derendorf  
HPLC method with UV detection for the quantification of cefaclor in biological samples  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
361. N.V. Nagaraja, Y.J. Park, H. Cha, C.D. Sands, H. Derendorf  
Population pharmacokinetics of digoxin in Korean patients  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
362. A. de la Peña, T. Dalla Costa, A.I. Webb, H. Derendorf  
Measurement of unbound tissue concentrations of antibiotics by microdialysis  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
363. A. de la Peña, A. Gräbe, M. Cheok, O. Abbas, K.H. Rand, H. Derendorf  
Instability of cefaclor in different bacterial growth media  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
364. S. Krishnaswami, M. Wolzt, C. Mensik, H. Eichler, L. Schmetterer, B. Mayer, H. Derendorf  
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition by L-NMMA in humans  
13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco, November 1998.
365. H. Derendorf  
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids as basis of rational therapy  
Pharmaceutical Care - Consultation by Hospital Pharmacists in Clinical Therapy, Hamburg, November 1998.
366. M. Wagner, G. Hochhaus, H. Möllmann, A. Möllmann, M. Krieg, H. Derendorf  
Duration of pulmonary efficacy after inhalation of fluticasone propionate  
171<sup>st</sup> Annual Meeting of the Society of Internal Medicine, Düsseldorf, November 1998.
367. M. Wagner, M. Kölsch, H. Dimova, A. Möllmann, G. Hochhaus, H. Derendorf, H.D. Tauschel, B. May, A. Tromm, H. Möllmann  
Rectal administration of budesonide foam: A therapeutic advance?  
171<sup>st</sup> Annual Meeting of the Society of Internal Medicine, Düsseldorf, November 1998.
368. S. Homrighausen, M. Wagner, H. Möllmann, A. Möllmann, J. Barth, M. Krieg, H. Derendorf, A. Tromm, G. Hochhaus

- Food effect on the pharmacokinetics and systemic effects of a budesonide ph-  
modified release capsule  
171<sup>st</sup> Annual Meeting of the Society of Internal Medicine, Düsseldorf, November  
1998.
369. H. Derendorf  
PK/PD modeling as a tool in drug development  
AAPS Indianapolis/Cincinnati Discussion Group, January 1999.
370. H. Derendorf, W. Colburn  
Acceleration of clinical drug development by the use of PK/PD modeling  
Annual Meeting of the Society of Applied Human Pharmacology, Heidelberg, February  
1999.
371. H. Derendorf  
Review of current 'in vivo' dose measurement techniques  
International Respiratory Forum, London, February 1999.
372. H. Derendorf  
The expanded role of PK/PD in drug development in the 21<sup>st</sup> century  
100<sup>th</sup> Annual meeting of the American Society for Clinical Pharmacology and  
Therapeutics, San Antonio, March 1999.
373. H. Derendorf  
Pharmacokinetic-pharmacodynamic approach to evaluate anti-infective therapy  
9<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Berlin,  
March 1999.
374. H. Derendorf  
Determination of free tissue levels of anti-infective agents using microdialysis  
Delaware Valley Drug Metabolism Discussion Group, Philadelphia, April 1999.
375. H. Derendorf, G. Hochhaus, S. Krishnaswami, H. Möllmann  
Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism  
2<sup>nd</sup> Retrometabolism Based Drug Design and Targeting Conference, Amelia Island, May  
1999.
376. H. Derendorf  
Pharmacokinetics of antihistamines  
Cleveland Allergy Group, Cleveland, May 1999.
377. H. Derendorf  
Pharmacokinetic methods of assessing lung deposition  
12<sup>th</sup> International Congress of the International Society for Aerosols in Medicine,  
Vienna, June 1999.
378. H. Derendorf  
Pharmacodynamic models to predict anti-infective activity  
21<sup>st</sup> International Congress of Chemotherapy, Birmingham, July 1999.
379. H. Derendorf  
Correlation of pharmacokinetics and pharmacodynamics  
2<sup>nd</sup> Rostock Antibiotic Days, Rostock, September 1999.
380. H. Derendorf  
Dose adjustment in impaired renal and hepatic function  
2<sup>nd</sup> Rostock Antibiotic Days, Rostock, September 1999.
381. H. Möllmann, M. Wagner, A. Möllmann, H. Dimova, Y. Tang, A. Tromm, H.D. Tauschel,  
M. Krieg, H. Weisser, H. Derendorf, G. Hochhaus  
Pharmacokinetics/pharmacodynamics of budesonide after single and multiple dosing  
28<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Rockville,  
September 1999.
382. M. Wagner, G. Hochhaus, H. Derendorf, S. Krishnaswami, Y. Tang, A. Möllmann, M.  
Krieg, H. Möllmann  
Pharmacokinetics of fluticasone propionate (FP) after single and bidaily inhaled  
administration over five days  
28<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Rockville,  
September 1999.

383. H. Derendorf  
Antimicrobial Therapy Pharmacokinetics/Pharmacodynamics  
39<sup>th</sup> ICAAC, San Francisco, September 1999.
384. H. Derendorf  
Protein binding: myths and facts  
6<sup>th</sup> International Symposium of the International Society of Anti-Infective  
Pharmacology, San Francisco, September 1999.
385. E.U. Graefe, J. Wittig, B. Drewelow, A. Riethling, S. Mueller, I. Wukasch, H.  
Derendorf, M. Veit  
Relative systemic availability of the flavonoids quercetin and rutin in humans  
Annual Meeting of the German Pharmaceutical Society, Frankfurt, September 1999.
386. H. Derendorf  
Evaluation/assessment of anti-infectives in research and practice  
28<sup>th</sup> European Symposium on Clinical Pharmacy, Berlin, October 1999.
387. H. Derendorf  
Pharmacokinetics of essential fatty acids  
1<sup>st</sup> Conference on The essential Fatty Acid Balance, Miami, October 1999.
388. S. Werner, J. Stark, H. Möllmann, S. Homrighausen, H. Derendorf, G. Hochhaus, M.  
Krieg  
Pharmacokinetics/pharmacodynamic modeling of lymphocyte subpopulations after oral  
budesonide administration  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
389. C. Rojas, N. Nagaraja, H. Derendorf  
In vitro recovery of triamcinolone acetonide in microdialysis  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
390. A. de la Peña, T. Dalla Costa, J.D. Talton, A.I. Webb, E. Rehak, U. Thyroff-  
Friesinger, H. Derendorf  
Plasma and tissue concentrations of cefaclor in rats  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
391. A. de la Peña, M. Müller, H. Eichler, E. Rehak, U. Thyroff-Friesinger, H.  
Derendorf  
Plasma and tissue concentrations of cefaclor in humans  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
392. N.V. Nagaraja, B. Pechstein, H. Derendorf  
A model for suppression of LH and delay in LH surge by cetrorelix in women  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
393. N.V. Nagaraja, B. Pechstein, R. Herrmann, P. Romeis, M. Locher, H. Derendorf  
PK-PD modeling of testosterone and luteinizing hormone suppression by cetrorelix  
in healthy volunteers  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
394. S. Krishnaswami, H. Möllmann, G. Hochhaus, M. Wagner, R. Stöckmann, H. Derendorf  
Pharmacokinetics of fluticasone propionate after single and multiple inhalations  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
395. S. Krishnaswami, H. Möllmann, H. Derendorf, G. Hochhaus  
Determination of fluticasone propionate in human plasma by liquid chromatography-  
tandem mass spectrometry  
14th Annual Meeting of the American Association of Pharmaceutical Scientists, New  
Orleans, November 1999.
396. A. Kovar, T. Drave, D.E. de Vries, H. Derendorf  
Pharmacokinetic/pharmacodynamic evaluation of eniporide

- 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, November 1999.
397. H. Derendorf  
Value of pharmacodynamic endpoints: Quantifiability, statistical power, and clinical relevance  
AAPS Workshop on Drug-Drug and Drug-Food Interactions, Arlington, December 1999.
398. H. Derendorf  
Clinical pharmacokinetics - specific applications in critically ill patients  
Pharma Hospital 2000 - Rational Drug Therapy in Critically Ill Patients, Sulzbach, February 2000.
399. H. Derendorf, A. de la Peña  
Pharmacokinetics and pharmacodynamics of betalactam antibiotics in patients with renal impairment  
8<sup>th</sup> Biennial Conference on Antiinfective Agents and Chemotherapy, Munich, March 2000.
400. H. Derendorf, A. de la Peña  
Determination of active drug levels at the site of infection  
8<sup>th</sup> Biennial Conference on Antiinfective Agents and Chemotherapy, Munich, March 2000.
401. H. Derendorf, P. Liu  
The clinical relevance of the pharmacokinetic properties of cefpodoxime - a new approach  
8<sup>th</sup> Biennial Conference on Antiinfective Agents and Chemotherapy, Munich, March 2000.
402. H. Derendorf, A. de la Peña  
Protein binding - myths and facts  
8<sup>th</sup> Biennial Conference on Antiinfective Agents and Chemotherapy, Munich, March 2000.
403. H. Derendorf  
Pharmacokinetics and systemic exposure of inhaled corticosteroids  
Inhaled Corticosteroids Relative Potency Workshop, Toronto, May 2000.
404. H. Derendorf  
The basic concepts of pharmacokinetics  
10<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 2000.
405. H. Derendorf  
General concepts of pharmacodynamics  
10<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 2000.
406. H. Derendorf  
General concepts of PK/PD modeling  
10<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, May 2000.
407. H. Derendorf  
PK/PD evaluation of antibiotics using microdialysis  
2<sup>nd</sup> International Symposium on Microdialysis in Drug Research and Development, Stockholm, June 2000.
408. A. de la Peña, T. Dalla Costa, J. Talton, P. Liu, A. Webb, H. Derendorf  
Microdialysis of beta-lactam antibiotics in rat muscle and lung  
2<sup>nd</sup> International Symposium on Microdialysis in Drug Research and Development, Stockholm, June 2000.
409. H. Derendorf  
Pharmacy Curriculum at the University of Florida  
2<sup>nd</sup> Workshop for Education in Clinical Pharmacy, Bonn, June 2000.
410. H. Derendorf  
Clinical Pharmacy - a field for all pharmacists  
Workshop of the Westphalian Chamber of Pharmacy, Münster, June 2000.

411. N.V. Nagaraja, B. Pechstein, K. Erb, M. Locher, R. Hermann, H. Derendorf  
A PK/PD model for suppression of LH and delay in LH surge by cetrorelix in women  
VII World Conference on Clinical Pharmacology and Therapeutics, Florence, July  
2000.
412. H. Derendorf  
Pharmacokinetics and drug interactions  
XVI Latinamerican Congress of Pharmacology, Aguas de Lindoia, September 2000.
413. H. Derendorf  
The general concepts of pharmacokinetics  
40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,  
September 2000.
414. H. Derendorf  
Microdialysis, protein binding and general concepts of pharmacodynamics  
40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,  
September 2000.
415. H. Derendorf  
General concepts of PK/PD modeling  
40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,  
September 2000.
416. M. Kurowski, J. Barrett, E. Waalberg, N.V. Nagaraja, H. Derendorf, H. Wiltshire  
Oral oseltamivir rapidly delivers active drug levels to middle ear and sinuses in  
humans  
40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,  
September 2000.
417. H. Derendorf  
The significance of antimicrobial concentrations in extravascular sites  
40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto,  
September 2000.
418. H. Derendorf  
Pharmacokinetics vs. pharmacodynamics: Which is more relevant in the 21<sup>st</sup> century?  
29<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Chicago,  
September 2000.
419. H. Derendorf  
Topical and systemic effects after pulmonar administration  
Annual Meeting of the German Pharmaceutical Association, Münster, October 2000.
420. H. Derendorf  
Contribution of pharmacokinetics and pharmacodynamics to drug development  
Annual Meeting of the German Pharmaceutical Association, Münster, October 2000.
421. H. Derendorf  
Integration of preclinical data into early clinical drug development  
2<sup>nd</sup> Annual Congress for Clinical Pharmacology, Berlin, October 2000.
422. H. Derendorf  
Pharmacokinetics and bioavailability of phytopharmaceuticals  
3<sup>rd</sup> International Congress on Phytomedicine, Munich, October 2000.
423. S. Krishnaswami, G. Hochhaus, H. Möllmann, M. Wagner, R. Stöckmann, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of inhaled fluticasone propionate  
15th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Indianapolis, November 2000.
424. A. de la Peña, T. Dalla Costa, J.D. Talton, A.I. Webb, M Müller, K. Rand, H.  
Derendorf  
Microdialysis and bacterial kill curves as tools in  
pharmacokinetic/pharmacodynamic modeling of antibiotics  
15th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Indianapolis, November 2000.
425. J.G. Stark, H. Derendorf, H. Möllmann, G. Hochhaus  
Interplay of endogenous and exogenous corticosteroids and the effects on blood

- lymphocytes  
15th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Indianapolis, November 2000.
426. H. Derendorf  
Pharmacokinetics in critical care patients  
Workshop on Rational Drug Therapy in Critical Care Patients, Frankfurt, November  
2000.
427. H. Derendorf  
Significance of pharmacokinetics and pharmacodynamics for anti-infectious therapy  
3<sup>rd</sup> Workshop on Infections in Neutropenia, Bonn, November 2000.
428. N.V. Nagaraja, B. Pechstein, K. Erb, C. Klipping, R. Hermann, M. Locher, H.  
Derendorf  
Pharmacokinetic/pharmacodynamic modeling of LH suppression and LH surge delay by  
cetorelix after single and multiple doses in healthy premenopausal women  
Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics,  
Orlando, March 2001.
429. H. Derendorf  
Optimizing oral delivery: PK and PD  
Strategies for Oral Drug Delivery, Garmisch-Partenkirchen, March 2001.
430. H. Derendorf  
PK/PD as a tool in clinical drug development  
Pharmaceutical Congress of the Americas, Orlando, March 2001.
431. C. Rojas, N.V. Nagaraja, H. Derendorf  
In vivo recovery of triamcinolone acetonide in microdialysis  
Pharmaceutical Congress of the Americas, Orlando, March 2001.
432. P.E. Fröhlich, H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann  
Pharmacokinetic/pharmacodynamic modeling of budesonide after oral administration  
in single and multiple doses  
Pharmaceutical Congress of the Americas, Orlando, March 2001.
433. J.G. Stark, H. Derendorf, H. Möllmann, G. Hochhaus  
The influence of administration time on the systemic effects observed during  
corticosteroid therapy  
Pharmaceutical Congress of the Americas, Orlando, March 2001.
434. H. Derendorf  
Can we predict therapeutic failure with pharmacodynamic models?  
16<sup>th</sup> International Course on Chemotherapy, Bratislava, May 2001.
435. H. Derendorf  
The role of the pharmacist in the new century  
Pharmacy Strategic Economic Forum, Oberhausen, May 2001.
436. H. Derendorf  
Basic concepts of pharmacokinetics and pharmacodynamics  
33<sup>rd</sup> Annual Meeting of the German Society for Internal Emergency Medicine, Halle,  
June 2001.
437. H. Derendorf  
Interstitial tissue concentrations of cefpodoxime in humans  
22<sup>nd</sup> International Congress of Chemotherapy, Amsterdam, July 2001.
438. H. Derendorf  
Rational dosing: The use of plasma concentrations versus tissue concentrations  
ISAP Symposium: Developments in PK/PD: Optimizing Efficacy and Prevention of  
Resistance, Nijmegen, July 2001.
439. E.S. El Desoky, N.V. Nagaraja, M.S. Abdel-Rahman, S. El Din Amry, H. Derendorf  
Population pharmacokinetics of digoxin in Egyptian pediatric patients  
7<sup>th</sup> International Congress on Therapeutic Drug Monitoring and Clinical Toxicology,  
Washington, September 2001.

440. H. Derendorf  
Innovations in antibiotics therapy  
4<sup>th</sup> Antibiotics Conference, Rostock, September 2001.
441. H. Derendorf  
Pharmacodynamics in the elderly  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
442. H. Derendorf  
PK/PD-based development of modified-release dosage forms of established drugs as  
an alternative to clinical efficacy testing  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
443. H. Derendorf  
Microdialysis-based PK/PD-approaches in antimicrobial drug development  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
444. A. Buchwald, W. Wu, N.V. Nagaraja, H. Derendorf, N. Bodor  
The rationale of soft drug design confirmed by pharmacokinetic and  
pharmacodynamic results on soft-cannabinoid analogs  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
445. J. Kurz, N.V. Nagaraja, S. Balbach, J. Barth, R. Schumann, G. Hochhaus, H.  
Möllmann, H. Derendorf  
Population pharmacokinetics of methylprednisolone in patients with acute spinal  
cord injury  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
446. P. Liu, A. Webb, H. Derendorf  
Tissue penetration of cefpodoxime measured by microdialysis  
16th Annual Meeting of the American Association of Pharmaceutical Scientists,  
Denver, October 2001.
447. H. Derendorf  
Pharmacokinetics and pharmacodynamics in the elderly  
ABDA Symposium Gesünder länger leben, Frankfurt, November 2001.
448. H. Derendorf  
Collaboration of Clinical Pharmacy and Clinical Pharmacology  
3<sup>rd</sup> Annual Conference of Clinical Pharmacology, Cologne, November 2001.
449. H. Derendorf  
Microdialysis for PK/PD-studies  
3<sup>rd</sup> Annual Conference of Clinical Pharmacology, Cologne, November 2001.
450. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
ISAP Workshop at the 41<sup>st</sup> Annual Interscience Conference on Antimicrobial Agents  
and Chemotherapy, Chicago, December 2001.
451. H. Derendorf  
The general concepts of PK/PD modeling  
ISAP Workshop at the 41<sup>st</sup> Annual Interscience Conference on Antimicrobial Agents  
and Chemotherapy, Chicago, December 2001.
452. A. Khunvichai, M. Hirt, M. Karmann, L. Joliff, K. Rand, H. Derendorf  
A novel indirect response pharmacokinetic/pharmacodynamic model to characterize  
the effect of faropenem on *Streptococcus pneumoniae* and *Haemophilus influenzae*  
41<sup>st</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy,  
Chicago, December 2001.
453. K. Erb, N.V. Nagaraja, B. Pechstein, C. Klipping, R. Hermann, H. Derendorf  
PK/PD modeling of hormone effects by cetrorelix  
Annual Meeting of the Association for Applied Human Pharmacology, Garmisch-  
Partenkirchen, January 2002.

454. H. Derendorf  
What constitutes the ideal inhaled corticosteroid?  
Current Status of Inhaled Corticosteroids for Asthma, New York, February 2002.
455. H. Derendorf  
Optimizing oral drug delivery: Pharmacokinetics and pharmacodynamics  
Strategies for Oral Drug Delivery, Lake Tahoe, March 2002.
456. H. Derendorf, V.A. Bhattaram, S. Boettcher, J. Dasenbrock, T. Machnig, T. Peters,  
A. Kovar, N.V. Nagaraja  
Population pharmacokinetics of eniporide and its metabolite in healthy volunteers  
and patients  
Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics,  
Atlanta, March 2002.
457. H. Derendorf  
PK/PD modelling of anti-Infectives  
Fourth International Symposium on Measurement and Kinetics of In Vivo Drug  
Effects, Noordwijkerhout, April 2002.
458. H. Derendorf  
New aspects for the evaluation of antibiotics  
Workshop Clinical Pharmacy, Munich, May 2002.
459. H. Derendorf, H. Möllmann  
Are all steroids alike?  
Workshop Clinical Pharmacy, Munich, May 2002.
460. H. Derendorf  
Pharmacokinetics and pharmacodynamics of anti-infective drugs  
Annual Meeting of the Slovak Society of Chemotherapy, Bratislava, May 2002.
461. H. Derendorf  
New insights into inhaled corticosteroids  
2002 American Thoracic Society Annual Meeting, Atlanta, May 2002.
462. H. Derendorf  
Integrating preclinical data into the clinical phase of the drug development  
process  
AAPS Workshop on Exposure Response Relationships, Arlington, June 2002.
463. S. Rohatagi, H. Derendorf, K. Zech  
Risk-benefit value of inhaled corticosteroids: A pharmacokinetic/pharmacodynamic  
perspective  
45<sup>th</sup> Annual Thomas L. Petty Lung Conference, Aspen, June 2002.
464. P. Liu, M. Müller, M. Grant, A.I. Webb, B. Obermann, H. Derendorf  
Interstitial tissue concentrations of cefpodoxime using microdialysis  
3<sup>rd</sup> International Symposium on Microdialysis in Drug Research & Development,  
Minneapolis, June 2002.
465. V. Schuck, M. Müller, M. Grant, G. Hochhaus, H. Derendorf  
Use of microdialysis to evaluate dexamethasone tissue distribution  
3<sup>rd</sup> International Symposium on Microdialysis in Drug Research & Development,  
Minneapolis, June 2002.
466. H. Derendorf  
Biomarkers and PK/PD Modeling  
AAPS National Biotechnology Conference, San Diego, June 2002.
467. R.P.E. Yanong, E.W. Curtis, V.A. Bhattaram, M. Gopalakrishnan, N. Ketabi, N.V.  
Nagaraja, H. Derendorf, R. Simmons  
Single-dose pharmacokinetics of florfenicol in Koi (*Cyprinus carpio*) and Gourami  
(*Trichogaster trichopterus*)  
4<sup>th</sup> International Symposium on Aquatic Animal Health, New Orleans, September 2002.
468. H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling in oncology  
Meeting of the Austrian Society of Oncology Pharmacy, Vienna, September 2002.



469. P. Liu, M. Müller, M. Grant, K. Rand, H. Derendorf  
Pharmacokinetics and pharmacodynamics of cefpodoxime and cefixime  
31<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2002.
470. V.A. Bhattaram, C. deMey, H. Stammer, C. Beichl, K. Erb, R. Beise, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of ACE inhibition by a modified release captopril formulation based on total and free concentrations  
31<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2002.
471. H. Derendorf  
Pharmacokinetics of beta-lactam inhibitors  
ICAAC Wyeth Symposium on Therapy of Nosocomial Infections, San Diego, September 2002.
472. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
ISAP Workshop at the 42<sup>nd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002.
473. H. Derendorf  
The general concepts of PK/PD modeling  
ISAP Workshop at the 42<sup>nd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002.
474. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Pharmacokinetic-pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form  
42<sup>nd</sup> Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002.
475. H. Derendorf  
Are all corticosteroids alike?  
57<sup>th</sup> Annual Meeting of the Southeastern Allergy, Asthma and Immunology Society, Sea Island, October 2002.
476. S. Wittmer, M. Ploch, T. Windeck, S. Müller, B. Drewelow, H. Derendorf, M. Veit  
Bioavailability of caffeoylquinic acids and flavonoids in humans after application of two different artichoke leaf extracts  
Annual Meeting of the German Pharmaceutical Society, Berlin, October 2002.
477. E.L. Schuck, V.A. Bhattaram, H. Derendorf  
Antibiotic therapy during space flights: A disaster bound to happen? Use of Monte Carlo Simulations to evaluate 1G recommended dosing regimens of ciprofloxacin in microgravity  
International Head-Out Water Immersion Symposium, Houston, October 2002.
478. H. Derendorf  
Relevance of protein binding and lung activation for inhaled corticosteroids  
Inhaled Corticosteroids in Asthma Management, Cannes, November 2002.
479. A. Khunvichai, M. Hirt, M. Karmann, K. Rand, H. Derendorf  
A novel indirect response PK-PD model to characterize the effect of faropenem on *Streptococcus pneumoniae* and *Haemophilus influenzae*  
Globalization of Pharmaceutics Education Network Meeting, Ann Arbor, November 2002.
480. J. Kurz, V.A. Bhattaram, H. Derendorf  
Predictions of dose-dependent pharmacokinetics of prednisolone  
Globalization of Pharmaceutics Education Network Meeting, Ann Arbor, November 2002.
481. P. Liu, M. Müller, M. Grant, K. Rand, H. Derendorf  
Pharmacokinetics and pharmacodynamics of cefpodoxime and cefixime  
Globalization of Pharmaceutics Education Network Meeting, Ann Arbor, November 2002.
482. Q. Liu, N. Lamberty, S. Hintze, K. Rand, H. Derendorf  
In vitro pharmacodynamic modeling of ceftriaxone

- Globalization of Pharmaceutics Education Network Meeting, Ann Arbor, November 2002.
483. V.A. Schuck, M. Müller, M. Grant, G. Hochhaus, H. Derendorf  
Use of microdialysis to evaluate dexamethasone tissue distribution after oral and topical administration  
Globalization of Pharmaceutics Education Network Meeting, Ann Arbor, November 2002.
484. J. Kurz, V.A. Bhattaram, H. Derendorf  
Predictions of dose-dependent pharmacokinetics of prednisolone  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
485. V.A. Schuck, M. Müller, M. Grant, G. Hochhaus, H. Derendorf  
Use of microdialysis to evaluate dexamethasone tissue distribution after oral and topical administration  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
486. V.A. Bhattaram, R.P.E. Yanong, E. Curtis, N. Ketabi, M. Gopalakrishnan, N.V. Nagaraja, H. Derendorf  
Single dose pharmacokinetic studies of florfenicol in Koi (*Cyprinus carpio*) and Blue Gouramis (*Trichogaster trichopterus*)  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
487. V.A. Bhattaram, A.L. Shroads, G.N. Henderson, A.D. Hutson, S. Krishna, G. Bedo-Addo, A. Owusu-Ofori, N.V. Nagaraja, T. Planche, T. Agbenyega, D. Ansong, H. Derendorf, P.W. Stacpoole  
Population kinetics-dynamics, efficacy and safety of dichloroacetate for lactic acidosis due to severe malaria  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
488. P. Liu, M. Grant, M. Müller, K. Rand, H. Derendorf  
Pharmacokinetics and pharmacodynamics of cefpodoxime and cefixime  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
489. Q. Liu, N. Lamberty, S. Hintze, K. Rand, H. Derendorf  
In vitro pharmacodynamic modeling of ceftriaxone  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
490. A. Khunvichai, M. Hirt, M. Karmann, K. Rand, H. Derendorf  
A novel indirect response PK-PD model to characterize the effect of faropenem on *Streptococcus pneumoniae* and *Hemophilus influenzae*  
2002 AAPS Annual Meeting and Exposition, Toronto, November 2002.
491. H. Derendorf  
Integrating preclinical data into clinical phases of drug development  
EUFEPS Conference on Optimising Drug Development, Basel, December 2002.
492. H. Derendorf  
Biomarkers and PK/PD Modelling  
Conference on Innovative Strategies for Achieving Clinical Proof-of-Concept, Phoenix, January 2003.
493. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Pharmacokinetic-pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form  
Hot Topics in Urinary Tract Infections, Budapest, January 2003.
494. S. Rohatagi, H. Derendorf, K. Zech, R. Nave, D. Banerji  
PK/PD of Inhaled Corticosteroids: The Risk/Benefit of Inhaled Ciclesonide  
60<sup>th</sup> Anniversary Meeting of AAAAI, Denver, March 2003.
495. H. Derendorf, H. Möllmann  
Are all steroids alike?  
Garmisch Drug Forum, Garmisch-Partenkirchen, April 2003.
496. H. Derendorf  
Microdialysis in drug development  
Health Care Forum NRW, Cologne, April 2003.

497. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
13<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Glasgow,  
May 2003.
498. H. Derendorf  
Kill curve analysis  
13<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Glasgow,  
May 2003.
499. H. Derendorf  
Clinical pharmacokinetic monitoring  
4<sup>th</sup> Spring Conference on Clinical Pharmacy, Lisbon, May 2003.
500. H. Derendorf  
Redirecting our attention to the PK/PD profile: Relevance in clinical practice  
XXII Congress of the European Academy of Allergology and Clinical Immunology,  
Paris, June 2003.
501. H. Derendorf  
Modelling of anti-infective drugs  
10<sup>th</sup> Scientific Meeting of the European Society of Chemotherapy  
Vienna, June 2003.
502. H. Derendorf  
PK/PD of ICS therapy and the clinical implications  
MST Asthma Educational Session, Baltimore, August 2003.
503. E.S. El Desoky, V.A. Bhattaram, S. El Din Amry, H. Derendorf  
Population analysis of intravenous digoxin therapy in pediatric patients  
8<sup>th</sup> International Congress of Therapeutic Drug Monitoring & Clinical Toxicology,  
Basle, September 2003.
504. H. Derendorf  
MIC indices or kill curve analysis. Pro and cons.  
Workshop on Predictive Value of PK/PD Models of Antimicrobial Drugs, Leiden,  
September 2003.
505. H. Derendorf  
New methods to investigate the antibacterial efficacy of antibiotics  
Workshop on Antibiotic Therapy of Ambulatory Acquired Pulmonary Infections,  
Zurich, September 2003.
506. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
43<sup>rd</sup> Annual ICAAC, Chicago, September 2003.
507. H. Derendorf  
Kill curve analysis  
43<sup>rd</sup> Annual ICAAC, Chicago, September 2003.
508. H. Derendorf  
New developments in tissue pharmacokinetics  
43<sup>rd</sup> Annual ICAAC, Chicago, September 2003.
509. Q. Liu, K.H. Rand, H. Derendorf  
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-  
tazobactam combinations  
43<sup>rd</sup> Annual ICAAC, Chicago, September 2003
510. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Modeling the biphasic killing kinetics of ciprofloxacin  
12<sup>th</sup> ISAP International Symposium, Chicago, September 2003.
511. Q. Liu, K. Rand, H. Derendorf  
PK/PD Modeling of antiinfective activity and resistance  
12<sup>th</sup> ISAP International Symposium, Chicago, September 2003.
512. Q. Liu, K. Rand, H. Derendorf  
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-

- tazobactam combinations  
12<sup>th</sup> ISAP International Symposium, Chicago, September 2003.
513. H. Derendorf  
Seeking to improve the benefit-risk ratio of inhaled steroids  
Child & Adolescent Asthma - Current & Future Management, Chicago, September 2003.
514. H. Derendorf  
New developments in the area of inhaled glucocorticoids  
32<sup>nd</sup> Annual Meeting of the American College of Clinical Pharmacology, Tampa, September 2003.
515. H. Derendorf  
Pharmacokinetics of natural products  
32<sup>nd</sup> Annual Meeting of the American College of Clinical Pharmacology, Tampa, September 2003.
516. J. Winkler, V.A. Bhattaram, H. Derendorf  
Predictions of dose-dependent pharmacokinetics and pharmacodynamics of prednisolone  
32<sup>nd</sup> Annual Meeting of the American College of Clinical Pharmacology, Tampa, September 2003.
517. A. Khunvichai, M. Karmann, M. Hirt, L. Joliffe, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of faropenem daloxate  
32<sup>nd</sup> Annual Meeting of the American College of Clinical Pharmacology, Tampa, September 2003.
518. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form  
32<sup>nd</sup> Annual Meeting of the American College of Clinical Pharmacology, Tampa, September 2003.
519. H. Derendorf  
Pharmacokinetics and pharmacodynamics of anti-infective agents in renal impairment  
NephroPharmacology 7, Ulm, October 2003.
520. H. Derendorf  
Integration of preclinical data to streamline clinical drug development  
2003 AAPS Annual Meeting, Salt Lake City, October 2003.
521. V.A. Schuck, I. Rinas, H. Derendorf  
In vitro microdialysis of docetaxel  
2003 AAPS Annual Meeting, Salt Lake City, October 2003.
522. A. Khunvichai, M. Hirt, M. Karmann, L. Joliff, I. Zdrojewski, K. Rand, H. Derendorf  
A novel indirect response PK-PD model to characterize the effect of faropenem on Streptococcus pneumoniae and Haemophilus influenzae  
2003 AAPS Annual Meeting, Salt Lake City, October 2003.
523. E.L. Schuck, A. Dalhoff, H. Stass, H. Derendorf  
Modeling the biphasic killing kinetics of quinolones  
2003 AAPS Annual Meeting, Salt Lake City, October 2003.
524. H. Derendorf  
How the lung handles drugs, permeability, metabolism and retention  
Transatlantic Airway Conference, Lucerne, January 2004.
525. H. Derendorf  
Pharmacokinetics of antimicrobial agents  
Antibiotic Therapy and DRGs, Berlin, January 2004.
526. H. Derendorf  
Pharmacokinetics and pharmacodynamics: Relevance for asthma therapy  
45<sup>th</sup> Congress of the German Society for Pulmonology, Frankfurt, March 2004.
527. H. Derendorf  
Comparing potencies of inhaled steroids  
Annual Meeting of the American Academy of Allergy, Asthma and Immunology, San Francisco, March 2004.

528. H. Derendorf  
Microdialysis as a key technique to evaluate exposure-response relationships in drug development  
Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Miami, March 2004.
529. H. Derendorf  
Microdialysis as a key technique to evaluate exposure-response relationships in drug development  
FDA Committee for Advanced Education Workshop, Rockville, March 2004.
530. R. Madabushi, V.A. Bhattaram, E.L. Desoky, H. Derendorf  
Population pharmacokinetic analysis of digoxin in Egyptian pediatric patients: A comparison of three different softwares  
6<sup>th</sup> Annual Conference & Themed Workshop of the East Coast Population Analysis Group, Rockville, April 2004.
531. H. Derendorf  
Pharmaceutical care and health care politics  
Konrad Adenauer Society, Langenfeld, April 2004.
532. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
14<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004.
533. H. Derendorf  
Kill-curve analysis  
14<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004.
534. H. Derendorf, P. Liu, K. Rand, B. Obermann  
Pharmacokinetic-pharmacodynamic modelling of activities of cefpodoxime and cefixime based on in vivo tissue concentrations and in vitro kill curves  
14<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 2004.
535. H. Derendorf  
What is the best marker for inhaled corticosteroid safety?  
Eastern Allergy Conference, Key Biscayne, May 2004.
536. H. Derendorf  
Dose selection for anti-infective drugs  
PharmForum 2004, Memphis, May 2004.
537. H. Derendorf  
The pharmacokinetic basis for once-daily dosing of inhaled corticosteroids  
100<sup>th</sup> International Conference of the American Thoracic Society, Orlando, May 2004.
538. Q. Liu, K. Rand, M. Müller, H. Stass, H. Derendorf  
Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of moxifloxacin  
Annual Infectious Diseases Pharmacotherapy Fellowship Forum, Vail, June 2004.
539. H. Derendorf  
Microdialysis as a key technique to evaluate exposure-response relationships in drug development  
4<sup>th</sup> International Symposium Microdialysis in Drug Research and Development, Vienna, June 2004.
540. E.L. Schuck, M. Grant, H. Deendorf  
Pharmacokinetics and tissue penetration of ciprofloxacin in simulated weightlessness: a pilot study  
4<sup>th</sup> International Symposium Microdialysis in Drug Research and Development, Vienna, June 2004.
541. V.A. Schuck, H. Derendorf  
In vitro and in vivo microdialysis of dexamethasone  
4<sup>th</sup> International Symposium Microdialysis in Drug Research and Development, Vienna, June 2004.

542. V.A. Schuck, I. Rinas, H. Derendorf  
In vitro microdialysis of docetaxel  
4<sup>th</sup> International Symposium Microdialysis in Drug Research and Development, Vienna,  
June 2004.
543. H. Derendorf  
Introduction to PK/PD  
World Conference on Dosing of Antiinfectives, Nürnberg, September 2004.
544. H. Derendorf  
PK/PD based on kill curves  
World Conference on Dosing of Antiinfectives, Nürnberg, September 2004.
545. H. Derendorf  
Dosing of antiinfectives in special populations  
World Conference on Dosing of Antiinfectives, Nürnberg, September 2004.
546. H. Derendorf  
Protein binding - a pharmacologist's view  
World Conference on Dosing of Antiinfectives, Nürnberg, September 2004.
547. H. Derendorf  
Pharmacodynamics of antibiotics  
World Conference on Dosing of Antiinfectives, Nürnberg, September 2004.
548. H. Derendorf  
PK/PD of inhaled corticosteroids  
Pharmacologists Workshop on Inhaled Corticosteroids, Konstanz, September 2004.
549. H. Derendorf  
PK/PD parameters and their impact on adverse events in inhaled corticosteroid  
therapy  
Asthma Management Update, New York, September 2004.
550. Q. Liu, K. Rand, M Müller, H. Stass, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling and simulation of moxifloxacin for the  
treatment of Streptococcus pneumoniae infections  
33<sup>rd</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix,  
October 2004.
551. E. Schuck, M. Grant, H. Derendorf  
Effect of modeled microgravity on the deposition and tissue enetration of  
ciprofloxacin in healthy volunteers  
33<sup>rd</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix,  
October 2004.
552. R. Madabushi, V. Bhattaram, E. ElDesoky, H. Derendorf  
Population pharmacokinetic analysis of digoxin in Egyptian pediatric patients with  
heart failure  
33<sup>rd</sup> Annual Meeting of the American College of Clinical Pharmacology, Phoenix,  
October 2004.
553. H. Derendorf  
Eng's principle and the fight against resistance  
Clinical PK/PD Symposium, Groton/New London, October 2004.
554. H. Derendorf  
Resistance development - A pharmacological approach  
Workshop on Antibiotic Therapy of Community Acquired Respiratory Tract Infections,  
Vienna, October 2004.
555. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
ISAP Workshop, Washington, October 2004.
556. H. Derendorf  
PK/PD based on kill curves  
ISAP Workshop, Washington, October 2004.
557. H. Derendorf  
Pharmacokinetics of beta-lactamase inhibitors

Symposium on New trends in the Therapy of Nosocomial Infections, Washington, October 2004.

558. H. Derendorf  
Can variability in tissue penetration explain failures or successes of therapy?  
44<sup>th</sup> ICAAC, Washington, October 2004.
559. E.L. Schuck, M. Grant, L. Putcha, H. Derendorf  
Pharmacokinetic and pharmacodynamic evaluation of ciprofloxacin in modeled  
microgravity  
44<sup>th</sup> ICAAC, Washington, November 2004.
560. H. Derendorf, E. Schuck, Q. Liu, A. Khunvichai  
MIC versus kill curve-based PK/PD indices  
44<sup>th</sup> ICAAC, Washington, November 2004.
561. H. Derendorf  
MIC vs. Kill corve-based PK/PD indices  
44<sup>th</sup> ICAAC, Washington, November 2004.
562. E.L. Schuck, M. Grant, L. Putcha, H. Derendorf  
Pharmacokinetic and pharmacodynamic evaluation of ciprofloxacin in modeled  
microgravity  
ISAP Symposium, Washington, November 2004.
563. H. Derendorf  
Examples of how PK/PD models that incorpore biomarkers and surrogate endpoints  
can be used to accelerate drug development: Corticosteroids  
AAPS Workshop Clinical Biomarkers in Drug Development, Baltimore, November 2004.
564. J. Shen, H. Bozigian, H. Derendorf, S. Struthers, T. Chen, R. Jimenez, B. Campbell  
Pharmacokinetic and pharmacodynamic evaluation of NBI-42902, a new gonadotropin  
releasing hormone antagonist, in healthy post-menopausal women  
2004 AAPS Annual Meeting, Baltimore, November 2004.
565. S. Sarawek, F. Qadan, H. Derendorf, V. Butterweck  
An extract of Gundelia tournefortii L. shows hypouricemic activity in in vitro and  
in vivo assays  
2004 AAPS Annual Meeting, Baltimore, November 2004.
566. V. Schuck, H. Derendorf  
Dexamethasone tissue penetration determined by microdialysis  
2004 AAPS Annual Meeting, Baltimore, November 2004.
567. R. Madabushi, V. Bhattaram, E. El Desoky, H. Derendorf  
Intravenously administered digoxin in Egyptian pediatric patients with heart  
failure: Population pharmacokinetic analysis  
2004 AAPS Annual Meeting, Baltimore, November 2004.
568. R. Madabushi, V. Bhattaram, E. El Desoky, H. Derendorf  
Mixed effects modeling of sparse data: A comparison of NONMEM and PKBUGS  
2004 AAPS Annual Meeting, Baltimore, November 2004.
569. Q. Liu, K. Rand, M. Mueller, H. Stass, H. Derendorf  
Pharmacokinetic/pharmacodynamic (PK/PD) modeling of antimicrobial effect and  
resistance development for moxifloxacin and ceftriaxone  
2004 AAPS Annual Meeting, Baltimore, November 2004.
570. E. Schuck, M. Grant, L. Putcha, H. Derendorf  
Pharmacokinetics and pharmacodynamics of ciprofloxacin in simulated microgravity  
2004 AAPS Annual Meeting, Baltimore, November 2004.
571. H. Derendorf, C.P. VanderMaelen, R.S. Brickl, W. Eisert  
Improved dipyridamole formulation insures absorption in elderly patients  
Karolinska Stroke Update, Stockholm, November 2004.
572. H. Derendorf  
Corticosteroid PK/PD parameters and their relationship to safety and efficacy  
Southwest Allergy Forum, Puerto Vallarta, January 2005.

573. H. Derendorf  
Integration of PK-PD modeling and simulation in the development of new anti-infective agents  
Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Orlando, March 2005.
574. H. Derendorf  
Pharmacology of inhaled corticosteroids: Are they all alike?  
Annual Meeting of the German Pulmunology Society, Berlin, March 2005.
575. H. Derendorf  
Basics of pharmacokinetics and pharmacodynamics  
Workshop on Optimum Therapy of Complicated Infections, Berlin, March 2005.
576. H. Derendorf  
Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam and tigecycline  
Workshop on Optimum Therapy of Complicated Infections, Berlin, March 2005.
577. H. Derendorf, P. Liu, K. Rand, B. Obermann  
MIC vs. kill curve based pharmacokinetic/pharmacodynamic modeling of activities of cefpodoxime and cefixime  
15<sup>th</sup> ECCMID, Copenhagen, April 2005
578. H. Derendorf  
The importance of protein binding and how to expose highly-protein bound antimicrobials in the in-vitro model  
Post-ECCMID ISAP Meeting, Copenhagen, April 2005.
579. H. Derendorf  
Pharmacology of inhaled corticosteroids - Are they all alike?  
Pneumological Workshop on Asthma, Frankfurt, April 2005.
580. H. Derendorf  
Daptomycin - Profile, pharmacokinetics, pharmacodynamics and side effects  
Daptomycin Expert Meeting, Berlin, April 2005.
581. H. Derendorf, G. Hochhaus  
Relevance of pharmacokinetic and pharmacodynamic data in the efficacy and safety of inhaled corticosteroids  
5<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Hakone, May 2005
582. H. Derendorf  
Special PK/PD characteristics of proteins and peptides  
1<sup>st</sup> PharmSciFair, Nice, June 2005.
583. H. Derendorf  
Optimizing drug development of anti-infective agents using pharmacokinetics and pharmacodynamics  
Faculty Award Presentation, University of Utrecht, June 2005.
584. H. Derendorf, S. Mertens-Talcott, V. Butterweck  
Recent advances in food-drug interactions: How concerned should we be?  
2005 Institute of Food Technologists Annual Meeting, New Orleans, July 2005.
585. H. Derendorf, V. Butterweck  
Pharmacokinetics and drug interactions of herbal medicinal products  
53<sup>rd</sup> Annual Congress of the Society for Medicinal Plant Research, Florence, August 2005
586. W.V. de Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, H. Derendorf  
Great variability of flavonoids and furanocoumarins in commercially available grapefruit juices: A source of inconsistency in grapefruit-drug interaction studies  
53<sup>rd</sup> Annual Congress of the Society for Medicinal Plant Research, Florence, August 2005
587. M.J. Salvador, S. Mertens-Talcott, E.O. Ferreira, W.V. de Castro, V. Butterweck, H. Derendorf, D.A. Dias  
Phenolic constituents and antioxidant capacity of *Alternanthera tenella* Colla  
53<sup>rd</sup> Annual Congress of the Society for Medicinal Plant Research, Florence, August 2005



588. W.V. de Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, H. Derendorf  
Flavonoids and furanocoumarins in grapefruit juice: Analysis and effect of  
naringin and 6',7'-dihydroxybergamottin on P-glycoprotein in vitro  
34<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Rockville,  
September 2005.
589. O. Burkhardt, R. Madabushi, C. Lehmann, T. Welte, H. Derendorf  
Once-daily tobramycin in cystic fibrosis: Better clinical outcome than tid but  
more resistance development?  
34<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Rockville,  
September 2005.
590. H. Derendorf  
In vitro and animal models for the development of surrogate markers for optimal  
microbiological and clinical outcome  
34<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Rockville,  
September 2005.
591. H. Derendorf  
Quantification of biomarkers and integration with exposure for dose optimization  
AAAPS Workshop on Integrated Roadmap to Biomarkers for Drug Development - Method  
Validation and Qualification, Rockville, September 2005.
592. H. Derendorf  
PK/PD in special populations  
7<sup>th</sup> European Congress of Chemotherapy and Infection, Florence, October 2005.
593. H. Derendorf  
PK/PD - does it make a difference?  
7<sup>th</sup> European Congress of Chemotherapy and Infection, Florence, October 2005.
594. H. Derendorf  
Trends in Pharmacy and opportunities for the future  
Forum Futurum, Miami, November 2005.
595. V. Kumar, R. Madabushi, L.A. Boothby, H. Derendorf  
Development and validation of an HPLC-UV method for oxytocin quantitation in  
Ringer lactate solution for stability studies  
AAAPS Annual Meeting, Nashville, November 2005.
596. W. Castro, S. Talcott-Mertens, A. Rubner, V. Butterweck, H. Derendorf  
Analysis of flavonoids and furanocoumarins in grapefruit juice  
AAAPS Annual Meeting, Nashville, November 2005.
597. O. Burkhardt, C. Lehmann, R. Madabushi, T. Welte, H. Derendorf  
Once daily tobramycin in cystic fibrosis: Better clinical outcome than TID but  
more resistance development?  
45<sup>th</sup> Annual ICAAC, Washington, December 2005.
598. H. Derendorf  
Is protein binding important for lipophilic drugs?  
45<sup>th</sup> Annual ICAAC, Washington, December 2005.
599. H. Deendorf  
Modeling and simulation for drug candidate selection  
AGAH/ACCP Workshop on Computer Simulation and its Role in Drug Development,  
Düsseldorf, February 2006.
600. H. Derendorf  
Improving asthma therapy through scientific innovation  
American Academy of Allergy, Asthma and Immunology, Miami, March 2006.
601. H. Derendorf, G. Hochhaus  
The effect of protein binding on adrenal suppression potential of inhaled  
corticosteroids  
American Academy of Allergy, Asthma and Immunology, Miami, March 2006.
602. H. Derendorf  
Biomarker-guided drug development

- 2006 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Baltimore, March 2006
603. H. Derendorf  
Use of PK/PD modeling to streamline drug development  
2006 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Baltimore, March 2006
604. H. Derendorf  
Pharmacokinetic exposure, response and dermal drug absorption  
2006 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Baltimore, March 2006
605. S. Mertens-Talcott, W.V. de Castro, V. Butterweck, H. Derendorf  
Grapefruit drug interactions: The effect of furanocoumarins and polymethoxylated flavones on P-glycoprotein activity in vitro  
2006 FASEB Meeting, San Francisco, April 2006.
606. W. Treyapasert, U. Suvanakoot, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains  
16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 2006.
607. S. Schmidt, O. Burkhardt, W. Treyapasert, H. Derendorf  
PK/PD challenges of in vitro time-kill curves - a new modelling approach  
16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 2006.
608. S. Schmidt, O. Burkhardt, S. Schubert, A. Dalhoff, H. Derendorf  
Carbapenems - differences in their antibacterial activity due to their protein binding  
16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 2006.
609. S. Schmidt, O. Burkhardt, M. Sahre, H. Derendorf  
Experimental pitfalls in protein binding measurements  
16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 2006.
610. J. Barth, D. Jäger, M. Müller, O. Burkhardt, H. Derendorf  
Penetration of moxifloxacin into normal and infected subcutaneous tissue in patients with spinal cord injury measured by microdialysis  
16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, April 2006.
611. H. Derendorf  
Use of biomarkers, modeling and simulation to streamline drug development  
11<sup>th</sup> Pharmacokinetic/Pharmacodynamic Expert Meeting, Berlin, May 2006.
612. H. Derendorf  
The race against resistance: How can we find new drugs against bad bugs  
South Eastern Regional Interdisciplinary Symposium, Gainesville, May 2006.
613. H. Derendorf  
Strengths and weakness of antimicrobial PK/PD analysis  
Third International Conference on Antimicrobial Agents in Veterinary Medicine, Orlando, May 2006.
614. H. Derendorf  
Clinical trials and FDA process  
British Medical Association, London, July 2006.
615. H. Derendorf  
Pharmacokinetic options  
Symposium on Multiresistance and New Antibiotics, Hannover, July 2006.
616. H. Derendorf  
Pharmacokinetic options  
Symposium on Multiresistance and New Antibiotics, Hamburg, August 2006.

617. W.V. DeCastro, S.U. Mertens-Talcott, H. Derendorf, V. Butterweck  
Grapefruit Juice Drug Interactions: grapefruit juice and its components inhibit P-glycoprotein mediated transport of talinolol in Caco-2 Cells  
47th Annual Meeting of the American Society of Pharmacognosy, Arlington, August 2006.
618. W.V. DeCastro, S.U. Mertens-Talcott, H. Derendorf, V. Butterweck  
Grapefruit Juice Drug Interactions: grapefruit juice and its components inhibit P-glycoprotein mediated transport of talinolol in Caco-2 Cells  
54th Annual Meeting of the Society of Medicinal Plant Research, Helsinki, September 2006.
619. H. Derendorf  
Which characteristics of an ICS do you consider to have the most significant impact of effectiveness of the agent?  
European Respiratory Society Annual Congress, Munich, September 2006.
620. H. Derendorf  
Pharmacokinetic options  
Symposium on Multiresistance and New Antibiotics, Berlin, September 2006.
621. H. Derendorf  
PK/PD as basis of dose optimization  
Annual Meeting of the German Society for Hygiene and Microbiology, Würzburg, October 2006.
622. H. Derendorf  
Information on GI performance: nice-to-know or essential tool for accelerated product development and approval?  
Symposium on Magnetic Marker Monitoring, Berlin, October 2006.
623. H. Derendorf  
Pharmacokinetics of lipoproteins  
Daptomycin Symposium, Langenlois, October 2006.
624. S. Sarawek, H. Derendorf, V. Butterweck  
Xanthine oxidase inhibitory activity of various flavonoids in vitro on plasma uric acid levels in oxonate-induced rats  
AAPS Annual Meeting, San Antonio, October 2006.
625. V. Kumar, O. Burkhardt, M. Pletz, T. Welte, H. Lode, H. Derendorf  
Comparison of pharmacodynamic target attainment of ertapenem in healthy volunteers and intensive care unit patients using Monte Carlo simulations  
AAPS Annual Meeting, San Antonio, October 2006.
626. V.W. DeCastro, S. Talcott, V. Butterweck, H. Derendorf  
Effects of grapefruit juice and its components on the activity of P-glycoprotein  
AAPS Annual Meeting, San Antonio, October 2006.
627. S. Talcott, V.W. DeCastro, H. Derendorf, V. Butterweck  
Citrus flavonoids in the inhibition of P-glycoprotein in vitro  
AAPS Annual Meeting, San Antonio, October 2006.
628. H. Derendorf  
Inhaled corticosteroids today: Are they lessening the systemic effects  
ACAAI Annual Meeting, Philadelphia, November 2006.
629. H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling: Current concepts  
Conference on Effective Integration of Systems Biology, Biomarkers, Biosimulation and Modelling in Streamlining Drug Development, Basel, November 2006.
630. M. Lobmeyer, H. Derendorf  
Clinical manifestation of polymorphisms - Consulting opportunities for pharmacists  
Bavarian Academy for Clinical Pharmacy, Würzburg, December 2006.
631. W. Treyprasert, U. Suvanakoot, H. Derendorf  
Pharmacokinetic-Pharmacodynamic Modeling of In Vitro Activity of Azithromycin Against Four Different Bacterial Strains

23rd Annual Research Conference in Pharmaceutical Sciences and JSPS of Asia/Africa Scientific Program, Bangkok, December 2006.

632. S. Schmidt, H. Derendorf  
PK/PD modeling of linezolid against MRSA  
17<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Munich, March 2007.
633. H. Derendorf  
Introduction to PK/PD of anti-infectives - the essentials in 60 minutes  
1<sup>st</sup> Symposium on PK/PD-approaches to suppression of resistance to anti-infectives, Munich, March 2007.
634. H. Derendorf  
Models of infection: In vitro vs. in vivo  
1<sup>st</sup> Symposium on PK/PD-approaches to suppression of resistance to anti-infectives, Munich, March 2007.
635. H. Derendorf  
Introduction to PK/PD  
25<sup>th</sup> ICC Educational Workshop on Pharmacokinetics and pharmacodynamics of anti-infective agents, Munich, March 2007
636. H. Derendorf  
Pharmacokinetic options  
Symposium on Multiresistance and New Antibiotics, Munich, April 2007.
637. H. Derendorf  
Pharmacotherapy in the elderly  
3<sup>rd</sup> Pharmaceutical Sciences World Congress, Amsterdam, April 2007.
638. J. Xu, J. Winkler, H. Derendorf  
A novel pharmacokinetic/pharmacodynamic (PK/PD) approach to predict total prednisolone levels in human plasma  
3<sup>rd</sup> Pharmaceutical Sciences World Congress, Amsterdam, April 2007.
639. Y. Li, C.J. Clancy, M.H.T. Nguyen, H. Derendorf  
Time-kill and post-antifungal effects (PAFE) of voriconazole against Candida clinical strains: Verifying experimental validity by determination of voriconazole concentrations using HPLC  
3<sup>rd</sup> Pharmaceutical Sciences World Congress, Amsterdam, April 2007.
640. H. Derendorf  
The significance of an optimized formulation for dipyridamole  
16<sup>th</sup> European Stroke Conference, Glasgow, May 2007.
641. H. Derendorf  
Pharmacokinetic/pharmacodynamic studies in drug product development  
6<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Göd, June 2007.
642. H. Derendorf  
Pharmacists in the USA - Experience and future opportunities  
Northrhine Chamber of Pharmacists, Neuss, June 2007.
643. V. Kumar, E.S. ELDesoky, M.M. Hamdi, M. Alorainy, H. Derendorf  
Population pharmacokinetics of lithium in Egyptian patients with bipolar affective disorder  
36<sup>th</sup> ACCP Annual Meeting, San Francisco, September 2007.
644. S. Schmidt, D. Abbanat, P. Manitpisitkul, J. Blake, S. Sha, H. Derendorf  
Linezolid against MRSA - A new modeling approach  
36<sup>th</sup> ACCP Annual Meeting, San Francisco, September 2007.
645. H. Derendorf  
Tissue levels of antibiotics  
HAI-Congress of Anesthesiology and Intensive Care Medicine, Berlin, September 2007.
646. H. Derendorf  
Tissue penetration and PK/PD of antibiotics

- HAI-Congress of Anesthesiology and Intensive Care Medicine, Berlin, September 2007.
647. H. Derendorf  
Introduction to PK/PD  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
648. H. Derendorf  
PK/PD based on kill curves  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
649. H. Derendorf  
Shortcomings of current pharmacodynamic assessment tools  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
650. S. Schmidt, A. Barbour, O. Ghobrial, D. Abbanat, P. Manitpisitkul, J. Blake, S. Sha, H. Derendorf  
Characterization of in vitro resistance to RWJ-416457 against MRSA compared to linezolid  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
651. Y. Li, H. Derendorf, M.H. Nguyen, C.J. Clancy  
Pharmacokinetic (PK)/pharmacodynamic (PD) modeling of voriconazole activity against *Candida* spp. using a dynamic in-vitro model  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
652. H. Badrane, M.H. Nguyen, V. Kumar, H. Derendorf, C.J. Clancy  
*Candida albicans* Irs4p interacts with Inp51p to regulate phosphatidylinositol-4,5-bisphosphate (PI(4,5)P<sub>2</sub>) levels, vesicle trafficking and virulence  
47<sup>th</sup> Annual ICAAC, Chicago, September 2007.
653. H. Derendorf  
Galenic formulations of dipyridamole  
Future Perspectives in Modern Stroke Management, Warsaw, September 2007.
654. H. Derendorf  
The use of PK/PD in drug development  
39<sup>th</sup> Brazilian Congress of Pharmacology and Experimental Therapeutics, Ribeirão Preto, October 2007.
655. J. Xu, J. Winkler, H. Derendorf  
Impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisone  
AAPS 2007 Annual Meeting, San Diego, November 2007.
656. H. Derendorf  
PK/PD modeling and the rational selection of dosage regimens for the prudent use of antimicrobial drugs  
2<sup>nd</sup> Symposium on Antimicrobial Resistance in Animals and the Environment, Tours, December 2007.
657. Y. Li, M. Nguyen, H. Derendorf, C. J. Clancy  
Dynamic time-kill experiments and pharmacokinetic/pharmacodynamic mathematical models of voriconazole activity against *Candida* isolates in vitro support target peak concentrations of 4×MIC  
9<sup>th</sup> ASM Conference on *Candida* and Candidiasis, Jersey City, March 2008.
658. H. Derendorf  
Special Populations: Geriatric Patients/Ageing  
Frontiers in Drug Development and Regulatory Science Series: Special Populations and Situations, Washington, May 2008.
659. H. Derendorf  
Integration of target site pharmacokinetics and in-vitro pharmacodynamics in the assessment of existing and new anti-infective agents  
Louvain Drug Research Institute, Brussels, September 2008.
660. H. Derendorf  
PK-PD modeling for anti-infectives  
GPEN 2008, Leuven, September 2008.

661. M. Sahre, S. Schmidt, A. Barbour, S. Sabarinath, R. Naik, C.N. Seubert, M.B. Grant, H. Derendorf  
Microdialysis as a tool for assessment of tissue concentrations of antibiotics in humans  
GPEN 2008, Leuven, September 2008.
662. J. Liu, H. Derendorf, D. Dennis, G.M. Janelle, C.N. Seubert  
Anesthesia in Space-PK/PD Modeling of propofol in simulated microgravity  
37<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, September 2008.
663. S. Sabarinath, N. Goyal, J. Winkler, B. Rosenkranz, H. Derendorf  
Population pharmacokinetics of the bradykinin B<sub>2</sub> receptor antagonist icatibant in Phase I and II clinical trials  
37<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, September 2008.
664. A. Barbour, S. Schmidt, H. Derendorf  
Combination of clinical microdialysis and in vitro pharmacodynamics for dose optimization of beta-lactam antibiotics  
37<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, September 2008.
665. S. Schmidt, A. Barbour, O. Burkhardt, W.R. Rout, K. Ben-David, H. Derendorf  
Soft tissue penetration of cefuroxime determined by clinical microdialysis in six obese patients undergoing abdominal surgery  
37<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Philadelphia, September 2008.
666. H. Derendorf  
Basic concepts of PK/PD for anti-infectives  
Ehrlich II - 2<sup>nd</sup> World Conference on Magic Bullets, Nürnberg, October 2008.
667. H. Derendorf  
Pharmacokinetics and pharmacodynamics of Anti-infectives  
Ehrlich II - 2<sup>nd</sup> World Conference on Magic Bullets, Nürnberg, October 2008.
668. H. Derendorf  
Streamlining drug development using modeling and simulation  
Ehrlich II - 2<sup>nd</sup> World Conference on Magic Bullets, Nürnberg, October 2008.
669. H. Derendorf  
Introduction to PK/PD  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.
670. H. Derendorf  
PK/PD based on kill curves  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.
671. S. Schmidt, K. Röck, M. Sahre, H. Derendorf  
In vitro protein binding needs to be measured in the respective medium and not estimated from reported serum binding  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.
672. A. Barbour, A. Childs, B. Murthy, S. Schmidt, S. Sabarinath, H. Tian, D. Desai-Krieger, D. Balis, M. Grant, C. Seubert  
Soft tissue penetration of ceftobiprole following single dose administration in healthy adults  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.
673. M. Sahre, S. Schmidt, A. Barbour, K.H. Rand, H. Derendorf  
In vitro pharmacodynamics of TR-700, the active moiety of prodrug TR-701, a novel oxazolidinone, in a kill curve model  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.

674. Y. Li, M. Nguyen, S. Schmidt, L. Zhong, H. Derendorf, C. Clancy  
Simulating voriconazole-Candida interactions using a mathematical model derived from a dynamic in vitro-kill method that mimics pharmacokinetics in vivo  
48<sup>th</sup> Annual ICAAC, Washington, October 2008.
675. H. Derendorf  
Pharmacokinetics and protein binding  
William A. Craig Symposium, Madison, October 2008.
676. I. Zadezensky, R. Frye, C. Galloway, H. Derendorf, V. Butterweck  
Assessment of the myopathy development in rats after simvastatin grapefruit juice coadministration  
2008 AAPS Annual Meeting, Atlanta, November 2008.
677. A. Barbour, S. Schmidt, H. Derendorf  
Microdialysis-based pharmacokinetic modeling of beta-lactam tissue concentrations  
2008 AAPS Annual Meeting, Atlanta, November 2008.
678. J. Xu, H. Derendorf  
Evaluation of growth retardation and cortisol suppression in pediatrics after inhaled corticosteroids using a mixed effects model  
2008 AAPS Annual Meeting, Atlanta, November 2008.
679. S. Schmidt, O. Burkhardt, H. Derendorf  
Protein binding pitfalls - in vitro and in vivo  
2008 AAPS Annual Meeting, Atlanta, November 2008.
680. J. Liu, K. Ren, H. Pan, M. Gold, A.W. Bruijnzeel, H. Derendorf  
PK/PD studies focusing on physical dependence of fentanyl in rats  
2009 Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics, Washington, March 2009.
681. K. Wölkart, R. Frye, H. Derendorf, R. Bauer, V. Butterweck  
Absolute Bioavailability and Metabolism of Dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides ("tetraene") after Intravenous and Oral Single Doses to Rats  
Annual Meeting of the Austrian Pharmaceutical Society, Vienna, April 2009.
682. H. Derendorf  
Rational development of new antibiotics  
7<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 2009.
683. B. Wu, H. Derendorf  
Utilizing Mechanism-Based Pharmacokinetic/Pharmacodynamic Models to Understand and Prevent Antimicrobial Resistance  
7<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 2009.
684. H. Derendorf  
Introduction to PK/PD  
19<sup>th</sup> ECCMID, Helsinki, May 2009.
685. H. Derendorf  
PK/PD modeling: Streamlining drug development  
2<sup>nd</sup> PharmSciFair, Nice, June 2009.
686. D. Gonzalez, S. Schmidt, H. Derendorf  
Effects of protein binding on half-life of elimination  
38<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, San Antonio, September 2009.
687. H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling: What can the TB field learn from other infectious diseases and cancer chemotherapy?  
2<sup>nd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, September 2009.

688. H. Derendorf  
The general concepts of pharmacokinetics and pharmacodynamics  
49<sup>th</sup> ICAAC Pre-Conference Workshop, San Francisco, September 2009.
689. H. Derendorf  
PK/PD based on kill curves  
49<sup>th</sup> ICAAC Pre-Conference Workshop, San Francisco, September 2009.
690. Sahre, S. Sabarinath, M. Grant, C. Seubert, C. DeAnda, H. Derendorf  
Evaluation of Tissue Distribution of TR-701 in Healthy Volunteers, Using  
Microdialysis  
49<sup>th</sup> ICAAC, San Francisco, September 2009.
691. B. Wu, H. Derendorf  
Utilizing mechanism-based pharmacokinetic/pharmacodynamic models to understand and  
prevent antimicrobial resistance  
49<sup>th</sup> ICAAC, San Francisco, September 2009.
692. E.S.ELDesoky, S.N. Sabarinath, M.M. Hamdi, M. Bewernitz, H. Derendorf  
Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy  
patients  
11th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology,  
Montreal, October 2009.
693. L. Zhuang, J. Gao, H. Derendorf, C. Liu  
Pharmacokinetic study of thermosensitive liposome-encapsulated lomustine in C6  
glioma model rats  
2009 AAPS Annual Meeting, Los Angeles, November 2009.
694. M. Zuehlsdorf, V.A. Bhattaram, S. Krösser, H. Derendorf, A. Kovar  
Population pharmacokinetics of cilengitide from a non-linear mixed effects  
analysis  
Annual Meeting of the American Association of Cancer Research (AACR), Boston,  
November 2009.
695. H. Derendorf  
Introduction to Pharmacokinetics and Pharmacodynamics  
Workshop Advanced Topics in Toxicology, Ribeirão Preto, December 2009.
696. H. Derendorf  
The effect of protein binding on pharmacokinetics and pharmacodynamics  
Universidade Federal do Rio Grande do Sul, Porto Alegre, December 2009.
697. H. Derendorf  
Introduction to Pharmacodynamic Principles  
ACDRS Workshop learning Trials: From Discovery to First in Humans, Washington,  
February 2010.
698. H. Derendorf, V. Butterweck  
Pharmacokinetics and Drug Interactions of herbal Medicinal Products  
Summer School in Pharmacognosy 2010, Florianopolis, February 2010.
699. S. Sabarinath, N. Goyal, H. Derendorf, K. Oreskovic, V. Schmith  
Modeling of target lesion scores over time in a psoriasis microplaque assay  
111<sup>th</sup> Annual meeting of the American Society for Clinical Pharmacology and  
Therapeutics, Atlanta, March 2010.
700. H. Derendorf  
Treatment with glycopeptides: intermediate dosing or continuous infusion?  
European Congress of Clinical Microbiology and Infectious Diseases, Vienna, April  
2010.



701. H. Derendorf  
Dose adjustments in patients with impaired renal function  
European Congress of Clinical Microbiology and Infectious Diseases, Vienna, April 2010.
702. H. Derendorf, D. Gonzalez  
Innate inflammation - A challenge for drug absorption and pharmacokinetics  
New York Academy of Sciences, Innate Inflammation as the Common Pathway of Risk Factors Leading to Transient Ischemic Attacks and Stroke: Pathophysiology and Potential Interventions, New York, May 2010.
703. H. Derendorf  
Modeling and simulation to streamline drug development  
Congresso Sul-Americano de Biofarmacia e Farmacocinetica, Porto Alegre, May 2010.
704. H. Derendorf  
Simulation and data modeling in drug development. Better drugs faster?  
IUPHAR World Conference on Basic and Applied Pharmacology, Copenhagen, July 2010.
705. K. Woelkart, M. Kollroser, H. Derendorf, V. Butterweck, R. Bauer  
Development and validation of a LC-MS/MS method based on a new 96-well HybridSPE™-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma  
GA Meeting, Berlin, August 2010.
706. S. Schmidt, A. Barbour, H. Derendorf  
Microdialysis: a valuable tool for identifying clinically relevant PK/PD relationships  
13th International Conference on In Vivo Methods: Monitoring Molecules in Neuroscience, Brussels, September 2010.
707. S. Sabarinath, N. Goyal, K. Oreskovic, V.D. Schmith, H. Derendorf  
Modeling of lesion scores over time in a psoriasis microplaque assay  
39<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Baltimore, September 2010.
708. R.P. Singh, S.N. Sabarinath, M. Sahre, H. Nguyen, T. Hoppe-Tichy, G. Egerer, M. Gronkowski, H. Derendorf  
Population pharmacokinetics of caspofungin in patients with acute leukemia or allogenic or autologous blood stem cell transplantation  
39<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Baltimore, September 2010.
709. B. Wu, H. Derendorf  
Using pharmacokinetic/pharmacodynamic models to guide the suppression of the emerged resistant population of Pseudomonas aeruginosa following ciprofloxacin treatment  
50<sup>th</sup> ICAAC, Boston, September 2010.
710. K. Ikawa, A. Nakashima, N. Morikawa, K. Ikeda, Y. Murakami, H. Ohge, H. Derendorf, T. Sueda  
Clinical pharmacokinetics and pharmacodynamics of meropenem and biapenem in bile  
50<sup>th</sup> ICAAC, Boston, September 2010.
711. S. Schmidt, O. Burkhart, H. Derendorf  
Effect of protein binding on the pharmacokinetics and pharmacodynamics of beta-lactams  
Annual Meeting of the Paul-Ehrlich-Society, Bonn, October 2010.
712. H. Derendorf  
Pharmacometrics: What is this, which skills are needed?  
South African Congress for Pharmacology and Toxicology, Cape Town, October 2010.
713. H. Derendorf  
Drug-drug interactions and traditional medicines  
South African Congress for Pharmacology and Toxicology, Cape Town, October 2010.

714. E. A. Ross, H. Derendorf, R. P. Singh  
Sodium thiosulfate (STS) dosing strategies for treatment of calciphylaxis  
ASN Renal Week, Denver, November 2010.
715. R. P. Singh, M. Vieira, A. Barbour, S. Schmidt, W. R. Rout, K. Ben-David, O.  
Burkhardt, H. Derendorf  
Physiological based pharmacokinetic modeling of cefuroxime clinical microdialysis  
data in morbidly obese females undergoing surgery  
AAPS Annual Meeting, New Orleans, November 2010.
716. R. Naik, R. Singh, C. Seubert, M. Garnt, U. Shukla, P. Manitpisitkul, K. Shalayda,  
N. Anderson, S. Sha, H. Derendorf  
Clinical tissue distribution study of a novel fluoroquinolone (JNJ-Q2) using  
microdialysis in healthy subjects  
AAPS Annual Meeting, New Orleans, November 2010.
717. M. Vieira, D. Conrado, H. Derendorf  
Intravenous microdialysis study in rats using triamcinolone acetonide as a model  
drug  
AAPS Annual Meeting, New Orleans, November 2010.
718. R. Shi, H. Derendorf  
Fixed dosing vs. body size-based dosing of anti-cancer drugs in adults: A  
population pharmacokinetic approach  
112<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and  
Therapeutics, Dallas, February 2011.
719. R.P. Singh, S. Sy, I. Hazza, S.A. Shilbayeh, H. Derendorf  
Population pharmacokinetics and adverse event analysis of tacrolimus in pediatric  
renal transplant recipients  
American Conference on Pharmacometrics, San Diego, April 2011.
720. H. Derendorf, K. RübSamen, A. Schäffler, J.R. Kirwan  
Pharmacokinetics of modified-release prednisone tablets are essentially unchanged  
from conventional immediate release prednisone tablets except for a programmed  
delay of 4-6 hours  
European League Against Rheumatism, London, May 2011.
721. H. Derendorf  
Eng's principle in pharmacokinetics  
8<sup>th</sup> Retrometabolism-based Drug Design and targeting Conference, Graz, June 2011.
722. J. Bousquet, U. Munzel, U. Petzold, C. Kolb, J. Maus, H. Mascher, R. Hermann, H.  
Derendorf  
A new treatment option for allergic rhinitis - Systemic bioavailability and  
disposition of fluticasone propionate administered in combination with azelastine  
30<sup>th</sup> Congress of the European Academy of Allergy and Clinical Immunology, Istanbul,  
June 2011.
723. J. Bousquet, U. Munzel, U. Petzold, C. Kolb, M. Weingart, J. Maus, R. Hermann, H.  
Derendorf  
A new treatment option for allergic rhinitis - Systemic bioavailability and  
disposition of azelastine administered in combination with fluticasone propionate  
30<sup>th</sup> Congress of the European Academy of Allergy and Clinical Immunology, Istanbul,  
June 2011.
724. H. Derendorf  
It's the patient, stupid  
150 Years Deutsche Apotheker Zeitung, Berlin, July 2011.
725. H. Derendorf  
How to handle protein binding in modeling and simulation  
Gordon Conference Drug Metabolism, Holderness, July 2011.
726. H. Derendorf, K. Ikawa, R.P. Singh, J. Straub  
Differences in exposure and response between East Asians and Caucasians  
40<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Chicago,  
September 2011.

727. R.P. Singh, V.R. Daniels, C.J. Crady, H. Derendorf, L. Putcha  
Pharmacokinetics of an intranasal scopolamine gel formulation during  
antiorthostatic bedrest - a microgravity analog  
40<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Chicago,  
September 2011.
728. D.J. Conrado, M. Bewernitz, S. Sy, M. Ding, J. Cibula, S. Eisenschenk, C. Seubert,  
H. Derendorf  
Population pharmacokinetics and pharmacodynamics of armodafinil: effects on  
electroencephalogram and alertness of sleep deprived adults  
40<sup>th</sup> Annual Meeting of the American College of Clinical Pharmacology, Chicago,  
September 2011.
729. S.A.R. Shilbayeh, R.P. Singh, H. Derendorf  
Population pharmacokinetics for individualization of tacrolimus dose in Jordanian  
pediatric renal transplant recipients  
12<sup>th</sup> International Congress of Therapeutic Drug Monitoring and Clinical  
Toxicology, Stuttgart, October 2011.
730. E.S. El Desoky, M.H. Ghazally, R.P. Singh, O.N. Abdelhamid, H. Derendorf  
Population pharmacokinetics of methotrexate in Egyptian children with  
lymphoblastic leukemia  
12<sup>th</sup> International Congress of Therapeutic Drug Monitoring and Clinical  
Toxicology, Stuttgart, October 2011.
731. H. Derendorf  
Patients with hepatic impairment - what dose?  
51<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,  
September 2011.
732. L. Zhuang, R.P. Singh, H. Xia, S.K.B. Sy, C. Liu, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of vertilmicin, a  
novel aminoglycoside against three bacterial strains  
51<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago,  
September 2011.
733. F. Qureshi, N. Guoqin, J. Hughes, H. Derendorf  
FGF2-targeted cationic lipid formulations for oligonucleotide delivery  
2011 AAPS Annual Meeting and Exposition, Washington, October 2011.
734. H. Derendorf  
Streamlining drug development by PL/PD-based modeling and simulation  
2011 CMDD Symposium on Marine Natural Products and Drug Discovery, Seoul, October  
2011.
735. H. Derendorf  
PK/PD-based development of anti-infective agents  
Past, Present and Future of Molecular Pharmacokinetics, Tokyo, January 2012.
736. H. Derendorf  
It's the patient, stupid  
20<sup>th</sup> NZW Oncological Pharmacy Congress, Hamburg, January 2012.
737. L. Zhuang, S. Sy, H. Xia, H. Derendorf  
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of vertilmicin  
against three bacterial strains  
Emerging Pathogens Institute Research Day, Gainesville, February 2012.
738. A.B. Barth, E.F. Egelund, Z. Ahmed, E.L. Nuermberger, C. Peloquin, H. Derendorf  
Exploratory pharmacokinetics-pharmacodynamics (PK-PD) target attainment analysis  
of PA-824  
Emerging Pathogens Institute Research Day, Gainesville, February 2012.
739. D.J. Conrado, M. Bewernitz, J.P. Juchem-Neto, M. Ding, J. Cibula, S. Eisenschenk,  
C. Seubert, H. Derendorf

- Pharmacokinetic-pharmacodynamic modeling of armodafinil: Effects on electroencephalogram and neurocognition of sleep deprived adults  
International Conference on Computational Biomedicine, Gainesville, March 2012.
740. D.J. Conrado, M. Bewernitz, M. Ding, J. Cibula, S. eisenschenk, C. Seubert, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling on alertness and electroencephalogram of sleep derived adults  
113<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbour, March 2012.
741. D. Gonzalez, A. van der Straten, T.E. Morey, S. Wasdo, J. Wishin, B. Quinn, M. Booth, R.J. Melker, H. Derendorf, D.M. Dennis  
Pharmacokinetic analysis of two flavorants used in a novel breath-based system (Smart™) designed to assess use of vaginally applied products  
113<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbour, March 2012.
742. R.P. Singh, M.D. Sahre, H. Derendorf, V.D. Schmith  
Disease progression modeling of inflammatory lesion counts (LES) in acne vulgaris  
113<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbour, March 2012.
743. R.P. Singh, M.D. Sahre, H. Derendorf, V.D. Schmith  
Modeling of investigative static global assessmentscore (ISGA) in acne vulgaris  
113<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbour, March 2012.
744. P. Brossard, A. Halabi, H. Derendorf, J. Dingemane  
Ascending single-dose study with ponesimod, a selective SIP<sub>1</sub>-receptor agonist: Safety, pharmacokinetics, pharmacodynamics, and modeling  
113<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, National Harbour, March 2012.
745. H. Derendorf  
Dose adjustments in special populations  
22<sup>nd</sup> ECCMID, London, March 2012.
746. K. Chooluck, R.P. Singh, K. Sathirakul, H. Derendorf  
Dermal Pharmacokinetics of Terpinen ~~allowing~~ Topical Application in Plai Oil: A Microdialysis Study  
The Thirteenth RGJ-Ph.D. Congress, Pattaya, April 2012.
747. H. Derendorf  
Pharmacodynamic Drug Interactions  
3<sup>rd</sup> International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions, Marbach Castle, May 2012.
748. D. Gonzalez, T.E. Morey, S. Wasdo, J. Wishin, B. Quinn, M. Booth, H. Derendorf, R. Melker, D. Dennis  
Population pharmacokinetics of two volatile markers used for assessment of definite adherence  
21<sup>st</sup> PAGE Meeting, Venice, June 2012.
749. W.V. deCastro, H. Derendorf, V. Butterweck  
Carrier mediated transport of talinolol in rats upon single and multiple dose administration of ruby red grapefruit juice  
1<sup>st</sup> Congress of the Brazilian Association of Pharmaceutical Sciences, Porto de Galinhas, October 2012.
750. K. Ardjomand-Woelkart, M. Kollroser, H. Derendorf, R. Bauer, V. Butterweck  
Herb-drug interactions: Effects of *Echinacea* preparations on Cytochrome P450 activities in rats  
International Congress on Natural Products Research, New York, July 2012.

751. L. Li, A.R. Han, A.D. Kinghorn, R. Frye, H. Derendorf, V. Butterweck  
The pharmacokinetic properties of  $\gamma$ -mangostin in rats in comparison to mangosteen extract  
International Congress on Natural Products Research, New York, July 2012.
752. H. Derendorf  
Pharmacokinetics of natural products  
International Congress on Natural Products Research, New York, July 2012.
753. H. Derendorf  
Introduction to PK/PD  
52<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 2012.
754. H. Derendorf  
PK/PD based on kill curves  
52<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 2012.
755. K. Ikawa, E. Kikuchi, J. Kikuchi, M. Nishimura, H. Derendorf, N. Morikawa  
Clinical pharmacokinetics and pharmacodynamics of clarithromycin and telithromycin in epithelial lining fluid of the bronchi  
41<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacology, San Diego, September 2012.
756. H. Derendorf  
Pharmacokinetic issues in overcoming resistance: protein binding and microdialysis  
41<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacology, San Diego, September 2012.
757. D.J. Conrado, M. bewernitz, M. Ding, J. Cibula, S. Eisenschenk, C. Seubert, H. Derendorf  
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of armodafinil: Correlation with behavioral alertness  
41<sup>st</sup> Annual Meeting of the American College of Clinical Pharmacology, San Diego, September 2012.
758. H. Derendorf  
It's the patient, stupid  
Annual Meeting of the German Society for Clinical Pharmacy, Stuttgart, October 2012.
759. H. Derendorf  
Dose adjustments in special patient populations  
2<sup>nd</sup> Congreso Sudamericano de Biofarmacia y Farmacocinetica, Montevideo, November 2012.
760. H. Derendorf  
Impact of aging on pharmacokinetics and pharmacodynamics  
2<sup>nd</sup> Congreso Sudamericano de Biofarmacia y Farmacocinetica, Montevideo, November 2012.
761. F.K. Hurtado, B. Weber, H. Derendorf, T. Dalla Costa  
Population pharmacokinetic modeling of the unbound concentrations in plasma and prostate tissue  
2<sup>nd</sup> Congreso Sudamericano de Biofarmacia y Farmacocinetica, Montevideo, November 2012.
762. H. Derendorf  
Overview of pharmacometrics as a discipline with perspectives on its application to safety and efficacy  
GPEN Meeting, Melbourne, November 2012.
763. F.K. Hurtado, B. Weber, H. Derendorf, T. Dalla Costa  
Population pharmacokinetic modeling of the unbound levofloxacin concentrations in

- plasma and prostate measured by microdialysis in rats  
III Encontro do Programa de Pós-Graduação em Ciências Farmacêuticas da  
Universidade Federal do Rio Grande do Sul, Porto Alegre, November 2012.
764. H. Derendorf  
It's the patient, stupid  
Interpharm 2013, Hamburg, March 2013.
765. H. Derendorf  
Don't judge too quickly - Lessons learned from PK/PD of inhaled corticosteroids  
3<sup>rd</sup> Open Forum on Pharmaceutics and Biopharmaceutics - Focus Forum on Dry Powder  
Inhalation, Boston, March 2013.
766. H. Derendorf  
Pharmacometrics to streamline drug development using modeling and simulation  
Arthur D. Broom Seminar, University of Utah, Salt Lake City, April 2013.
767. M. Fueth, H. Derendorf, P. Okunieff  
Utilization of a synthesized fibroblast growth factor (FGF-P) as a novel  
mitigation agent to treat various acute and chronic radiation related syndromes  
First Annual Postdoc research Symposium, University of Florida, April 2013.
768. H. Derendorf  
Pharmacometrics in drug development  
1<sup>st</sup> ACTREC Symposium on Clinical Pharmacology in Cancer Therapeutics, Mumbai, April  
2013.
769. H. Derendorf  
PK/PD-guided development of anti-infective agents to combat resistance  
6<sup>th</sup> South Asian Chapter of ACCP Conference, Mumbai, April 2013.
770. H. Derendorf  
Impaired renal function: how, where and when to adjust?  
23<sup>rd</sup> ECCMID, Berlin, April 2013.
771. A. Völkner, C. Lebert, H. Derendorf  
Population pharmacokinetic/pharmacodynamic (PK/PD) assessment of vancomycin in  
adult patients indicates vanishing appropriateness of vancomycin therapy  
23<sup>rd</sup> ECCMID, Berlin, April 2013
772. L. Zhuang, S.K.B. Sy, H. Xia, R.P. Singh, C. Liu, H. Derendorf  
Characterization of in-vitro antimicrobial activity of vertilmicin alone and in  
combination with ceftazidime by using semi-mechanistic  
pharmacokinetic/pharmacodynamic models  
American Conference on Pharmacometrics, Fort Lauderdale, May 2013.
773. L. Li, H. Möllmann, J. Barth, S. Rohatagi, G. Hochhaus, H. Derendorf  
PK/PD modeling of methylprednisolone and prednisolone after multiple oral doses  
American Conference on Pharmacometrics, Fort Lauderdale, May 2013.
774. R. Singh, J. Sutcliffe, A. Rutcliff, H. Derendorf  
Development of an empirical model to explain atypical nonlinear plasma protein  
binding of eravacycline  
American Conference on Pharmacometrics, Fort Lauderdale, May 2013.
775. H. Derendorf  
Benefits and risks of pharmacokinetic and pharmacodynamic drug-drug interactions  
in anti-infective therapy  
9<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 2013.
776. J. Kast, D.J. Conrado, M. Bewernitz, M. Ding, J. Cibula, S. Eisenschenk, C.  
Seubert, H. Derendorf  
EEG as a potential biomarker to assess armodafinil drug effect in sleep deprived  
patients  
9<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 2013.
777. M. Fueth, I. Prasanchairmontri, R. Singh, H. Derendorf, L. Zhang, S. Vidyasagar,  
P. Okunieff  
Utilization of a synthesized fibroblast growth factor (FG-P) as a novel mitigation  
agent to treat various acute and chronic radiation related syndromes

- 9<sup>th</sup> Retrometabolism Based Drug Design and Targeting Conference, Orlando, May 2013.
778. H. Derendorf  
Drug-drug-interactions involving antibiotic agents  
4<sup>th</sup> International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug-Interactions, Schloss Marbach, May 2013.
779. H. Derendorf  
Vancomycin trough levels - What can we learn?  
Annual Conference of the German Society of Hospital Pharmacists, Dresden, May 2013.
780. A. Barth, R. May, J. Johnson, C. Peloquin, H. Derendorf  
Development of an in vitro system to perform time-kill curves of levofloxacin against Mycobacterium tuberculosis  
34<sup>th</sup> Annual Congress of the European Society of Mycobacteriology. Florence, Italy, May 2013.
781. P. M. Tulkens, P. Wallemacq, H. Derendorf  
Vancomycin (VAN) administered by continuous infusion (CI) should be dosed according to clearance (CL) and not as a the patient's body weight  
28<sup>th</sup> International Congress of Chemotherapy and Infection, Yokohama, June 2013
782. H. Derendorf  
Introduction to Pharmacokinetics  
53<sup>rd</sup> ICAAC, Denver, September 2013.
783. R.S. Singh, N. Falcao, J.A. Sutcliffe, H. Derendorf  
Plasma protein binding of eravacycline in mouse, rat, rabbit, cynomolgus monkey, african green monkey and human using microdialysis  
53<sup>rd</sup> ICAAC, Denver, September 2013.
784. L. Zhuang, S.K. Sy, H. Xia, R.P. Singh, C. Liu, H. Derendorf  
Characterization of in vitro antimicrobial activity of vertilmicin alone and in combination with ceftazidime by using semi-mechanistic pharmacokinetic/pharmacodynamics modeling  
53<sup>rd</sup> ICAAC, Denver, September 2013.
785. S.K. Sy, M.E. Beaudoin, V.J. Schuck, H. Derendorf  
Modeling of the potentiation of in vitro activities by avibactam against four beta-lactam-resistant bacterial strains  
53<sup>rd</sup> ICAAC, Denver, September 2013.
786. H. Derendorf  
Pharmacokinetics of Daptomycin  
4<sup>th</sup> Infectiology Expert Workshop, Dresden, October 2013.
787. H. Derendorf  
Modeling and simulation in drug development  
STEM Seminar, Daytona State College, Daytona Beach, November 2013.
788. H. Derendorf  
Role of microdialysis for in vivo characterizations in evaluating safety and efficacy of anti-infective drugs  
2013 AAPS Annual Meeting, San Antonio, November 2013.
789. J.K. Mukker, R.S. Singh, H. Derendorf  
Metal ion chelation by tigecycline explains atypical nonlinear plasma protein binding behavior  
ASCPT 2014 Annual Meeting, Atlanta, March 2014
790. R.S. Singh, J.K. Mukker, H. Derendorf  
Monte Carlo simulation to determine the effect of atypical nonlinear protein binding on clinical breakpoint of tigecycline  
ASCPT 2014 Annual Meeting, Atlanta, March 2014
791. H. Derendorf  
Pharmacodynamic evaluation of inhaled corticosteroids  
Respiratory Drug Delivery 2014, Puerto Rico, May 2014.

792. H. Derendorf  
Optimizing therapy in obese and frail patients  
ECCMID 2014, Barcelona, May 2014.
793. V. Zabela, M. Oufir, F. Moradi-Afrapoli, H. Derendorf, V. Butterweck, M. Hamburger  
Validation of UHPLC-MS/MS Methods for Quantification of Kaempferol and 4-Hydroxy-phenylacetic acid in Rat Plasma, and Application to Pharmacokinetic Studies  
International Mass Spectrometry Conference, Geneva, August 2014.
794. A. Voelkner, B. McCullough, K. Klinker, H. Derendorf  
Assessment of vancomycin AUC/MIC and clinical outcome in MRSA patients  
GPEN 2014, Helsinki, August 2014.
795. N. Falcao, S. Morales, C. Heinrichs, K. Hernandez, P. Kima, S. Sy, H. Derendorf  
Assessment of antileishmanial activity of pyrazinamide by in vitro time-kill-curve experiments against *Leishmania amazonensis*  
GPEN 2014, Helsinki, August 2014.
796. H. Derendorf  
Introduction to Pharmacokinetics  
ICAAC 2014, Washington, September 2014.
797. S. Worrall, K. Klinker, A. Voelkner, S. Borgert, H. Derendorf  
Acute kidney injury associated with beta-lactam antimicrobials  
ICAAC 2014, Washington, September 2014.
798. A. Voelkner, B.J. McCullough, K. Klinker, H. Derendorf  
Evaluation of clinical outcome and AUC/MIC in patients receiving vancomycin for MRSA bacteremia  
ICAAC 2014, Washington, September 2014.
799. S.K. Sy, M.E. Beaudoin, W.W. Nichols, V.J. Schuck, H. Derendorf  
Avibactam and ceftazidime combination against multidrug-resistant organisms in an invitro pharmacokinetic/pharmacodynamics model  
ICAAC 2014, Washington, September 2014.
800. **A.N. Deitchman**, R.P. Singh, J.K. Mukker, S.K.B. Sy, H. Derendorf  
Tigecycline and tetracycline as a synergistic *in vitro* combination against *Pseudomonas aeruginosa*  
ICAAC 2014, Washington, September 2014.
801. **H. Derendorf**  
MIC vs. time-kill curves: Which is the better PK/PD approach?  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
802. K. Ikawa, K. Matsumoto, N. Kanazawa, Y. Yokuyama, Y. Takeda, H. Derendorf, N. Morikawa  
Population pharmacokinetics of methotrexate in pediatric patients: A simultaneous analysis of the serum and urine concentration data  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
803. X. Song, H. Lu, P. Ji, Y.M. Wang, Y. Wang, C. Sahajwalla, J. Lee, J. Maynard, S. Yim, H. Derendorf, E.D. Bashaw, L. Fang  
Meta-analysis of esex impact on rheumatoid arthritis treatment response with biologics  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
804. R.S. Singh, J.K. Mukker, S. Drescher, H. Derendorf  
A need to revisit the clinical breakpoint of tigecycline: Effect of atypical nonlinear plasma protein binding  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
805. N.M. Falcao, P. Kima, C. Heinrichs, S. Morales, K. Hernandez, H. Derendorf  
Assessment of antileishmanial activity of pyrazinamide by in-vitro time-kill curve experiments against *Leishmania amazonensis*  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta,



September 2014.

806. R.S. Singh, A. Deitchman, J.K. Mukker, T. Schumacher, N.D. Bharose, S. Sy, D. Rensing, N.M. Falcao, H. Derendorf  
Increase in the efficacy of tigecycline: Effect of metal-ion chelation  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
807. A. Barth, R.S. Singh, R. May, J. Johnson, R. Isaza, H.M. Blumberg, S. Vashakidze, C. Peloquin, H. Derendorf, R. Kempker  
Levofloxacin dose optimization for multidrug resistant tuberculosis based on lung microdialysis in patients  
2014 Annual Meeting of the American College of Clinical Pharmacology, Atlanta, September 2014.
808. H. Derendorf  
Protein binding as a modulator of PK and PD variability  
5th Annual American Conference on Pharmacometrics, Las Vegas, October 2014.
809. H. Derendorf  
Pharmacokinetics and pharmacodynamics - What we can learn from glucocorticoids  
Workshop on Inhalative Antibiotics, Berlin, October 2014.
810. A. Deitchman, R.S. Singh, J.K. Mukker, S.Sy, A. Zoehner, H.Derendorf  
Exploring in vitro antipseudomonal activity of synergistic tigecycline-tetracycline combinations  
ASCPT 2015 Annual Meeting, New Orleans, March 2015.
811. H. Derendorf  
Advances in pulmonary drug delivery  
1<sup>st</sup> European Conference on Pharmaceutics, Reims, April 2015.
812. H. Derendorf  
Drug level monitoring recommendations - facts and myths  
European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, April 2015.
813. A. Deitchman, R. Singh, A. Zoehner, H. Derendorf  
In vitro pharmacodynamics of tigecycline and tetracycline combinations against *Pseudomonas aeruginosa*  
European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, April 2015.
814. H. Derendorf  
Plasma protein binding and its implications for intracellular drug concentrations  
6<sup>th</sup> International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug-Interactions, Marbach Castle, May 2015.
815. H. Derendorf  
PK/PD modeling and simulation for efficacy and safety of corticosteroids in asthma and inflammation  
3rd Joint Conference of European Human Pharmacological Societies, Brussels, May 2015.
816. H. Derendorf  
Applications of pharmacokinetic/pharmacodynamics models for the development of antimicrobial agents  
1<sup>st</sup> International Congress of Controlled Release Society- Greek Local Chapter, Athens, May 2015.
817. S.P. Zvada, S. Sy, N. Bauer, M. von Bibra, Daniel ClemensH. Klinker, H. Derendorf, B. Rosenkranz  
Population pharmacokinetics of efavirenz among HIV infected South Africans across different age groups including pregnant women  
24<sup>th</sup> PAGE Meeting, Hersonissos, June 2015.
818. F. Azeredo, M. Adelino, C. Assunção da Silva, H. Derendorf, S. Egito  
Comparing the fungicidal effect of free amphotericin B with to a novel micelle system against *Candida*

24<sup>th</sup> PAGE Meeting, Hersonissos, June 2015.

819. H. Derendorf  
An introduction of pharmacokinetic and pharmacodynamic modeling  
Emory-Georgia TB Research Training Program, Kazbegi, June 2015.
820. H. Derendorf  
Modeling and simulation to streamline drug development - Examples from earth and space  
8<sup>th</sup> Swiss Pharma Science Day, Bern, August 2015.
821. H. Derendorf  
Introduction to Pharmacokinetics  
ICAAC 2015, San Diego, September 2015.
822. A. Voelkner, T. Hoffmeister, J. Keuth, R. Boone, H. Derendorf  
Characterization of retapamulin in vitro activity against *Staphylococcus aureus* using a semi-mechanistic pharmacodynamics model  
ICAAC 2015, San Diego, September 2015.
823. A.N. Deitchman, J. Kast, A. Voelkner, H. Derendorf  
Describing tigecycline activity against *Pseudomonas aeruginosa*: Modeling of in vitro time-kill curves  
ICAAC 2015, San Diego, September 2015.
824. N.F. Voelkner, A. Voelkner, S. Sy, P.E. Kima, H. Derendorf  
Dose optimization of pyrazinamide based on dermal microdialysis in Wistar rats for cutaneous leishmaniasis treatment  
ICAAC 2015, San Diego, September 2015.
825. H. Derendorf  
Considering target site concentrations when choosing a dosing regimen  
Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2015.
826. S.K. Sy, R. Malmberg, A. Matsushima, E. Asin-Preto, B. Rosenkranz, M.F. Cotton, S. Innes, H. Derendorf  
Application of a physiologically-based pharmacokinetic model in pediatric stavudine dose reduction  
Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2015.
827. T. Heinrichs, R. May, R. Kempker, J. Johnson, C. Peloquin, H. Derendorf  
Moxifloxacin and pyrazinamide dose optimization for multi-resistant and extensively drug-resistant tuberculosis  
Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2015.
828. J.K. Mukker, R.S. Singh, M.K. Wimmer, R.P. Singh, H. Derendorf  
Physiologically-based pharmacokinetic modeling as a tool for in silico bioequivalence predictions: A case of telmisartan  
Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2015.
829. S.K. Sy, L. de Kock, B. Rosenkranz, A. Diacon, K. Hernandez, p. Donald, H. Derendorf  
Pharmacokinetic interaction of para-aminosalicylic acid and efavirenz in HIV-uninfected and HIV-coinfected tuberculosis patients managed for multidrug-resistant and extensively drug-resistant tuberculosis  
Annual Meeting of the American College of Clinical Pharmacology, San Francisco, September 2015.
830. D. de Joeng, A.N. Deitchman, R.S.P. Singh, H. Derendorf  
Investigating robustness of proposed models to describe the novel mechanism of atypical plasma protein binding behavior of tigecycline  
American Conference on Pharmacometrics 6, Arlington, October 2015.
831. H. Derendorf  
Clinical pharmacokinetics in the elderly  
III Congreso Sudamericano de Biofarmacia y Farmacocinética, Cordoba, November

- 2015.
832. J.C. da Costa, N.M.S. Falcao, E.V.S. Motta, B.V. Araujo, H. Derendorf, J.K. Bastos  
Pharmacokinetic study of quercitrin and evaluation of free levels in kidney using  
microdialysis  
III Congresso Sudamericano de Biofarmacia y Farmacocinética, Cordoba, November  
2015.
833. H. Derendorf  
Dosing medications in zero gravity  
Science in Space Workshop, Lake Nona, FL, March 2016.
834. H. Derendorf  
Drug level monitoring and dosing recommendations - facts and myths  
26<sup>th</sup> ECCMID, Amsterdam, April 2016.
835. H. Derendorf  
Locally applied - locally acting drugs: Predictive value of systemic vs. local  
exposure for efficacy assessment with focus on dermal, pulmonary and ocular  
application - Scientific aspects and regulatory thinking  
20<sup>th</sup> PK/PD Expert Meeting, Berlin, April 2016.
836. H. Derendorf  
Introduction to Pharmacokinetics  
International Certificate Course on PK/PD, South Asian Chapter of ACCP, Mumbai,  
April 2016.
837. H. Derendorf  
Introduction to Pharmacodynamics  
International Certificate Course on PK/PD, South Asian Chapter of ACCP, Mumbai,  
April 2016.
838. A.W. Bruijnzeel, X. Qi, L.V. Guzhval S. Wall, J.V. Deng, A. Ravula, M.S. Gold, H.  
Derendorf, M. Febo, B. Setlow  
Behavioral characterization of the effects of Cannabis smoke in rats  
Sixth Annual Aspen Brain Forum, New York, May 2016.
839. S. Lampotang, D. E. Lizdas, H. Derendorf, N. Gravenstein, B. Lok, J. Quarles  
Simulation-based assessment of awareness to race differences in propofol  
pharmacodynamics  
International Anesthesia Research Society Meeting, San Francisco, May 2016.
840. H. Derendorf  
The street light effect - Target site concentration measurements in drug  
development using microdialysis  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.
841. N. Voelkner, A. Voelkner, P. Kima, H. Derendorf  
Dose optimization of pyrazinamide based on dermal microdialysis in wistar rats for  
cutaneous leishmaniasis treatment  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.
842. A. Voelkner, N. Voelkner, F. Martins, H. Derendorf  
Dermal microdialysis of the topical antibiotic retapamulin to quantify skin  
concentrations and evaluate its pharmacokinetics in Wistar rats  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.
843. T. Heinrichs, A. Barth, R. Kempker, C.A. Peloquin, H. Derendorf  
Dose optimization for multidrug resistant and extensively drug resistant  
tuberculosis based on lung microdialysis in patients  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.
844. S.B. Jadhav, V. Khaowroongrueng, M. Fueth, W. Richter, M.B. Otteneder, H.  
Derendorf  
In vitro microdialysis of a therapeutic monoclonal antibody  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.
845. S. Schroepf, D. Burau, H.G. Muench, H. Derendorf, D. Adam, C. Kloft  
Microdialysis for therapeutic drug monitoring in infants  
8<sup>th</sup> International Symposium on Microdialysis, Uppsala, May 2016.

846. H. Derendorf  
Introduction to pharmacokinetics  
ASM Microbe, Boston, June 2016.
847. H. Derendorf  
Why do highly protein bound drugs still work?  
ASM Microbe, Boston, June 2016.
848. H. Derendorf  
The role of clinical pharmacology in drug development - Successes and mistakes  
PK/PD International Workshop for NDA, Taipei, August 2016.
849. H. Derendorf  
Why MIC is poison for the mind  
World Conference on Pharmacometrics, Brisbane, August 2016.
850. H. Derendorf  
New developments in monitoring drug dosing - Cornerstone for measurement, analysis  
and improvement of a patient's adherence to prescribed medication  
FIP World Congress, Buenos Aires, August 2016.
851. A.N. Deitchman, R.S> Singh, J. Kast, U. Liebchen, H. Derendorf  
Potential implications of atypical nonlinear plasma protein binding on tigecycline  
clinical pharmacokinetics  
2016 Annual Meeting of ACCP, Bethesda, September 2016.
852. R. Abhigyan, A. Bruijnzeel, B. Setlow, M. Febo, D. Jagnarine, H. Derendorf  
Development of dependence after exposure to cannabis smoke in rats  
2016 Annual Meeting of ACCP, Bethesda, September 2016.
853. H. Derendorf  
Evidence-based dose finding using modeling and simulation on earth and in space  
Annual Meeting of the German Pharmaceutical Society, Munich, October 2016.

## Research Group

Dr. Gotelind Mullersman (Post-doc)  
Dr. Richard Vistelle (Post-doc)  
Dr. Jobst Limberg (Post-doc)  
Dr. Volker Keuth (Post-doc)  
Dr. Hans-Günter Schäfer (Post-doc)  
Dr. Klaus Dietzel (Post-doc)  
Dr. Burkhard Wichert (Post-doc)  
Dr. Long-Shiuh Chen (Post-doc)  
Dr. George Henderson (Post-doc)  
Dr. Stefan Balbach (Post-doc)  
Dr. Siyawosh Moghaddam (Post-doc)  
Dr. Andreas Kovar (Post-doc)  
Dr. Bernd Meibohm (Post-doc)  
Dr. Birgit Pechstein (Post-doc)  
Dr. Nelamangala Nagaraja (Post-doc)  
Dr. Atul Bhattaram (Post-doc)  
Dr. Maria Gogova (Post-doc)  
Dr. Rajanikanth Madabushi (Post-doc)  
Dr. Susanne Mertens-Talcott (Post-doc)  
Dr. Olaf Burkhardt (Post-doc)  
Dr. Vipul Kumar (Post-doc)  
Dr. Eliane Oliveira Ferreira (Post-doc)  
Dr. Marcos Salvador (Post-doc)  
Dr. Hao Pan (Post-doc)  
Dr. Sreedharan Nair Sabarinath (Post-doc)  
Dr. Michael Bewernitz (Post-doc)  
Dr. Rajendra Pratap Singh (Post-doc)  
Dr. Giscardo Panzavolta (Post-doc)  
Dr. Ravi Singh (Post-doc)  
Dr. Matthias Fueth (Post-doc)  
Dr. Daniel Gonzalez (Post-doc)  
Dr. Jatinder Kaur Mukker (Post-doc)  
Dr. Jafar Basha Shaik (Post-Doc)  
Dr. Andrea Diniz (Post-Doc)  
Dr. Valvanera Vozmediano Esteban (Post-Doc)  
Dr. Ana Amelia Lira (Post-Doc)  
Dr. Jose Rodrigo Gonzalez (Post-Doc)  
Dr. Najla Kassab (Post-Doc)  
Dr. Girish Bende (Post-Doc)  
Dr. Satyawan Jadhav (Post-Doc)  
Dr. Hardik Chandasana (Post-Doc)

Prof. Maritza Cediel (Visiting Professor)

Prof. Carolina Vivas (Visiting Professor)  
Prof. Cioli Rojas (Visiting Professor)  
Prof. Dr. Markus Müller (Visiting Professor)  
Prof. Dr. Samia Mostafa (Visiting Professor)  
Prof. Dr. Bernd Jilma (Visiting Professor)  
Prof. Dr. Sandrine Marchard (Visiting Professor)  
Prof. Dr. Kazuro Ikawa (Visiting Professor)  
Prof. Socrates Egito (Visiting Professor)  
Dr. Monica Rodriguez (Visiting Professor)  
Kiman Kim (Visiting Scientist)  
Dr. Yan-hong Liu (Visiting Scientist)  
Dr. Heinz-Dieter Held (Visiting Scientist)  
Marc Rohrschneider (Visiting Scientist)  
Xiaoyun Zhang (Visiting Scientist)  
Jeong-Woo Lee (Visiting Scientist)  
Fenghuan Wei (Visiting Scientist)  
Takamasa Endo (Visiting Scientist)  
Kewei Zhang (Visiting Scientist)  
Maria Eugenia Avilan (Visiting Scientist)  
Muhammad Ubaid (Visiting Scientist)  
Lorena Ivette Medina Aymerich (Visiting Scientist)

Susan Stout (Graduate Student)  
Robert Townsend (Graduate Student)  
Matthieu Kaltenbach (Graduate Student)  
Sumia Mohamed (Graduate Student)  
Arno Nolting (Graduate Student)  
Michael Marcon (Graduate Student)  
Ajit Suri (Graduate Student)  
Shashank Rohatagi (Graduate Student)  
Viny Srinivasan (Graduate Student)  
Teresa Dalla Costa (Graduate Student)  
Pedro Froehlich (Graduate Student)  
Sanja Modric (Graduate Student)  
Amparo de la Peña (Graduate Student)  
Sriram Krishnaswami (Graduate Student)  
Ulrike Gräfe (Graduate Student)  
Ping Liu (Graduate Student)  
Julia Winkler (Graduate Student)  
Ariya Khunvichai (Graduate Student)  
Dorothee Krone (Graduate Student)  
Antina Barger (Graduate Student)  
Claudia Kohlert (Graduate Student)  
Edgar Schuck (Graduate Student)  
Virna Schuck (Graduate Student)  
Qi Liu (Graduate Student)

Sabine Wittemer (Graduate Student)  
Whocely Victor de Castro (Graduate Student)  
Immo Zdrojewski (Graduate Student)  
Wanchai Treyaprasert (Graduate Student)  
Elizabeth Potocka (Graduate Student)  
Stephan Schmidt (Graduate Student)  
Yanjun Li (Graduate Student)  
Jiang Liu (Graduate Student)  
Jian Xu (Graduate Student)  
April Barbour (Graduate Student)  
Oliver Ghobrial (Graduate Student)  
Martina Sahre (Graduate Student)  
Rong Shi (Graduate Student)  
Runa Naik (Graduate Student)  
Manuela Vieira (Graduate Student)  
Julia Glöde (Graduate Student)  
Benjamin Wu (Graduate Student)  
Daniel Gonzalez (Graduate Student)  
Daniela Conrado (Graduate Student)  
Luning Zhuang (Graduate Student)  
Carolina de Miranda Silva (Graduate Student)  
Yuanqing Yan (Graduate Student, with Maria Grant)  
Xuyang Song (Graduate Student)  
Kotchaphan Chooluck (Graduate Student)  
Li Li (Graduate Student)  
Sherwin Sy (Graduate Student)  
Aline Barth (Graduate Student)  
Manasa Tatipalli (Graduate Student)  
Mingming Yu (Graduate Student)  
Alexander Voelkner (Graduate Student)  
Nivea Falcao (Graduate Student)  
Ingorn Prasanchaimontri (Graduate Student)  
Amelia Deitchman (Graduate Student)  
Joseline Ruela (Graduate Student)  
Johannes Kast (Graduate Student)  
Eduardo Asín Prieto (Graduate Student)  
Juliana de Carvalho da Costa (Graduate Student)  
Frederico Severino Martins (Graduate Student)  
Aoi Matsushima (Graduate Student)  
Vipada Khaowroongrueng (Graduate Student)  
Yichao Yu (Graduate Student)  
Abhigyan Ravula (Graduate Student)  
Tobias Heinrichs (Graduate Student)  
Di Bei (Graduate Student)  
Taiki Nishimoto (Graduate Student)  
Ana Paula Lançanova Moreira (Graduate Student)

Martina Butschkau (Research Intern)  
Sophie Toufflin (Research Intern)  
Jean-Frederic Lefevre (Research Intern)  
Yau-Lin Kan (Research Intern)  
Elsbeth Brunt (Research Intern)  
Tessa Ververs (Research Intern)  
Olivier Makil (Research Intern)  
Herbert Schmidt (Research Intern)  
Hanneke Schreurs (Research Intern)  
Bettina Goldberg (Research Intern)  
Myriam Damoiseaux (Research Intern)  
Ewoud van Winden (Research Intern)  
Andrea Soldner (Research Intern)  
Jan Georg Möller (Research Intern)  
Eric Galia (Research Intern)  
Bart Metselaar (Research Intern)  
Heike Bauer (Research Intern)  
Christine Schäfer (Research Intern)  
Ulrike Gräfe (Research Intern)  
Andrea Hämmerlein (Research Intern)  
Christine Wellsov (Research Intern)  
Meyling Cheok (Research Intern)  
Otmar Abbas (Research Intern)  
Anne Gräbe (Research Intern)  
Jana Pfeifer (Research Intern)  
Cornelia Dressler (Research Intern)  
Ulrike Krauss (Research Intern)  
Frank Deselaers (Research Intern)  
Julia Kurz (Research Intern)  
Petra Lensing (Research Intern)  
Olaf Orthen (Research Intern)  
Daniel Svedmyr (Research Intern)  
Kennia Rocha Rezende (Research Intern)  
Susanne Kunz (Research Intern)  
Marion Stoll (Research Intern)  
Nahal Ketabi (Research Intern)  
Jörg Stütz (Research Intern)  
Marion Hirt (Research Intern)  
Michaela Karmann (Research Intern)  
Juliane Platz (Research Intern)  
Richard Fuhrherr (Research Intern)  
Sabine Hintze (Research Intern)  
Saskia Stilke (Research Intern)  
Nina Lamberty (Research Intern)  
Anja Klein (Research Intern)  
Irene Rinas (Research Intern)  
Immo Zdrojewski (Research Intern)



Jana Kroll (Research Intern)  
Christian Scheerans (Research Intern)  
Christian Hampp (Research Intern)  
Ralph Rüdiger Holl (Research Intern)  
Dirk Krane (Research Intern)  
Nina Schulte-Loebbert (Research Intern)  
Birgit Hemsch (Research Intern)  
Stephan Schmidt (Research Intern)  
Stefan Galler (Research Intern)  
Anne Wandrey (Research Intern)  
Sarah Thum (Research Intern)  
Anne Wandrey (Research Intern)  
Anke Rubner (Research Intern)  
Melanie Hübner (Research Intern)  
Vanessa Klett (Research Intern)  
Franziska Ihle (Research Intern)  
Matthias Fueth (Research Intern)  
Sarah Dizayee (Research Intern)  
Philos Shtapit (Research Intern)  
Dörthe Ludwig (Research Intern)  
Kira Namockel (Research Intern)  
Martina Sahre (Research Intern)  
Sandra Weiss (Research Intern)  
Rebecca Banks (Research Intern)  
Katharina Röck (Research Intern)  
Benjamin Ma (Research Intern)  
Christiane Müller (Research Intern)  
Nina Kranz (Research Intern)  
Franziska Koenner (Research Intern)  
Nora Siegle (Research Intern)  
Arnaud Dufraisse (Research Associate)  
Alexander Völkner (Research Intern)  
Almuth Kaune (Research Intern)  
Julia Legler (Research Intern)  
My-Hanh Nguyen (Research Intern)  
Gesa Nippel (Research Intern)  
Sebastian Wicha (Research Intern)  
Michael Pöttsch (Research Intern)  
Malte Christophersen (Research Intern)  
Nívea Falcão (Research Intern)  
Manuel Haas (Research Intern)  
Christina Wörtz (Research Intern)  
Theresa Müller (Research Intern)  
Helen Habteab (Research Intern)  
Isabelle Frensch (Research Intern)  
Jan Frederik Schlender (Research Intern)  
Nina Deppisch (Research Intern)

Julie Straub (Research Intern)  
Annette Raab (Research Intern)  
Maria Alice Maciel Tabosa (Research Intern)  
Noely Camila Tavares Cavalcanti (Research Associate)  
Philipp Kircher (Research Intern)  
Almut Glinzer (Research Intern)  
Kathrin Loeblein (Research Intern)  
Mareike Mieroff (Research Intern)  
Christian Grunwitz (Research Intern)  
Marlene Kissel (Research Intern)  
Clemens Lux (Research Intern)  
Johannes Merkle (Research Intern)  
Midas Mulder (Research Intern)  
Emilien Folzer (Research Intern)  
Claudia Al-Karawi (Research Intern)  
Christian Frank (Pharmacist, Research Associate)  
Johanna Kurre (Research Intern)  
Robin Tremmel (Pharmacist, Research Associate)  
Christoph Steinhauser (Research Intern)  
Elisabeth Schmitz (Research Intern)  
Marina Weissenborn (Research Intern)  
Sebastian Pieper (Research Intern)  
Franziska Benker (Research Intern)  
Melisa Softa (Research Intern)  
Miguel Adelino (Research Intern)  
Henrique Marcelino (Research Intern)  
Katarina Reljac (Research Intern)  
Severin Strasser (Research Intern)  
Julia Richartz (Research Intern)  
Nora Brüll (Research Intern)  
Lena Klopp-Schulze (Research Intern)  
Jules Heuberger (Research Intern)  
Hester van der Helden (Research Intern)  
Benjamin Gavalda (Research Intern)  
Jean-Baptiste Balen (Research Intern)  
Nina Werries (Research Intern)  
Maurice El Talia (Research Intern)  
Michaela Wimmer (Research Intern)  
Cordula Heinrichs (Research Intern)  
Stephanie Drescher (Research Intern)  
Correntin Guy (Research Intern)  
Tim Schumacher (Research Intern)  
Bettina Graupner (Research Intern)  
Ruben Malmborg (Research Intern)  
Lukas Diederich (Research Intern)  
Mareike Ahrends (Research Intern)  
Britta Krampe (Research Intern)

Dorothee Ressing (Research Intern)  
Lukas Diederich (Research Intern)  
Sylvia Kunze (Research Intern)  
Olga Zabela (Research Intern)  
Justus Garve (Research Intern)  
Laura Laqua (Research Intern)  
Elsa Neubert (Research Intern)  
Fabian Heider (Research Intern)  
Meike Hasenzahl (Research Intern)  
Johanna Weitzel (Research Intern)  
Anna Zoehner (Research Intern)  
Juliane Hermes (Research Intern)  
Jacqueline Keuth (Research Intern)  
Daniel de Jong (Research Intern)  
Theresa Hoffmeister (Research Intern)  
Daniel Bäcker (Research Intern)  
Nam Hoang Duc (Research Intern)  
Lena Kapitz (Research Intern)  
Laura Mahlert (Research Intern)  
Sebastian Franck (Research Intern)  
Thomas Arnold (Research Intern)  
Jasmin Ishak (Research Intern)  
Rosalie Boone (Research Intern)  
Uwe Liebchen (Research Intern)  
Dirk Beckmann (Research Intern)  
Ulrike Söpper (Research Intern)  
Carolin Dreier (Research Intern)  
Tobias Reimers (Research Intern)  
Guang Yan (Research Intern)  
Katharina Tessnow (Research intern)  
Romain Michot (Research Intern)  
Robert Möcker (Research Intern)  
Astrid Bröker (Research Intern)  
Janina Bittmann (Research Intern)

## Funding for Research

1983 Division of Sponsored Research, University of Florida,  
New Faculty Research Support (\$9,480).

Hoechst-Roussel Pharmaceuticals, Inc. (with R.L. Yost)  
Prepharmacokinetic studies on cefotaxime and its  
metabolites (\$7,000).

Hoechst-Roussel Pharmaceuticals, Inc. (with R.L. Yost)  
Pharmacokinetic studies in morbidly obese patients  
using cefotaxime (\$22,000).

College of Pharmacy, University of Florida  
Biomedical Research Support Grant (\$5,000).

Perkin-Elmer Corp.  
Research Donation (\$2,687).

State of Florida  
Development of electrochemical techniques to determine  
morphine - derivatives (\$4,000).

1984 State of Florida  
Development of electrochemical techniques to determine  
morphine- derivatives (\$24,000).

College of Pharmacy, University of Florida  
Biomedical Research Support Grant  
(\$5,000).

Hugh Little  
Research Donation (\$12,000).

1985 Boots Inc. (with J. Perrin)  
Bioavailability of codeine and ibuprofen (\$65,520).

State of Florida  
Development of electrochemical techniques to determine  
morphine - derivatives (\$24,000).

Boots Inc. (with J. Perrin)  
Plasma levels of a new ibuprofen formulation  
(\$22,464).

Glaxo Inc.  
Interaction of sucralfate and ranitidine (\$9,000).

- Boots Inc. (with J. Perrin)  
Bioavailability of ibuprofen suspensions (\$13,690).
- 1986 College of Pharmacy, University of Florida  
Biomedical Research Support Grant (\$1,950).
- Janssen Pharmaceuticals  
Comparison of Sufentanil vs Fentanyl vs Isoflurane in  
Neuroanesthesia (PI B. L. Grundy, \$35,000).
- Cyanamid  
Interaction between diclofenac and triamcinolone  
acetate (\$5,000).
- Embil Pharmaceuticals  
Analysis and stability of conjugated estrogens  
(\$1,500).
- State of Florida  
Development of electrochemical techniques to determine  
morphine - derivatives (\$18,638).
- 1987 Hoechst  
Pharmacokinetics of methylprednisolone phosphate  
(\$10,000).
- Hoffmann-LaRoche  
Erythrocyte binding of fleroxacin (\$8,300).
- Pharmatec Inc.  
Bioavailability of estradiol-CDS (\$9,000).
- Merck (with J. Perrin)  
Pharmacokinetic interactions between glipizide and  
lovastatin (\$10,395).
- 1988 Organon  
Pharmacokinetics of intraarticular glucocorticoids  
(\$10,816).
- Schering  
Bioavailability of theophylline (\$25,760).
- Pharmatec Inc.  
Bioavailability of estradiol-CDS (\$18,000).

- 1989 Pharmatec Inc.  
Bioavailability of estradiol-CDS (\$30,000).
- Xenon Inc. (with G. Hochhaus)  
Pharmacokinetics of glucocorticoids (\$11,000)
- Bristol-Myers (with H. Schreier)  
Amikacin microemulsions for drug delivery (\$24,000)
- 1990 Pharmatec Inc.  
Bioavailability of estradiol-CDS (\$20,000).
- PMA Foundation  
Evaluation of calcium blocker/beta blocker interactions (\$5,000)
- Bristol-Myers (with H. Schreier)  
Amikacin microemulsions for drug delivery (\$46,000.00)
- Xenon Inc. (with G. Hochhaus)  
Pharmacokinetics of loteprednol in dogs (\$16,000.00)
- 1991 Xenon Inc.  
Stability of soft drugs (\$3,500.00)
- Thomae (with G. Hochhaus)  
Pharmacokinetics and pharmacodynamics of dexamethasone isonicotinate (\$43,000.00)
- Schering-Plough  
Graduate Student Fellowship (\$15,000.00)
- NASA  
Effects of simulated microgravity on the pharmacokinetics and pharmacodynamics of antibiotics (\$22,000)
- 1992 Dept. of Anesthesiology, University of Florida  
Patient controlled morphine analgesia (\$2,000)
- Hefa Frenon (with G. Hochhaus)  
Pharmacokinetics of dexamethasone sulfobenzoate (\$10,000)

Dorsch  
Pharmacokinetics and pharmacodynamics of prednisolone  
(\$10,000)

Schering-Plough  
Graduate Student Fellowship (\$15,000)

Daniels Pharmaceuticals, Inc.  
Research Donation (\$30,000)

Hartford Foundation (with D. Lowenthal)  
Hepatic Blood Flow and Propranolol Kinetics in  
Response to Exercise Training in the Elderly (\$5,000)

Pfizer, Inc.  
Evaluation of analgesic activity using tooth pulp  
evoked potentials (\$42,350)

NIH RO1 GM45922 (co-PI, with R. Gonzalez-Rothi)  
Targeted Liposomal Corticoids for Lung  
Immunomodulation (\$156,563)

1993 Schering-Plough  
Graduate Student Fellowship (\$15,000)

NIH RO1 GM45922 (co-PI, with R. Gonzalez-Rothi)  
Targeted Liposomal Corticoids for Lung  
Immunomodulation (\$163,234)

Falk (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids (\$40,000)

1994 Glaxo Inc. (with G. Hochhaus)  
Pharmacokinetics and Pharmacodynamics of  
Corticosteroids (\$120,000)

Byk-Gulden (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids (\$25,000)

NIH RO1 GM45922 (co-PI, with R. Gonzalez-Rothi)  
Targeted Liposomal Corticoids for Lung  
Immunomodulation (\$163,234)

Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$50,000)

Falk (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids (\$60,000)

1995 Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$50,000)

Falk (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids (\$15,000)

1996 Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$50,000)

Boehringer Ingelheim (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids (\$237,440.00)

1997 Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$50,000)

Hexal  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$40,000)

NIH N01-A1-75317  
Pathobiology and Treatment of Malaria in Africa (co-I,  
with P. Stacpoole)  
(\$536,389)

NASA  
Undergraduate Space Research Grant (with J. Hughes)  
(\$4,000)

Boehringer Ingelheim (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids in Humans  
(\$146,020)

1998 Glaxo-Wellcome  
Pharmacokinetics and Pharmacodynamics of  
Corticosteroids (with G. Hochhaus)  
(\$154,560)

Hexal  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$40,000)



Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$50,000)

Boehringer Ingelheim (with G. Hochhaus)  
Pharmacokinetics of Corticosteroids in Mice  
(\$13,600)

Berlex  
Stability of fludarabine  
(\$5,000)

1999 Hexal  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$25,000)

Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$35,000)

Wyle Laboratories  
Pharmacokinetics of flurazepam  
(\$9,000)

2000 Hexal  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$25,000)

Sankyo  
Pharmacokinetics and Pharmacodynamics of Cefpodoxime  
(\$37,500)

Cyanamid  
Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$25,000)

Tropical Aquaculture Laboratory  
Pharmacokinetics of Flurfenicol  
(\$12,075)

Bayer  
Pharmacokinetics and Pharmacodynamics of Faropenem  
(\$46,875)

2001 Sankyo  
Pharmacokinetics and Pharmacodynamics of Cefpodoxime

(\$62,500)

Bayer

Determination of kill curves of Faropenem

(\$187,500)

Cyanamid

Pharmacokinetics and Pharmacodynamics of Antibiotics

(\$25,000)

CAPES

Bioavailability of 4-Nerolidylcatechol

(\$5,774)

Berlex

Stability and Sterility of Campath

(\$5,000)

2002 Sankyo

Protein Binding of Cefpodoxime

(\$12,500)

Innaphase

Pharmacokinetic/pharmacodynamic Modeling

(\$30,000)

Wyeth

Pharmacokinetics and Pharmacodynamics of Antibiotics

(\$25,000)

Center for Biological Defense (with J. Hughes)

Expression of Defensins as Novel Anthrax Agents

(\$125,000)

2003 Sankyo

Pharmacodynamics of Cefpodoxime

(\$75,000)

Florida Department of Citrus

Drug Interaction with Citrus Fruits

(\$24,000)

US Department of Agriculture

Grapefruit Juice-Drug Interaction

(\$232,180)

2004 Wyeth

Pharmacokinetics and Pharmacodynamics of Antibiotics  
(\$25,000)

Eisai  
Microdialysis in Tissues  
(\$5,000)

US Department of Agriculture  
Grapefruit Juice-Drug Interaction  
(\$207,085)

Pfizer  
Pharmacokinetics and Skin Microdialysis of Cefpodoxime  
(\$80,000)

State of Florida Department of Citrus  
Analysis of Atorvastatin  
(\$80,000)

2005 State of Florida Department of Citrus  
Drug Interactions with Grapefruit Juice  
(\$20,000)

US Department of Agriculture  
Grapefruit Juice-Drug Interaction  
(\$321,318)

Pfizer  
Graduate Student Support  
(\$100,000)

Merck  
Graduate Student Support  
(\$50,000)

2006 Geni Herbs  
Bioavailability and antioxidant effects of Pomella, a  
Pomegranate extract  
(\$15,437)

Pfizer  
Graduate Student Support  
(\$100,000)

Johnson & Johnson  
In vitro study investigating the effects of

antibiotics on bacterial strains  
(\$163,125)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

Johnson & Johnson  
Microdialysis validation of ceftobiprole  
(\$43,650)

US Department of Agriculture  
Grapefruit Juice-Drug Interactions After Acute and  
Chronic Use (with V. Butterweck)  
(\$317,933)

Merck  
Graduate Student Support  
(\$50,000)

2007 Johnson & Johnson  
Evaluation of BAL9141 Solution  
(\$14,650)

Johnson & Johnson  
An Exploratory Study to Evaluate the Penetration of  
Ceftobiprole Into Soft Tissue Determined by In Vivo  
Microdialysis in Healthy Volunteers  
(\$272,845)

Pfizer  
Graduate Student Support  
(\$100,000)

Merck  
Graduate Student Support  
(\$50,000)

2008 Johnson & Johnson  
Pharmacokinetics of Ceftobiprol  
(\$22,000)

Trius  
In vitro PK/PD Investigations of TR-700  
(\$163,125)

Trius

Microdialysis Validation of TR-700  
(\$37,500)

Merck  
Graduate Student Support  
(\$50,000)

Pfizer  
Graduate Student Support  
(\$100,000)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

Trius  
Microdialysis Study TR-701-102  
(\$325,250)

Glaxo SmithKline Croatia  
Disease Modeling in Psoriasis  
(\$37,500)

Johnson&Johnson  
Microdialysis Validation of a new Fluoroquinolone  
Antibiotic  
(\$43,950)

Florida Department of Citrus  
Drug Interactions  
(\$40,000)

2009 Pfizer  
Graduate Student Support  
(\$100,000)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

Johnson&Johnson  
Microdialysis of a new Fluoroquinolone Antibiotic  
(\$304,586)

2010 Pfizer

Graduate Student Support  
(\$100,000)

Roche

Optimizing siRNA Delivery Dosage Form Design For  
Receptor-Mediated Endocytosis  
(\$337,740)

Clinical and Translational Science Institute (CTSI)  
Pharmacokinetic / Pharmacodynamic Modeling of the  
Psychomotor Vigilance, Simulated Driving, Go/No-Go  
Performance, and Electroencephalogram Effects of  
Armodafinil in Sleep Deprived Healthy Adults  
(\$62,500)

UF Research Opportunity Fund

Intravaginal Delivery of Novel Tumoricidal Penetratin-  
Tagged Small Decoy Peptides Using Thermosensitive and  
Mucoadhesive Biopolymers as an Efficacious and Cost-  
Effective Alternative Treatment for Cervical Cancer  
(PI Stephen Hsu)  
(\$85,000)

Boehringer Ingelheim

Comparative Dissolution Study of Commercial  
Telmisartan Tablets  
(\$78,417)

Florida Department of Citrus

Drug Interactions  
(\$40,000)

2011 Pfizer

Graduate Student Support  
(\$100,000)

FDA

Effect of skin type and other factors on transdermal  
bioequivalence  
(\$500,000)

GSK Stiefel Laboratories

Disease Modeling in Acne  
(\$30,000)

State of Florida  
Detection, Prevention and Treatment of Vector Borne  
Diseases in Florida (PI G. Hochhaus, co-PI G. Morris)  
(\$275,000)

JMJ Technologies, Inc.  
Physiological based pharmacological modeling for  
second and third hand exposure to opiates in children  
in Afghanistan  
(\$12,500)

UF Opportunity Fund  
Intravaginal Delivery of Novel Tumoricidal Penetratin-  
Tagged Small Decoy Peptides Using Thermosensitive and  
Mucoadhesive Biopolymers as an Efficacious and Cost-  
Effective Alternative Treatment for Cervical Cancer  
(PI Stephen Hsu)  
(\$17,600)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

2012 Pfizer  
Graduate Student Support  
(\$100,000)

Astra Zeneca  
In vitro PK/PD investigations of Beta-Lactam/Beta-  
Lactamase-Combinations for the treatment of infections  
caused by multidrug resistant Gram-negative bacteria  
(I)  
(\$36,625)

Astra Zeneca  
In vitro PK/PD investigations of Beta-Lactam/Beta-  
Lactamase-Combinations for the treatment of infections  
caused by multidrug resistant Gram-negative bacteria  
(II)  
(\$131,120)

Florida Department of Citrus  
Drug Interactions  
(\$120,000)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

CUBRC, Inc.  
Two phase protein binding study in six species  
(\$87,500)

2013 Pfizer  
Graduate Student Support  
(\$100,000)

Florida Department of Citrus  
Drug Interaction Center  
(\$45,000)

Emory University  
Intracavitary Drug Levels in Patients with Drug  
Resistance (with C. Peloquin)  
(\$10,195)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

2014 Pfizer  
Graduate Student Support  
(\$100,000)

Florida Department of Citrus  
Drug Interaction Center  
(\$45,000)

GlaxoSmithKline  
A Study to Evaluate the Feasibility of Microdialysis  
(\$143,805)

Clinical and Translational Science Institute (CTSI)  
Tigecycline-tetracycline coadministration for the  
treatment of Pseudomonas aeruginosa infections  
(\$24,953)

Golin & Harris  
Drug Interaction Website  
(\$5,000)



Emory University  
Intracavitary Drug Levels In Patients With Drug  
Resistant Tuberculosis (with C. Peloquin)  
(\$13,349)

GlaxoSmithKline  
Postdoctoral Support  
(\$62,624)

2015 Pfizer  
Graduate Student Support  
(\$100,000)

Florida Department of Citrus  
Drug Interaction Center  
(\$45,000)

GlaxoSmithKline  
Postdoctoral Support  
(\$64,503)

Clinical and Translational Science Institute (CTSI)  
Effect of armodafinil on simulated driving,  
electroencephalogram and cognitive performance in  
sleep deprived healthy subjects  
(\$22,745)

Roche  
Determination of interstitial concentrations of  
therapeutic antibody immunoglobulin in tissues  
(\$290,245)

University of Florida  
PROSPER Award  
Effect of armodafinil on simulated driving,  
electroencephalogram and cognitive performance in  
sleep deprived healthy subjects  
(\$20,000)

NASA/Universities Space Research Association (USRA)  
Inflight Pharmacokinetic and Pharmacodynamic Responses  
to Medications Commonly used in Spaceflight  
(\$351,228)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

GlaxoSmithKline  
Development of a microdialysis technique  
(\$89,829)

2016 Pfizer  
Graduate Student Support  
(\$100,000)

GlaxoSmithKline  
Postdoctoral Support  
(\$151,662)

Golin & Harris  
Drug Interaction Website  
(\$5,000)

NIH R21 AI122001(PI R. Kempker & C. Peloquin)  
A clinical pharmacology study of a novel drug regimen  
for pre-XDR and XDR tuberculosis  
(\$8,784)

GlaxoSmithKline  
Clinical Kinetics/Dynamics Fellowship  
(\$35,816)